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Abstract 
Background: Up to 70% of nursing home patients with dementia suffer from 
disrupted sleep, often characterized by multiple awakenings at night and excessive 
daytime sleep. Sleep disruption may have negative effects on the cognition, mood, 
behaviour, and well-being of nursing home patients, while also representing a 
challenge for nursing home staff. However, few sleep scales are developed and 
validated specifically for the nursing home setting.  
Sleep problems among nursing home patients are frequently treated by medications, 
which are associated with severe side effects, including daytime sleepiness, and an 
increased risk of falls. Thus, there is a need for non-pharmacological interventions to 
improve sleep in this population. Bright light treatment (BLT) may represent such an 
intervention, providing increased light exposure aiming to impact sleep, circadian 
rhythmicity, mood, and/or behaviour.  
Light is the most important zeitgeber to the circadian system, and consequently has a 
significant impact on sleep-wake behaviour. Unfortunately, studies have reported low 
indoor light levels in nursing homes, which in combination with dementia-related 
neuropathology and age-related reductions in light sensitivity, are likely to contribute 
to sleep problems in this population. The aim of this thesis was to investigate whether 
increasing daytime light exposure, by means of BLT, can improve sleep in nursing 
home patients with dementia, and also to address methodological challenges in this 
field of research.   
Methods: Paper 1 is a systematic review of the literature, focusing on the 
methodological features of the included studies, in addition to their findings. Paper 2 
and 3 are based on data from the DEM.LIGHT trial; a cluster-randomized placebo-
controlled trial conducted in Norwegian nursing homes, including 69 patients. The 
intervention comprised a diurnal cycle of ambient light with a maximum of 1,000 lux 
and 6,000 Kelvin (K) from 10:00-15:00, administered using light emitting diode 
(LED) light. Before and after this interval, the light levels gradually 
increased/decreased in lux and K. In the placebo condition, standard light levels were 
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maintained at 150-300 lux and approximately 3,000 K throughout the day. The 
intervention and placebo lights were installed in the common rooms of the included 
nursing home units. Outcomes were measured at baseline and at follow-up at week 8, 
16, and 24. Paper 2 was a validation study of a proxy-rated sleep scale, using the 
baseline data from the DEM. LIGHT trial. Actigraphy was used as the reference 
standard. Paper 3 reported on the sleep outcomes of the trial, which were the primary 
outcomes. 
Results: Paper 1 found that there are promising, though inconsistent, results regarding 
the effect of BLT on sleep and circadian rhythmicity in dementia. Large heterogeneity 
in terms of interventions, study designs, population characteristics, and outcome 
measurement tools may explain some of the inconsistencies of results across studies. 
Paper 2 showed that the proxy-rated Sleep Disorder Inventory (SDI) had satisfactory 
internal consistency and convergent validity. Using actigraphy as the reference 
standard, the SDI was termed clinically useful, and we suggested a cut-off score of 
five or more as defining disrupted sleep in nursing home patients with dementia. These 
results should be interpreted keeping in mind that actigraphy have some important 
weaknesses, such as underestimating wake time. Paper 3 evaluated the effects of the 
BLT on sleep and found an improvement in sleep according to the SDI scores in the 
intervention group, as compared to the control group, from baseline to week 16 and 
baseline to week 24. There was no effect in terms of sleep measured by actigraphy.  
Conclusion: In summary, this thesis found that the evidence for an effect of BLT on 
sleep in nursing home patients with dementia is promising, but equivocal. Importantly, 
the research field faces some important methodological challenges, such as accurately 
measuring sleep. The SDI may represent a valid tool to measure sleep in the nursing 
home setting, which may be used both by researchers and by practitioners. Although 
the results of this thesis are not conclusive regarding the effect of BLT on sleep in 
nursing home patients with dementia, it may represent a step forward in understanding 
the potential value of BLT in this population, and may lay the ground for further 
investigation. The lack of an improvement on the SDI at week 8 indicates that the 
effect of BLT may take a long time to manifest in this population. 
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Samandrag på norsk 
Bakgrunn: Opp til 70% av personar med demens i sjukeheim har forstyrra søvn, ofte 
karakterisert av hyppige oppvakningar om natta og mykje søvn på dagtid. 
Søvnforstyrringar har negative konsekvensar for kognisjon, humør, åtferd og 
livskvalitet hos pasientane, og symptoma er krevjande å handtere for personalet. 
Likevel finst det få kartleggingsinstrument som er utvikla og validert spesifikt for bruk 
i sjukeheim.  
Søvnproblem hos sjukeheimspasientar blir ofte behandla medikamentelt, men slik 
behandling er assosiert med alvorlege biverknader, inkludert søvnigheit på dagtid og 
auka fallrisiko. Det er difor behov for å finne ikkje-medikamentelle intervensjonar for 
å betre søvn i denne populasjonen. Lysbehandling, eller ‘bright light treatment’ (BLT), 
kan vere eit  slikt behandlingsalternativ. BLT inneber å auke lyseksponering for å 
påverke søvn, døgnrytme, humør og/eller åtferd.  
Lys er den viktigaste stabiliserande faktoren for døgnrytmen, og er difor avgjerande  
for regulering av søvn-vaken-syklusen. Forskarar har funne lave nivå av innandørs lys 
på sjukeheimar. I kombinasjon med demensrelatert nevropatologi og aldersrelatert 
reduksjon i sensitiviteten for lys, bidreg dette venteleg til den høge førekomsten av 
søvnproblem i denne populasjonen. Målet med denne avhandlinga var å undersøke om 
ein kan betre søvn hos personar med demens i sjukeheim ved å auke lyseksponering på 
dagtid, samt å sjå nærare på dei metodologiske utfordringane i dette forskingsfeltet.  
Metode: Artikkel 1 er ein systematisk litteraturgjennomgang der vi fokuserte på 
metodologiske trekk ved dei inkluderte studiane, i tillegg til studiane sine resultat. 
Artikkel 2 og 3 var basert på data frå DEM.LIGHT-studien; ein klynge-randomisert 
placebo-kontrollert studie gjennomført på norske sjukeheimar, som inkluderte 69 
pasientar. Intervensjonen bestod av takmontert LED-lys, som gav ein syklus av lys 
med maksimalt nivå på 1,000 lux og 6,000 Kelvin (K) frå kl. 10:00 til kl. 15:00. Før og 
etter dette intervallet vart lyset gradvis auka/dempa i lux og K. Kontrollgruppa hadde 
standard lys på 150-300 lux og rundt 3,000 K gjennom heile dagen. Intervensjonen og 
placebo-lyset vart installert i daglegstova til dei inkluderte sjukeheimsavdelingane. 
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Utfalla vart målt på baseline og ved oppfølging i veke 8, 16 og 24. Artikkel 2 var ein 
validerings-studie av ein søvnskala, basert på baseline-data frå DEM.LIGHT-studien. 
Aktigrafi vart brukt som referanse. Artikkel 3 rapporterte søvnutfalla (primærutfall) frå 
DEM.LIGHT-studien.  
Resultat: Artikkel 1 viste at det finst lovande, men inkonsistente funn om effekten av 
BLT på søvn og døgnrytmeforstyrringar hos personar med demens. Vi fann store 
skilnader i val av intervensjonar, design, karakteristikkar ved studiepopulasjonen og 
mellom utfallsmål, som kan forklare dei ulike resultata på tvers av studiar. Artikkel 2 
viste at søvnskalaen Sleep Disorder Inventory (SDI), utfylt av sjukeheimspersonale, 
hadde tilfredsstillande indre konsistens og konvergent validitet. Samanlikna med 
aktigrafi som referanse, fann vi at SDI var klinisk nyttig, og vi foreslo ein skår på fem 
eller meir som cut-off for å definere forstyrra søvn hos personar med demens i 
sjukeheim. Desse resultata må tolkast i lys av at aktigrafi har nokre viktige ulemper, til 
dømes at dei kan underestimere vakentid på natta. Artikkel 3 evaluerte effekten av 
BLT på søvn og fann ei betring av SDI i intervensjonsgruppa frå baseline til veke 16 
og frå baseline til veke 24, samanlikna med kontrollgruppa. Det var ingen effekt på 
søvn målt med aktigrafi.  
Konklusjon: Oppsummert viste denne avhandlinga at effekten av BLT på søvn hos 
personar med demens i sjukeheim er lovande, men ikkje eintydig. Forskingsfeltet har 
nokre viktige metodologiske utfordringar, mellom anna nøyaktige mål for søvn. SDI 
kan representere et valid verktøy for bruk i sjukeheimar og kan nyttast både av 
forskarar og i klinisk praksis. Sjølv om resultata av denne avhandlinga ikkje er 
konkluderande om effekten av BLT på søvn hos personar med demens i sjukeheim, 
representerer dei eit steg framover i å forstå den potensielle verdien av BLT for denne 
populasjonen, og kan bidra til vidare forsking. Manglande betring av SDI i veke 8 
tyder på at effekten av BLT kjem først etter ei stund i denne populasjonen. 
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1. Introduction and background 
Life expectancy has increased during the last decades, and it has been estimated that 
one in six people will be over the age of 65 by 2050 [1]. Although epidemiological 
studies have demonstrated an increase in the number of healthy years in old age [2], 
the relative increase in older people in the global population, implies an increased 
number of people with dementia [3] and a growing need of continuous care. The 
demand for nursing home places is consequently likely to escalate. Disrupted sleep is 
one of the central challenges related to nursing home patients with dementia [4]. Sleep 
is essential for good health, and many of the symptoms and challenges associated with 
dementia, such as impaired cognition, depression, anxiety, agitation, and psychotic 
symptoms [5], seem to be exacerbated by severely disrupted sleep [6–10].  
Unfortunately, assessing sleep in nursing home patients is particularly challenging in 
dementia. Patients may not retain experiences of their own sleep and may have lost 
their ability to communicate. Further, treating sleep disturbances in this population is 
complicated due to multimorbidity, and pharmacological treatments often cause side 
effects such as sedation and increased risk of falling [11, 12]. Thus, adequate non-
pharmacological treatments are warranted.  
One promising non-pharmacological intervention is Bright Light Treatment (BLT), 
where patients are exposed to bright light during the day. Light exposure plays a key 
role in regulating sleep and wakefulness [13]. Alas, several studies have reported 
suboptimal light levels in nursing homes [14–17], and insufficient light exposure 
seems to contribute to sleep problems among nursing home patients with dementia 
[14, 18]. Some studies have shown promising effects of BLT on sleep in people with 
dementia [e.g., 19, 20], but there is a general lack of rigorous clinical trials including 
this population.  
1.1 Purpose and scope of the dissertation 
The main aim of this thesis was to investigate the effect of BLT on sleep in nursing 
home patients with dementia. In order to achieve this goal, we first performed a 
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systematic review of relevant literature (Paper 1). To get a broader and clinically 
meaningful sense of the use of BLT as a treatment option for people with dementia, we 
included studies evaluating the effect on sleep and circadian rhythmicity, and also 
Behavioural and Psychological Symptoms of Dementia (BPSD), such as depression 
agitation, functional status, and quality of life. Further, the use of different valid 
measures of sleep may be a prerequisite to reach an approximation of the actual sleep 
pattern in people with dementia. Hence, we addressed the challenges of measuring 
sleep in people with dementia and investigated the validity of a sleep scale designed 
for use in this population (Paper 2). Lastly, we evaluated the effect of a BLT 
intervention on sleep in nursing home patients with dementia by means of a cluster-
randomized placebo-controlled trial (Paper 3).  
The following background section will present key research on sleep and sleep-wake 
regulation, including the role of light in sleep-wake regulation. Following this, the 
nursing home context and sleep in this context will be presented. Then, previous 
studies evaluating the effect of BLT on sleep problems in dementia will be reviewed, 
and finally, some central challenges pertaining to BLT research will be outlined.  
1.1.1 Current research and development 
A systematic literature search was conducted in June 2016, covering medical subject 
headings (MeSH) terms and free text phrases synonymous with “nursing home”, 
“bright light treatment” and “dementia”. We searched Medline, Embase, PsycINFO, 
Cochrane library, CINAHL, and Web of Science. Updated searches were performed in 
2018 and 2019. These searches became the basis of Paper 1 and updated searches 
performed in 2020, last performed in August 2020, provided literature for the present 
thesis.   
1.2 Sleep  
Humans spend approximately one third of their lives sleeping [21]. Although there are 
still many undiscovered mechanisms related to our need for sleep, considerable 
evidence suggest that sleep serves several essential functions, such as brain restitution 
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[e.g., 22], and metabolic and hormone regulation [e.g., 23]. In addition, sleep is 
essential to cognitive functions such as learning and memory [24, 25]. Prolonged sleep 
problems have consequently been shown to have severe health consequences. For 
example, one recent meta-analysis including more than 5 million participants, reported 
that short sleep duration (less than six hours each night) is associated with an increased 
risk of diabetes mellitus, cardiovascular disease, and obesity [26]. Also long sleep 
duration (more than eight hours each night) has been linked to poor health outcomes 
[27]. Longitudinal studies of humans have shown that sleep problems and circadian 
disturbances at baseline are associated with an increased risk of developing cognitive 
impairment and dementia [28, 29].  
Sleep is a reversible state that is characterized by reduced responsiveness, motor 
activity, and metabolism [30]. While sleeping, people are normally lying down, 
immobile, and with their eyes closed. At the same time, sleep is a highly complex 
behavioural and physiological state, with characteristic brain and body activity (see 
below) [31]. Human sleep normally occurs at night, and adults on average report 
sleeping for about 7 hours [32]. However, sleep timing and duration varies 
significantly across individuals and across nights [31, 33]. With aging, sleep quality 
and quantity are affected [34], and even more so in dementia [4, 35].  Basic research 
on sleep is most often performed on young adults, and the following description of 
sleep and sleep-wake regulation (section 1.2 and 1.3) refers to sleep as it typically 
presents itself in a healthy young adult. How sleep is affected by aging and dementia is 
described in section 1.4 and 1.5.1.  
1.2.1 Characteristcs of sleep-wake patterns 
The discovery of the electric activity of the brain and the invention of the 
electroencephalogram (EEG) represent the start of the modern scientific study of sleep 
[36]. The EEG records the electric activity of the brain, producing distinct wave 
patterns when measured by electrodes placed on the scalp. Today, the gold standard of 
sleep monitoring is polysomnography (PSG), a technique encompassing EEG, 
electrooculography (recording eye movements), and electromyography (recording 
muscle activity), followed by a manual analysis of the recordings [37]. Clinical PSG 
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additionally include electrocardiography, and recordings of respiration, activity of the 
musculus tibialis, and oxygen saturation. By recording the changes in the electrical 
activity of the brain throughout the sleep episode, different sleep stages have been 
identified. In humans, sleep is broadly classified into Non-Rapid Eye Movement 
(NREM) sleep and Rapid Eye Movement (REM) sleep, which occur in cycles of 
approximately 90 minutes throughout the sleep episode [31]. Traditionally, NREM 
sleep has been divided in four substages based on the EEG activity [38]. In 2007, the 
NREM sleep stages were redefined by the American Academy of Sleep Medicine into 
three stages of successively deeper sleep (N1-N3) [39] (see Table 1). N3 is 
characterized by high-amplitude slow waves, or slow-wave activity, and is also 
referred to as slow-wave-sleep (SWS).  





EEG characteristics Approximate 
distribution of sleep 





N1 Stage 1 Slowing of the EEG wave pattern 2-5% 
N2 Stage 2 Characteristic EGG waveforms of 
sleep spindles and K-complexes 
45-55% 
N3 Stage 3-4 Scored when at least 20% of the 
epochs (30 sec) are slow-wave 
activity; slow waves with high-
amplitude called delta waves. N3 is 
also referred to as slow-wave sleep. 
13-23% (3-8% in Stage 3 
and 10-15% in Stage 4) 
 R REM sleep The EEG pattern resembles the 
activity during wakefulness (low 
amplitude, high frequency). 
20-25% 
AASM= American Academy of Sleep Medicine, EEG= Electroencephalogram, REM= Rapid-eye-
movement. 
The proportion of NREM and REM sleep changes in a predictable pattern across the 
sleep period, as initially documented by Dement and Kleitman [40], and that has been 
confirmed in later studies [e.g., 41]. Following sleep onset into NREM sleep, sleep 
becomes gradually deeper, and approximately 30 minutes are spent in N3 during the 
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first sleep cycle (approximately 90 minutes in total). Subsequently, sleep becomes 
‘lighter’, moving rapidly through N3 and N2, followed by REM sleep. During REM 
sleep, visual dreams often occur, and the subject displays saccadic eye movements [42, 
43]. REM sleep is also accompanied by muscle atonia, which is detected by 
electromyography [37]. Following the first REM episode, sleep again becomes 
gradually deeper and the process is repeated. The longest SWS episodes occurs during 
the first third of the night, while REM sleep and N2 dominate the last third. The 
approximate distribution of sleep stages are given in Table 1.  
1.2.2 The neurobiological and neurophysiological basis of sleep 
Sleep is an active process that is generated by brain areas mainly located in the 
brainstem, thalamus, hypothalamus, and the basal forebrain [44]. The transitions 
between sleep and wakefulness are driven by a reciprocal inhibition between the 
circuits involved in sleep and those involved in wake and arousal. The transition has 
been compared to a flip-flop switch, where the activity of one system inhibits the 
activity of the other [45].  
Wakefulness is induced by the activity of multiple neurochemical systems originating 
in the brainstem and forebrain, projecting to the thalamus and/or the neocortex, 
resulting in widespread cortical activity [46]. The thalamus, located above the 
brainstem, act as a relay station between sensory input and the cerebral cortex, where 
sensory inputs are processed and interpreted.  
During the transition to drowsiness, sleep-promoting neurons inhibit the arousal 
systems [47]. The evidence suggests that GABAergic neurons (i.e., neurons releasing 
the neurotransmitter γ-Aminobutyric Acid, GABA) located in the ventrolateral 
preoptic area (VLPO) and in the median preoptic nucleus of the hypothalamus, are 
largely responsible for initiating and maintaining sleep [47]. During sleep onset, these 
sleep-promoting neurons are activated by excitatory input from the suprachiasmatic 
nucleus (SCN) of the hypothalamus and from the neurotransmitter adenosine [46]. The 
SCN is responsible for the circadian 24 hour rhythm of the sleep-wake cycle (see 
below), and activates the VLPO when it is time to sleep [46]. Adenosine is a waste 
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product of brain activity that accumulates during wakefulness and activates the sleep-
promoting neurons of the VLPO. The activity of sleep-promoting neurons inhibit the 
activity of systems involved in wakefulness [46]. Thus, the thalamus and the cerebral 
cortex are quiet during SWS, tuning out the outside world. Conversely, the sleep-
promoting GABAergic neurons are inhibited by the neurotransmitters involved in 
wakefulness [48]. 
The transition from SWS to REM sleep involves inhibitory interaction between 
“REM-on” neurons and “REM-off” neurons located in the midbrain and hindbrain. In 
transitioning to REM sleep, the cholinergic neurochemical system becomes active, 
while serotonergic and noradrenergic neurons become inhibited [49]. The cerebral 
cortex, thalamus, and basal forebrain are active, while neurons from the “REM-on” 
neuronal centres project to the spinal cord and cause muscle atonia [46].  
1.3 Sleep-wake regulation 
1.3.1 The two-process model  
One highly influential model for describing sleep regulation is the two-process model, 
initially presented by Borbély in the early 1980s [50]. According to the model, sleep 
timing and structure are the products of i) a build-up of sleep pressure following 
wakefulness, termed the homeostatic process, and ii) endogenously generated near-24-
hour rhythms in sleep and arousal, termed the circadian process. Since the model was 
proposed by Borbély [50], it has been revised and inspired other models of sleep 
regulation [51]. However, the two-process model remains highly influential and serves 
as a guide to understanding sleep regulation. 
The homeostatic process  
The homeostatic sleep drive increases during wakefulness and decreases during sleep 
[52]. Slow-wave EEG activity is regarded the principal marker of the homeostatic 
sleep drive. The magnitude of slow-wave activity increases after prolonged 
wakefulness, signalling the build-up of sleep pressure, and diminishes during sleep. 
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Adenosine is a key mediator of the homeostatic process, where the accumulation of 
adenosine in the basal forebrain accompanies the build-up of sleep pressure [53]. 
The circadian process 
Circadian rhythms are near-24-hour rhythms in cellular activity, protein expression, 
and finally behaviour, evident in rhythms of sleep and wakefulness, core body 
temperature, metabolic function, hormone production, and a range other biological 
processes [54]. These rhythms are produced by a molecular clockwork present in most 
cells [55].  
The SCN of the hypothalamus has been identified as the “master clock” or circadian 
pacemaker, which synchronizes, or orchestrates, the different rhythms throughout the 
body [56], ensuring that the brain and body are prepared to carry out functions 
appropriate to the time of day/night. Two prominent circadian rhythms are the daily 
fluctuations of melatonin secretion and core body temperature, which are often used to 
assess circadian phase. Melatonin is a hormone secreted by the pineal gland inducing 
sleepiness, which increases during the evening, reaches its peak levels during the 
night, and shows low levels during the day. Core body temperature, on the other hand, 
reaches its minimum (nadir) approximately two hours prior to habitual wake-up time 
[57]. Because the internal rhythm of the circadian pacemaker for most people is 
slightly longer than 24 hours [54, 58], the circadian pacemaker depends on exposure to 
environmental time signals (zeitgebers) to synchronize to geophysical time [54]. The 
most important zeitgeber is the light/dark cycle [54] (see section 1.3.2). Although light 
and darkness are the most potent zeitgebers, other non-photic events, such as changes 
in temperature, physical activity, or food consumption, may also act as entraining 
signals [59–62]. 
Importantly, the homeostatic and circadian processes affect each other [63, 64]. For 
example, while homeostatic sleep pressure increases with wakefulness and decreases 
with sleep, its contribution to sleep timing is restricted by the oscillation of the 
circadian rhythm, which is normally entrained to the 24-hour day [52]. Thus, 
following the same amount of time spent awake, sleep onset latency and the quality of 
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the sleep, depend on when the person goes to bed. Conversely, sleep restriction or 
advancing/delaying the sleep episode changes the activity of the circadian system [65].  
In addition to the homeostatic and circadian processes, ultradian rhythms (shorter than 
24 hours) are aspects of sleep-wake regulation. One example is the 90 min NREM-
REM cycles [66]. There is also some ultradian rhythmicity in waking EEG, with a 
period of 3-4 hours, with accompanying variations in vigilance and alertness [67]. In 
sum, sleep is produced by a complex interaction of homeostatic and circadian 
processes [63, 64, 66, 68], as well as ultradian rhythms [52, 69].  
Environmental/behavioural influences on sleep 
Under ideal circumstances, the rhythms of sleep-wake, metabolism, hormone 
secretion, and other rhythms throughout the body are synchronized in a temporal order 
securing optimal functioning [57]. However, people frequently behave in ways that 
misaligns the sleep-wake cycle from the light dark-cycle. Perhaps the most prominent 
example is shift work, where people work during the night and go to sleep in the 
morning. Consequently, behaviour is a major factor in sleep-wake regulation, where 
people advance, delay, or shorten their sleep episode. This behaviour may also affect 
how much light a person is exposed to, and the timing of exposure. 
1.3.2 Light and entrainment of circadian rhythms 
As light exposure is the most important zeitgeber to the circadian system [54], it is 
fundamentally implicated in sleep and circadian rhythm entrainment [13]. Light 
information is projected directly from the retina to the SCN by a group of ganglion 
cells in the retina, called intrinsically photosensitive retinal ganglion cells (ipRGCs) 
[70, 71]. The ipRGCs are intrinsically photosensitive as they contain the photopigment 
melanopsin [72], and are maximally sensitive to short wavelength light of about 480 
nm, corresponding to blue light [73, 74]. There are five subtypes of ipRGCs [75], 
which in addition to projecting to the SCN and entraining circadian rhythms, have a 
widespread pattern of projection to areas such as the VLPO and the lateral 
hypothalamus, areas implicated in the regulation of sleep, wakefulness/alertness, and 
mood [72]. All of these “non-visual” effects of light, including circadian effects, are 
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collectively termed “non-image-forming” (NIF) functions [72]. While the ipRGCs are 
sufficient to drive circadian responses to light, rods and the three kinds of cone 
photoreceptors (the “classical” photoreceptors involved in image-forming functions) 
also contribute to NIF responses [76, 77]. 
The “optimal” dose of daily light exposure in terms of timing, intensity, and spectral 
composition has not been established [78]. However, research have demonstrated how 
these aspects of light impact the circadian system. Firstly, the effect of light exposure 
on the circadian system depends on the circadian phase in which the light is delivered, 
a phenomenon referred to as phase-response curves [79, 80]. Phase-response curves 
estimate the direction and magnitude of phase shifts following light exposure at 
specific times. Exposure to bright light following nadir (the time of the lowest point of 
the temperature rhythm) advances the circadian rhythm (i.e., shifts the rhythm to an 
earlier time), while bright light prior to nadir delays the rhythm (i.e., shifts the rhythm 
to a later time) [79, 81, 82]. The magnitude of the circadian response to a light 
stimulus may be expressed as how much the phase of the circadian rhythm is delayed 
or advanced, where the largest phase shifts occur close to nadir [57]. Importantly, the 
human circadian system is sensitive to light input throughout the day, and phase 
advances may be invoked by bright light for up to 8 hours after habitual waking [81, 
83]. Bright light at midday has been shown to advance the phase of the melatonin 
rhythm and increase nocturnal plasma melatonin [84]. Light exposure during the 
evening and night may significantly disrupt circadian rhythms [85, 86]. 
In addition to the timing of light exposure, the physiological response to light partly 
depends on the level of illumination [87]. Illuminance is a commonly used measure 
that refers to how much the incident light illuminates a surface [88]. Traditionally, the 
most widely used photometric unit for illuminance is lux [89]. This metric, however, is 
weighted by the spectral sensitivity of cones (peak sensitivity at ~555 nm), and not 
ipRGCs (peak sensitivity at ~480 nm). Given that NIF responses are largely driven by 
ipRGCs, lux inadequately predicts NIF responses to light [89]. Lucas and colleagues 
[90] developed a toolbox for quantifying the activation of each photoreceptor 
(equivalent “α-opic” illuminance), including a metric quantifying the activation of 
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melanopsin, the ‘equivalent melanopic lux’. Building on this work, the International 
Commission on Illumination (CIE S 026/E:2018) recently developed a toolbox 
offering metrics compliant to the International System of Units [91]. The CIE 
developed the metric “melanopic equivalent daylight illuminant” (melanopic EDI), 
closely reflecting the “equivalent melanopic lux” presented by Lucas et al. [90]. In 
recent years, researchers have increasingly used these metrics, which are superior in 
predicting the circadian response to a light stimulus, compared to photopic illuminance 
(lux) [90, 92]. Yet others have used the metric “circadian stimulus”, quantifying the 
circadian effectiveness of a light stimulus in terms of melatonin suppression [93–95]. 
However, as these developments are fairly recent, the majority of BLT studies 
involving people with dementia to date have reported lux.  
One of the first demonstrations of the physiological effects of light showed that at least 
1,000 lux of polychromatic white light was needed to suppress melatonin in humans 
[96]. Daylight illumination can typically range from 13,500 lux (overcast) to 63,000 
lux (clear sky), and can reach a maximum level of over 100,000 lux [97]. Later, 
Brainard et al. [98] demonstrated that much lower light intensities (3-7 lux) of 
monochromatic (single wavelength) light of 509 nm and could cause a significant 
reduction in nocturnal plasma melatonin in humans when the pupil was artificially 
dilated. Under normal circumstances, with normal pupil constriction, higher 
illuminance is needed. One study demonstated that daytime exposure to 200 lux, i.e., 
typical indoor illumination, was not sufficient to maintain circadian phase at 24 hours 
[99]. In contrast, daytime exposure to 1,000 lux entrained the circadian rhythm [99].  
The physiological response to light also depends on spectral composition, i.e., which 
wavelengths the light consists of [87, 100]. Since the ipRGCs are maximally sensitive 
to short wavelength light, short wavelength light has a stronger impact on the circadian 
system than light of longer wavelengths [101, 102]. The spectral composition of light 
is often expressed as the correlated colour temperature (CCT) of the light, reported in 
Kelvin (K). Sunlight contains all visible wavelengths (it is polychromatic), including 
high amounts of blue light. The CCT of daylight lies around 6,000 Kelvin (K), 
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depending on weather conditions [103]. Typical indoor light is about 200 lux and 
2,700-4,000 K [16, 17].  
In addition, the response to light, in terms of NIF responses, also depends on the 
duration of exposure and on previous light exposure, or light history. Generally, the 
phase shifting properties of light is stronger when the duration of exposure is increased 
[104], although phase shifts can also occur in response to very short light bursts [105]. 
Further, exposure to bright light decreases the sensitivity of the ipRGCs. One study 
demonstrated that exposure to blue-white light in the morning reduced the phase-
shifting response to evening light exposure [106]. Conversely, limiting daytime light 
exposure to dim light only, has been shown to increase melatonin suppression in 
response to nocturnal light exposure [107, 108], and hence increase the risk of 
circadian disruption. Thus, sufficient daytime light exposure seems to protect against 
circadian disruption caused by evening/nocturnal light. In conditions with extremely 
weak or absent zeitgebers, circadian rhythms decouple from geophysical time and 
‘free-run’ according to the intrinsic oscillation of the circadian pacemaker [54].  
Importantly, bright light exposure also has well-demonstrated effects on alertness; 
indirectly through suppressing melatonin, and directly by stimulating the arousal 
system [109–111]. Thus, light may shift the timing of sleep through its effect on the 
circadian system, and also by suppressing sleepiness and enhance alertness.  
The consequences of non-optimal light exposure 
Due to the intimate relationship between the circadian system and the light-dark cycle, 
changes in the light dark-cycle often lead to circadian dysregulation, including the 
disruption of the sleep-wake rhythm [72]. Common causes of circadian dysregulation 
is shift work and travelling across time zones [112], which misaligns the main sleep 
episode from the light-dark cycle. This often results in sleep deprivation and sleep 
fragmentation [113], and misaligns sleep from other circadian rhythms. Such internal 
misalignment of different circadian rhythms may in itself be detrimental to health and 
well-being [114]. 
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Modern life often entails spending the majority of time indoors, largely cut off from 
daylight, as well as using electrical light and light-emitting devices in the evening. 
This life style diminishes the amplitude of the light-dark cycle [115]. As mentioned 
above, the circadian system is more susceptible to night-time light exposure in the 
absence of a robust light input during the day. Research suggests that a robust light-
dark cycle promote a stable rhythm, and standard indoor light levels seem to be 
insufficient to maintain a stable circadian rhythm [99]. As will be elaborated in section 
1.5, this may be particularly relevant in nursing homes. 
1.4 Sleep and aging  
With increasing age, some well-documented changes in sleep timing and structure also 
occur. Firstly, circadian rhythms become less robust [116]. The output from the SCN 
is altered, with a reduced amplitude of hormone-secretion, electrophysiological 
activity, and gene expression [117]. Also, there is some evidence that sleep 
homeostasis becomes less robust, with diminished sleep pressure with increasing age 
[118, 119]. By the age of 60, total sleep time, sleep efficiency (SE; the percentage of 
time spent asleep while in bed), SWS, and REM sleep decrease, and there is 
commonly an increase in the time spent awake after sleep onset, sleep onset latency 
(the time it takes to fall asleep), time spent in sleep stages N1 and N2 (i.e., lighter 
sleep), and more arousals from sleep [34, 120]. Beyond 60 years, the amount of time 
spent in N1 increases and SE decreases further, while other sleep parameters remain 
stable [34]. However, this stability of sleep parameters beyond 60 years of age pertain 
to healthy adults and not those with medical issues. Somatic diagnoses and their 
treatment, such as hypertension, heart disease, and diabetes, seem to contribute to 
sleep disturbances [121–124]. These conditions are more common in older populations 
[125]. 
With increasing age, the amount of light reaching the retina is reduced due to lens 
yellowing and pupil constriction [126–128], which may contribute to sleep 
disturbances. Brøndsted, Lundeman, and Kessel [129] measured the transmission of 
light through donor lenses and calculated that the ability of photoentrainment 
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decreases by 0.6-0.7% for each year of life because yellowing of the lens increasingly 
absorbs short wavelengths. Tuner and Mainster [128] calculated the age-related 
decline in circadian photoreception based on both lens yellowing and senescent miosis 
(age-related decline in pupil size). According to their calculations, a 45-year old have 
roughly half the circadian photoreception of a 10-year old, and 80- and 90-year olds 
retain only about 10% of the circadian photoreception of a 10-year old. Indeed, such 
changes may contribute to sleep disturbances in older adults. Clinically, lens yellowing 
is associated with more subjectively reported sleep disturbances and sleep medication 
use [130]. In addition, the sensitivity of the SCN to photic input may also decrease 
with age [131]. Duffy and colleagues [132] reported that older adults (65 or older) 
were less sensitive to low-to-moderate light levels (50-1,000 lux) than young adults in 
terms of the delaying effect of evening light exposure on the circadian rhythm. 
Herljevic and colleagues [133] found a smaller suppression of melatonin following 
light exposure in older adults compared to younger adults. There is some evidence for 
compensatory mechanisms preserving the melatonin response to light [127], and 
diminished responses to light seem to be more pronounced at low-to-moderate light 
levels, while the responses to very bright light (8,000-10,000 lux) is largely preserved 
by age [132, 134, 135]. These changes in light sensitivity implies that older adults are 
particularly dependent on a robust light-dark cycle to retain a stable circadian rhythm.  
1.5 Sleep in the nursing home 
Nursing homes are the largest institutions in Norway, and 32,234 people were 
registered with long-term placement in 2018 [136]. In Norway, long-term placement is 
offered primarily to older people who are no longer able to live at home [137]. In other 
words, to be eligible for nursing home placement, the person has to be in need of 
continuous care beyond what can be offered by visits at home [138]. Hence, the 
average age of long term nursing home residents is relatively high (84 years) [138], 
80% suffer from dementia [125, 139, 140], and many have poor somatic health [125]. 
Coronary disease, congestive heart failure, cerebrovascular disease, and diabetes are 
common, where one study found prevalences at admission to the nursing home of 
 28 
25%, 21%, 24%, and 15%, respectively [125]. Consequently, nursing home patients 
represent a frail group with multiple somatic and psychological needs [138]. 
Unfortunately, findings from a Norwegian study indicated a lack of sufficient 
competence among staff to meet the complex needs of nursing home patients [141], 
which may lead to insufficient patient care and distress among staff. Among 
physicians, a Norwegian report found that there was high turnover and little continuity, 
where most were engaged in part time positions [142]. There is on average one 
registered nurse per 11 patients, one licensed practical nurse per seven patients, and 
one unskilled nurse per 16 patients during the day shift [143]. During the night, these 
numbers are 24, 20, and 23, respectively. Numbers may vary across municipalities and 
depending on the nursing home, the number of patients per nurse may be even higher. 
Not surprisingly, sleep problems, in particular agitation and confusion during the 
night, can be difficult to handle for a small night staff.   
Sleep disruption is common among nursing home patients, with prevalences of 25-
67% [144–148], and studies have reported that up to 50% use hypnotics [149–151]. 
Dementia is a major contributor to sleep disruption among nursing home patients, and 
the following section wil describe dementia and the impact of dementia on sleep. 
1.5.1 Dementia – Diagnoses, symptoms, and sleep regulation 
Among people of 60 years of age or more, 5-7% suffer from dementia [152]. Dementia 
is associated with significant economic costs related to medical treatment and formal 
and informal care. The total costs make up between 0.2 and 1.4% of the gross 
domestic product in low- and high-income countries, respectively, and the World 
Health Organization have recognized dementia as a social health priority [153]. In 
Norway, it is estimated that between 80,000-100,000 people suffer from dementia, and 
this number is expected to double by 2050 [3].    
Dementia is caused by progressive neurodegenerative and/or vascular damage to the 
brain that result in cognitive impairment, behavioural and psychological changes, and 
the loss of ability to perform everyday tasks [153]. In the Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition (DSM-5), dementia, or major neurocognitive 
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disorder, is now subsumed in the broader category of “neurocognitive disorders”, 
alongside delirium and mild neurocognitive disorder. The term ‘dementia’ is still 
frequently used [154]. These diseases are progressive in nature and ultimately fatal 
[155]. Each of the dementia subtypes are associated with specific underlying brain 
pathology, with changes in brain structure, function, and chemistry [156]. Importantly, 
people often have brain abnormalities corresponding to more than one type of 
dementia. Post-mortem autopsies have shown that about half of the presumed 
Alzheimer’s disease cases involve additional pathology associated with other 
dementias [156]. Thus, patients with the same diagnosis may differ significantly in 
underlying pathology and also on how this pathology translates to function, behaviour, 
and well-being. Additionally, dementia is under-diagnosed in Norwegian nursing 
homes, likely due to resource limitations and advanced dementia with mixed 
pathologies [125]. As such, studies in nursing homes often include all patients with 
likely dementia. 
Dementia subtypes 
The most common dementia subtypes in old age includes Alzheimers disease, vascular 
dementia, dementia with Lewy-Bodies, frontotemporal dementia, and Parkinsons 
disease dementia [156]. AD is the most common cause of neurodegenerative dementia, 
causing roughly 60% of dementia cases [157]. Alzheimer’s disease is recognized by an 
insidious onset and a gradual progression, with memory and learning impairments as 
typical early symptoms [156]. The aggregation of the proteins amyloid-β and tau in the 
brain into amyloid plaques and neurofibrillary tangles, are the hallmark 
pathophysiological characteristics of Alzheimer’s disease, causing neuronal 
dysfunction, neuronal death, and atrophy (schrinkage) of the brain [158]. Alzheimer’s 
disease neuropathology arises 10-20 years prior to the clinical manifestation of the 
disease. Following initial diagnosis, the average life expectancy of Alzheimer’s 
disease patients range from 3-12 years [159]. 
Vascular dementia is regarded as the second most common subtype of dementia in old 
age, making up approximately 15% of dementia cases [157, 160]. The cognitive 
changes associated with vascular dementia are variable and depend on the location of 
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the vascular pathology in the brain [160]. Vascular dementia may arise from different 
vascular events, such as stroke, small-vessel disease, or multiple cortical infarcts. In 
contrast to Alzheimer’s disease, vascular dementia does not necessarily include 
memory impairment. Rather, it is commonly associated with deficits in information 
processing, attention, and executive functioning due to subcortical pathology [160]. 
Following initial diagnosis, life expectancy of people with vascular dementia is 3-5 
years [159]. Importantly, only 5-10% of people with dementia have vascular damage 
alone, as vascular changes are more common in combination with Alzheimer’s disease 
pathology [161, 162]. 
Dementia with Lewy-Bodies make up 4-5% of dementia cases [163]. It resembles 
Alzheimer’s disease as it is characterized by progressive cognitive impairment, 
however, with early change observed in executive functions and complex attention 
tasks, rather than memory and learning [154]. Lewy-bodies are aggregations of the 
alpha-synuclein protein in neurons, causing dementia with Lewy-bodies when they 
develop in the cortex [156]. 
Frontotemporal dementia accounts for almost 3% of dementia cases among people 
older than 65 [164]. Frontotemporal dementia is a pathologically heterogeneous group 
of dementias that are associated with shrinkage of the frontal and temporal lobes [156]. 
Typical symptoms include behavioural impairments such as apathy and disinhibition, 
resulting in socially inappropriate behaviour and a lack of insight, and/or difficulties 
with language production or comprehension. Cognitive decline often presents itself 
later in the course of the disease, mainly dominated by executive impairment [156]. 
Parkinson’s disease dementia accounts for approximately 3-4% of dementia cases 
[165]. People with Parkinson’s disease may develop dementia as the disease progress, 
on average 8-10 years after an initial diagnosis of Parkinson’s disease. In Parkinson’s 
disease dementia, cognitive decline develop due to pathophysiological processes either 
similar to dementia with Lewy-Bodies or similar to Alzheimer’s disease [156].  
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Behavioural and psychological symptoms of dementia  
The diagnostic criteria for dementia mainly focus on cognitive domains, however, 
dementia is typically also characterized by a range of non-cognitive symptoms. These 
“Behavioural and Psychological Symptoms of Dementia” (BPSD) include depression, 
agitation, anxiety, hallucinations, apathy, and disrupted sleep, among other symptoms 
[5]. Up to 90% of people with dementia develop one or more BPSD during the course 
of their disease [166]. The individual symptoms may have a fluctuating course, and 
very few symptoms are continuously present across time [167]. BPSD are associated 
with high levels of distress for the afflicted person, as well as for informal (family 
members) and formal caregivers (nursing home staff, in-home assistance) [168]. Some 
symptoms may be associated with specific dementias. For example, apathy, 
depression, anxiety, and emotional lability are more common in vascular dementia 
compared to Alzheimer’s disease [169, 170]. Importantly, the clinical presentation of 
BPSD vary substantially both within dementia subtypes and within each individual [5].    
Sleep and circadian rhythm disruption in dementia 
Sleep problems are considered one aspect of BPSD [5]. Many of the brain areas and 
neural systems that are involved in sleep and circadian regulation are affected by the 
pathological brain changes seen in Alzheimer’s disease and other dementias, and are 
often increasingly affected as neurodegeneration progresses [171]. Alzheimer’s 
disease is also associated with pathological changes in the retina and the optic nerve, 
including the loss of ipRGCs [172]. In addition, other ocular changes associated with 
Alzheimer’s disease, such as glaucoma, macular degeneration, pupillary dysfunction, 
and reduction in optical nerve fibre thickness may disrupt circadian regulation [173]. 
Thus, dementia increase the risk of disrupted sleep, beyond the impact of 
environmental influences and somatic conditions. Irregular sleep-wake rhythm 
disorder is common, which is characterized by fragmentation of the sleep-wake 
rhythm, with multiple sleep and wake episodes throughout the day and night [174]. 
Observational studies have demonstrated extremely fragmented sleep among nursing 
home patients with dementia, where patients rarely spent one full hour asleep or awake 
[175, 176]. One recent meta-analysis reported that 70% of nursing home patients with 
dementia had disrupted sleep as measured by actigraphy [4]. Different dementia 
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subtypes are associated with specific underlying neuropathology and consequently 
different patterns of sleep disturbances may occur [177].  
Subtypes of dementia and sleep 
In Alzheimer’s disease, sleep and circadian disturbances often debut early in the 
disease, even prior to the onset of cognitive symptoms, and may contribute to the 
pathogenesis of Alzheimer’s disease [178]. Alzheimer’s disease is characterized by 
severely disturbed sleep at night and excessive napping during the day [7, 179–181]. 
The neurodegeneration in Alzheimer’s disease includes the SCN, and as a 
consequence, there is a general disturbance of all circadian rhythms [182]. The 
daytime EEG pattern is characterized by more slow-wave activity compared to older 
people without dementia [183], and the nocturnal EEG pattern by less SWS [183]. 
Around 25% of people with mild to moderate Alzheimer’s disease and 50% of people 
in moderate to severe stages suffer from disrupted sleep [183, 184].  
In vascular dementia, the frequency of disrupted sleep has been shown to be two times 
the frequency in Alzheimer’s disease [7]. Particularly, vascular dementia is associated 
with a high frequency of sleep disordered [7]. Sleep disturbances are also more 
prevalent in people with Lewy-Body dementia, compared to Alzheimer’s disease, with 
more movement disorders and daytime sleepiness [185, 186]. Up to 80% suffer from 
REM sleep behaviour disorder, where the absence of muscle atonia, which normally 
accompanies REM sleep, results in vocalization and motor activity while dreaming 
[187]. In people with frontotemporal dementia, one study found a fragmented sleep 
pattern that varied considerably across days, but with a general increase in activity 
during the night and lower activity during the morning compared to healthy controls 
[188]. Compared to Alzheimer’s disease, patients with frontotemporal dementia 
develop sleep disturbances even earlier in the course of the disease [189]. Sleep 
problems are highly prevalent in people with Parkinson’s disease, with one study 
showing that 98% experienced sleep problems [190], manifested as a wide range of 
sleep disturbances [191]. Factors such as coughing, cold/heat sensations, and pain, 
which are more common in PD, may contribute to the disturbed sleep [192]. 
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Other factors contributing to disrupted sleep in the nursing home 
Importantly, the aetiology of sleep disturbances among nursing home patients is 
multifactorial and a range of different factors contribute to disrupted sleep beyond 
dementia [193], such as medical conditions, pain [194, 195], and psychiatric 
conditions [144]. Further, multimorbidity is often accompanied by taking multiple 
medications, referred to as polypharmacy, which also increase the risk of sleep 
problems [144]. Polypharmacy is often defined as taking five or more drugs daily 
[196]. Further, sleep problems may be exacerbated by nursing home routines that are 
at odds with recommendations for good sleep hygiene. For example, Norwegian 
studies of nursing homes have found a mean time in bed (bedtime to rise time) of more 
than 12 hours, not including time in bed during the day [197, 198]. Other examples are 
little daytime activity [199], noise during the night [200], and diminished light input 
[14].  
Thus, the risk of developing sleep disturbances is high among nursing home patients, 
due to dementia, multimorbidity, polypharmacy, and poor sleep hygiene [193] 
(summarized in Figure 1).  
 
Figure 1: A schematic overview of factors that may contribute to sleep disturbances in 
nursing home patients. 
Consequences of sleep disturbances 
Importantly, disrupted sleep in people with dementia add to the impairment caused by 
the underlying neuropathology, such as reduced memory and concentration, slowed 
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response time, and increased risk of falls [201]. In severe dementia, the consequences 
of poor sleep, such as impaired cognitive function, agitation, and depressive 
symptoms, may be interpreted as part of the dementia [122], but are more prevalent 
among those with sleep disturbances compared to those without [6–10, 169, 202]. A 
study by Anderson and colleagues found that older people with abnormal sleep-wake 
cycles had over 3 times the risk of death over a two-year period, compared to elderly 
with a normal sleep-wake cycle [8].  
In the community, sleep disruption causes significant distress for the caregiver [203], 
and is an important cause of institutionalization [204]. In the nursing home context, 
sleep disturbances are disruptive for the staff [205]. For example, one study found that 
patients were more likely to be agitated when awakening during the night than during 
the day [206]. In a qualitative study, nursing home staff described patients getting up 
at night, moving around the common areas and into other residents’ rooms [207]. 
Patients may even attempt to leave the nursing home during the night, and make noise 
that disturb other patients. Further, the nursing home staff described how poor 
nocturnal sleep caused the patients to be more agitated the following day. The staff 
experienced it as difficult to care for patients with sleep disturbances, particularly if 
they woke up other residents [207].  
1.5.2 Light conditions in nursing homes  
The lowered sensitivity to light in old age and dementia suggests that they need a 
strong light input during the day to stimulate the circadian system and increase 
alertness. Unfortunately, field studies in nursing homes and in the homes of people 
with dementia have reported low light intensities [14–17, 208]. These studies used 
different standards for indoor illumination. One standard is the European Lighting 
Standard EN 12464-1 [209], which states that areas used for writing, reading, and 
similar activities should have an illuminance of 500 lux, measured horizontally on the 
task surface. This and other standards emphasize visual focus and comfort, but focus 
less on the non-visual effects of light. De Lepeleire et al. [15] added 55% to the EN 
12464-1 standard to account for the decline in light sensitivity associated with 
increasing age, amounting to an illuminance of 775 lux. In their study, they found that 
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the percentage of measurements that met this adapted standard varied considerably 
across nursing homes and across outdoor light conditions (sunny, cloudy, at dusk, and 
during darkness). When it was sunny outside, 20% to 60% of the measurements made 
in eight nursing homes met the adjusted standard, while only 13% of the 
measurements met the adjusted standard during darkness. These findings hints that 
during winter in high-latitude countries such as Norway, with few hours of daylight, 
indoor light availability is poor.  
Sinoo et al. [16] measured light levels in 59 common rooms and corridors. They found 
that 65-96% of the measurements were below the chosen 750 lux reference, varying 
across nursing homes, while the median CCT values varied from 3,300-4,500 K. 
Further, even close to the window, 70% of measurements fell below 750 lux, while 
100% of the measurements fell below this threshold at the back of the rooms. Similar 
findings have been reported by Konis et al. [17]. 
We conducted a field study measuring the light levels in dementia unit common rooms 
in Bergen, Norway [210]. During the winter, measurements at midday did not 
significantly differ from measurements made after dark. The daytime illuminance 
during winter had a median of 125 lux (range 63-185), when measured in the middle 
of the room, vertically at 1,2 m above the floor and facing away from the windows. 
Facing the windows, the median value was 176 lux (range 49-507).  
Some early studies continuously measured light exposure among nursing home 
patients using actigraphs with a light sensor. Ancoli-Israel et al. [18] reported that 
nursing home patients with severe dementia spent less time in >1,000 lux and had a 
lower mean lux exposure during the day compared to those with mild and moderate 
dementia. Forty-seven percent of the patients with severe dementia spent no time in 
illuminations above 1,000 lux. Importantly, this was also the case for 20% of those 
with mild to moderate dementia. Shochat et al. [14] continuously measured light 
exposure and activity in 77 nursing home patients (96% had dementia), and found a 
mean daytime light exposure of 485 lux, and a median light exposure of 52 lux. The 
participants spent a median of 10 minutes in light of above 1,000 lux and a median of 
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2 minutes in more than 2,000 lux. Seventeen percent of the participants were never 
exposed to light levels of more than 1,000 lux across the three days of measurement. 
They also found that higher light exposure was associated with fewer night-time 
awakenings. Mishima et al. [211] reported diminished nocturnal melatonin secretion 
and a low amplitude of the melatonin rhythm among those with low levels of light 
exposure. In home-dwelling seniors with dementia, Figueiro and colleagues [212] 
found lower light exposure and more circadian disruption during the winter months, 
compared to the summer months.  
These findings suggest that insufficient light exposure may represent a factor that 
exacerbates sleep problems in nursing home patients. Thus, reintroducing a strong 
light input during the day, by means of BLT, may ameliorate sleep problems in this 
population.  
1.6 Treatment of sleep problems in nursing home patients 
and people with dementia 
Sleep problems among nursing home patients are frequently treated by 
pharmacological means, using psychotropic drugs such as benzodiazepines, atypical 
antipsychotics, z-hypnotics, sedating antidepressants, melatonin, and antihistamines 
[11, 213–215]. There is generally a lack of evidence regarding the effect of 
pharmacological sleep aids in people with dementia [214, 216]. The evidence for a 
beneficial effect of exogenous melatonin on sleep in Alzheimer’s disease patients is 
equivocal, but no adverse effects have been reported [11, 214]. There is limited 
evidence for the effectiveness of hypnotics on sleep in people with Alzheimer’s 
disease [11], and hypnotics and sedatives are associated with the highest increase in 
fall risk, where the risk increase with higher dosages and in combination with other 
psychotropics [12]. Further, antidepressants may cause nausea, drowsiness, and 
sedation [217], while antipsychotics and atypical antipsychotics are associated with 
severe cardiac side effects [11] and an increased risk of mortality [218]. Patients may 
already use many of these medications when they are admitted to the nursing home, 
and discontinuing them may be challenging.  
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Considering the severe side effects associated with pharmacological treatment of sleep 
disturbances in dementia, the evaluation and implementation of non-pharmacological 
interventions should be prioritized in this population. A range of non-pharmacological 
treatments for sleep problems among nursing home patients exist [219, 219], including 
interventions such as individualized social activities [220] and physical resistance 
strength training [221]. Although such treatments have shown some positive results in 
terms of improved sleep [222], they require a high level of staff involvement and can 
be challenging in terms of implementation [219]. Thus, identifying interventions that 
are feasible and effective in the nursing home context, without the side-effects 
associated with pharmacological treatment, is of great interest. Importantly, the 
essential role of light exposure in regulating sleep may represent an opportunity in this 
regard.  
1.6.1 Bright ligh treatment (BLT) for treating sleep problems in 
dementia 
BLT may be defined as an enhanced indoor electrical light scheme aimed at impacting 
NIF responses including mood, behaviour, sleep, and/or circadian rhythmicity. BLT 
research may be placed in the broader fielt of “daylight research”, encompassing 
research on the effectiveness of daylight and electrical light in promoting general 
health and quality of life [78]. Bright light was initially used to treat Seasonal 
Affective Disorder (SAD), where lengthening the photoperiod by means of daily 
exposure to 2,500 lux for three hours at dusk and at dawn for two weeks, had an 
antidepressant effect on patients [223]. Subsequent research has refined the treatment 
and BLT is today the first-line therapy for SAD [224]. The antidepressant effect is 
thought to be caused by stabilizing the circadian rhythm and/or by increasing synaptic 
serotonin [225]. Several studies have evaluated the effect of BLT on depression and 
agitation in dementia, with mixed results [226]. Due to the impact of light on sleep and 
wakefulness, BLT has also been used to treating sleep disturbances, including sleep 
disturbances in people with dementia [226, 227]. The following section will provide an 
overview of this research.  
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There is no commonly accepted gold standard for the timing, duration, spectral 
composition, illumination, or method of delivery of BLT for treating sleep and/or 
BPSD in people with dementia. The standard practice in treating SAD has been to 
provide daily light exposure of between 2,500 and 10,000 lux white light (around 
4,000 K) for 30 minutes (when using 10,000 lux) and two hours (when using 2,500 
lux), delivered using light boxes [228]. Light boxes are devices that deliver light of 
high illumination, often polychromatic white light.  
Similar approaches have been used with people with dementia, and based on the latest 
systematic search, 11 studies evaluating the effect of BLT on sleep and circadian 
rhythmicity in people with dementia using light boxes were identified [19, 20, 198, 
229–236]. Six of these were Randomized Controlled Trials (RCTs) [19, 20, 229–231, 
233], and are summarized in Table 2. RCTs are considered the gold standard for 
evaluating the effect of interventions [237]. 
Bright light treatment using light boxes 
Ancoli-Israel et al. [229] completed a RCT including 77 nursing home patients with 
dementia. The study compared two BLT conditions, either two hours of 2,500 lux 
white light in the morning (09:30-11:30) or in the evening (17:30-19:30), with a dim 
light control condition. The treatment lasted for 10 days. They found no effects on 
sleep during the night or activity during the day, as measured by actigraphy. In a 
subsequent study using the same protocol but only including people with Alzheimer’s 
disease, the same researchers found an increase in the length of nocturnal sleep bouts 
from baseline to follow-up in the two BLT groups, but not in the dim light group [20]. 
A RCT by Burns and colleagues, including 48 nursing home patients, delivered two 
hours of 10,000 lux from 10:00-12:00 for two weeks [230]. That study found no 
changes in sleep duration, either observed sleep or sleep measured by actigraphy. In 67 
home-dwelling participants with dementia, McCurry et al. [19] found a decrease in 
total wake time at night in the treatment group following two months of evening BLT 
(2,500 lux for 1 hour), compared to a control group. Several smaller pre-post studies 
(comparing the same patients before and after treatment, also called open clinical 
trials) have reported improved sleep following BLT using light boxes [198, 231–234, 
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236]. One Norwegian study found improvements on several sleep outcomes measured 
by actigraphy from baseline to follow-up after two weeks of 6,000-8,000 lux in the 
morning [238]. The improvement in sleep efficiency lasted for four weeks after 
treatment termination and the decrease in sleep onset latency lasted for 12 weeks. 
Thus, there are some indications that BLT using light boxes may cause improvements 
in sleep among people with dementia, as shown in RCTs [19, 20] and pre-post studies 
[198, 231–234, 236], some even long-lasting [238].  
Bright light treatment using ambient light 
Using light boxes may however not be feasible in the context of dementia. Dementia 
patients may not adhere to the treatment protocol unless they are reminded or 
motivated to stay in front of the light box and face the light. As a consequence, studies 
using light boxes have had staff accompanying the patients during BLT to ensure 
adherence [198, 230–233], which is time consuming for the staff. Additionally, it is 
possible that the increased staff presence (i.e., increased social contact) may have 
impacted the results. Therefore, BLT using ambient ceiling-mounted light, where the 
light condition in entire areas or rooms can be manipulated, may represent a more 
feasible treatment option, which also may increase the internal validity of studies. This 
approach has been used in studied of shift work [239, 240]. Ambient room 
illumination allows for people to be exposed to bright light while engaging in their 
normal activities. This approach has been increasingly utilized in studies on the effect 
of BLT in dementia, enabled by a rapid development of light emitting diode (LED) 
technology [241]. These advances have also allowed for the manipulation of the 
spectral composition of light [242]. Thus, several of the more recent studies have used 
light with high CCT and a more modest lux compared to light boxes, and with low 
CCT and illumination during the evening. 
Using a systematic search, twelve studies that used ambient light were identified [106, 
243–253], where three were RCTs [244, 247, 252] (Table 2). In the randomized cross-
over study (all patients receive both the intervention and the control) by Sloane et al. 
[244], including 17 home-dwelling people with dementia, they evaluated the effect of 
six weeks of ambient light of 13,000 K and 400 lux on sleep. The treatment was 
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compared to a low-CCT placebo condition of 2,700 K and 400 lux. In addition to the 
ambient light, participants had a light box delivering monochromatic blue light of 470 
nm in the high-CCT condition and red light of 638nm in the low-CCT condition. The 
two conditions were separated by a four-week wash-out. Sleep efficiency measured 
using a sleep scale improved during treatment compared to standard light, but not 
compared to the control low-CCT condition. There was no effect on daytime 
sleepiness or on sleep or circadian rhythmicity measured by actigraphy. In another 
randomized cross-over study, Figueiro et al. [252] evaluated the effect of a tailored 
light intervention in 47 nursing home patients with dementia. The intervention 
comprised floor luminaires, light boxes, and light tables, each providing between 350-
750 lux and 5,000-7,000 K, all day (until 18:00) for four weeks. The placebo condition 
administered low illumination and CCT using the same equipment. Proxy-rated sleep, 
and also intradaily variability (circadian rhythm fragmentation) improved from 
baseline to follow-up in the intervention condition compared to the placebo condition.  
Table 2: An overview of RCTs assessing the effect of bright light treatment in dementia 









10 days, 2 hours in the 
morning (09:30-11:30) or 
evening (17:30-19:30).  
Light box delivering 2,500 
lux. Control dim red light.  
No significant change in sleep or 
activity parameters (actigraphy). 
Within-group increase in mean activity 
level (mesor) and a delay of acrophase 








10 days, 2 hours in the 
morning (09:30-11:30) or 
evening (17:30-19:30).  
Light box delivering 2,500 
lux. Control dim red light.  
There was a within-group increase in 
the duration of the longest sleep bouts, 
as measured by actigraphy. Mean wake 
bout length decreased from end of 
treatment to post treatment in the 
evening treatment group. Other 
actigraphy sleep outcomes ns. 
Rhythmicity improved in the evening 
treatment group. Other circadian 








Two weeks, 2 hours in the 
morning (10:00-12:00).  
Light box delivering 10,000 
lux. Control dim light.  
No effect on sleep duration measured 
by actigraphs or by nurses. At follow 
up, the BLT group had lower mean 









Four weeks, 10-12 hours 
(from between 06:00-08:00 
to 18:00). Floot luminaires 
(6,000 lux and 5,000 K or 
550 lux and 7,000 K), light 
box (350 lux and 6,000 K) 
and light table (750 lux and 
5,000 K) 
Proxy-rated sleep (PSQI) improved and 
intradaily variability (actigraphy) 
reduced (improved) from baseline to 
follow-up compared to the control 








10 days, 2 hours in the 
afternoon/evening (17:00-
19:00). Light box delivering 
3,000 lux. Control dim 
light.  
The intervention induced a phase delay 









Four weeks, 1 hour in the 
morning (unknown time).  
Light box delivering 10,000 
lux. Control low-frequency 
blinking light.  
There was a within-group increase in 
sleep time at night. Between-groups ns.   
McCurry 





Two months, 1 hour before 
bedtime.  
Light box delivering 2,500 
lux. Control care as usual. 
Total wake time at night decreased at 
follow-up compared to the control 






AD and VD.  
Two weeks, 2 hours in the 
morning (09:00-11:00). A 
set-up of light bulbs around 
the patients face delivering 
5,000-8,000 lux. Control 
dim light.  
There was a decrease in night-time 
activity in the VD group during BLT 
compared to dim light. Total activity 






Six weeks, all-day light 
(wake-up until 18:00).  
Proxy-rated sleep sleep efficiency 
(PSQI) improved after the intervention 




Ambient light delivering 
13,000 K and 400 lux, and 
also a LED light box 
delivering blue light. 
Control 2,700 K and 400 
lux (ambient), and a light 
box delivering red light.   
compared to placebo. There was no 
effect on sleep or circadian rhythmicity 









4 days, all-day light (08:00-
18:00).  
Ceiling-mounted above a 
table delivering a maximum 
of 12,500 K and 400-500 
lux. Control light of 2,700 
K and 400-500 lux.  
No change in tympanic 
temperature/circadian rhythm.  
Note: For a more detailed overview of the populations, interventions, study procedures, and results, 
see Paper 1.  
AD= Alzheimer’s Disease, K= Kelvin, LED= Light Emitting Diode, NH= Nursing home, ns= not 
significant, PSQI= Pittsburgh Sleep Quality Index, RCT= Randomized Controlled Trial, SDI= Sleep 
Disorder Inventory, VD= Vascular Dementia. 
*RCT with cross-over  
Three meta-analyses have summarized the results of BLT studies including people 
with dementia [226, 227]. One Cochrane meta-analysis from 2014 including 13 RCTs 
concluded that “there is insufficient evidence to justify the use of bright light therapy 
in dementia” [226, p. 2]. Van Maanen et al. [227] conducted a meta-analysis of BLT 
for a range of sleep disorders, of which eleven RCTs and open clinical trials studied 
people with dementia. They reported a significant positive effect of BLT on sleep 
problems in people with dementia, specifically for objectively measured sleep onset 
latency, total sleep time, time in bed, sleep efficiency, and for sleep quality evaluated 
by questionnaires. Circadian outcomes (melatonin or core body temperature), bedtime 
and wake-time, and sleepiness/alertness had been examined by too few studies to do 
analyses on these outcomes. Non-significant effects were found for wake-after-sleep-
onset and early morning awakenings [227]. Chiu et al. [255] included six RCTs 
assessing the effect on sleep and found an effect on total sleep time at night. 
Importanly, these meta-analyses also included studies using daylight and dawn-dusk 
simulation, in addition to electric light. 
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In summary, previous studies evaluating the effect of BLT on sleep in dementia 
populations show promising, albeit mixed effects. Importantly, previous studies vary 
in terms of intervention strategies, using different methods of delivering light (light 
box, ambient light), light values (lux, CCT), duration of daily exposure, and duration 
of treatment. Few RCTs have been completed, and most studies have few participants 
and short treatment durations (days or weeks). In general, open clinical trials tend to 
find favourable results, while controlled studies (comparing the intervention group to a 
control group not receiving the intervention) are less consistent. Thus, there is a need 
for more high-quality studies, i.e., RCTs including more participants and with a longer 
duration of treatment.  
1.7 Challenges in studying the effect of light in nursing 
home patients with dementia 
Studying the effect of BLT in nursing home patients with dementia entails some 
specific challenges.  
1.7.1 Measuring light 
Illumination levels vary significantly depending on the direction of measurement [246, 
247, 256]. When measuring light received by a ceiling-mounted light source, the 
highest light values are obtained when measuring light horizontally, e.g., the amount 
of light hitting a horizontal surface. Another approach is to measure light positioning 
the photometer vertically, which more closely reflects the amount of light entering the 
eye [91, 256] (Figure 2).  
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Figure 2: A schematic figure of vertical vs horizontal measurements using a photometer. 
Approximate lux values based on van Hoof et al. [246]. 
The rapid technological and theoretical developments of the field of BLT research 
means that no established standard for measuring and reporting light characteristics are 
consistently used by researchers. Previous studies vary in terms of the level of detail 
regarding light measurement, complicating the interpretation and comparison of 
results.  
1.7.2 Estimating light exposure 
Securing adherence to treatment is challenging when including people with dementia. 
When using light boxes, staff have to motivate patients to sit in front of the box, 
preventing them from wandering off or turning away from the light source. Using 
ceiling-mounted light, and thus providing BLT in entire rooms, reduces the need for 
supervision. However, measuring the exact amount of light received by each patient is 
challenging. Some studies have estimated light exposure based on data from wrist-
worn devices [e.g., 249, 257]. While such devices may provide continuous data on 
light exposure, light levels at the wrist may deviate significantly from light exposure at 
eye level [258]. Also, the device may be covered by clothing or blankets during the 
day. Some studies have used a light meter (Daysimeter) worn as a pendant [248, 252, 
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253]. This also requires that the device is not covered by clothes or blanckets, and may 
not be tolerated by people with severe dementia. Other researchers have estimated 
light exposure by averaging light measurements at eye level made in intervals during 
treatment [246, 247]. While this approach may produce more accurate estimates of 
actual light exposure, it requires the presence of research staff to do the measurements 
and it may represent a disturbance in the nursing home environment. Another 
approach is to measure light at predetermined locations frequently occupied by 
residents. While this represents a systematic way of measuring light levels, a range of 
factors may impact the exact amount of light each participant is exposed to, such as the 
time spent in the BLT room, head position, and if their eyes are closed or open. The 
latter is a problem regardless of how light exposure is measured.  
1.7.3 Assessing sleep in the nursing home and in people with 
dementia  
Although disrupted sleep is common among nursing home patients, no optimal tool to 
assess sleep in this population exists to date. Measuring sleep in people with dementia 
by PSG is often not feasible, as it entails multiple electrodes and wires, which may not 
be tolerated by people with dementia [11, 259]. Further, it may be difficult to 
distinguish between wake and sleep, as the EEG pattern during wakefulness has been 
observed to contain slow EEG activity in this population [260, 261]. Another objective 
sleep measurement is activity-monitors, such as actigraphs. Actigraphs are small 
accelerometers, commonly worn on the wrist, that measure activity over days or weeks 
[20]. These are frequently used in dementia populations as they are non-intrusive and 
generally well tolerated. Actigraphs have an agreement rate with PSG of 72-97% (i.e., 
the percentage of observations scored identically by PSG and actigrapy), with a 
sensitivity of 87-99% (accurate detection of sleep) and a specificity of 28-67% 
(accurate detection of wake) [262]. Poor wake detection means that actigraphy may 
overestimate sleep. Further, the accuracy of actigraphy has been shown to decline with 
lower sleep efficiencies [263].  
Sleep diaries and self-report questionnaires are important clinical tools in sleep 
research, however, they may be unfeasible and unreliable in the context of dementia. 
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People with dementia, particularly those with severe dementia, have significantly 
impaired abilities to communicate and may not remember how they slept. Thus, proxy-
rated questionnaires, completed either by a cohabiting relative or by nursing home 
staff, are widely used in the clinical context [4]. A major challenge with proxy-rated 
questionnaires is that they might not be sensitive enough to detect sleep problems, 
especially when the rater does not share bed with the person with dementia. For 
example, one recent meta-analysis reported a pooled prevalence of sleep disturbances 
of 70% among institutionalized dementia patients when sleep was measured by 
actigraphy, while the prevalence was 20% when sleep was assessed using validated 
questionnaires [4]. Hoekert et al. [264] found that compared to actigraphy, nursing 
staff overestimated sleep time by an average of 1.5 hours. Blytt et al. [197] found that 
proxy-raters underreported sleep disturbances using sleep items from two commonly 
used BPSD assessment scales, as compared to actigraphy. One possible reason for the 
discrepancy between proxy-rated and actigraphy-assessed sleep, is that nursing home 
staff may not observe that someone is awake during the night. Conversely, validated 
questionnaires may provide important clinical information that is not registered by 
actigraphy, such as snoring or the impact of the disturbances on daytime function, on 
carers, or other residents [4]. 
Importantly, few sleep scales have been validated for people with dementia and for the 
nursing home context specifically [4]. Considering the negative impact of disrupted 
sleep, identifying a reliable and easy-to-administer sleep scale for the use in the 
nursing home context would be of great clinical value.  
1.7.4 Ethical challenges 
Some unique ethical dilemmas and consequences need to be considered in depth when 
planning to include people with dementia in research. People with dementia may not 
have the capacity to provide informed consent to participate due to diminished 
decision-making capacity [134]. Informed consent means that a potential participant 
provide voluntary consent after being informed about the study and about their right to 
refuse participation or to withdraw at any time, as stated in the Declaration of 
Helsinki: Ethical Principles for Medical Research Involving Human Subjects [265]. 
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Assessing decision-making capacity generally involves the assessment of four 
abilities: i) the ability to communicate a choice of participation, ii) the ability to 
understand relevant information, iii) the ability to appreciate the medical consequences 
of their choice, and iv) the ability to reason about choices [266]. A diagnosis of 
dementia should not, however, necessarily be presumed to indicate a lack of capacity 
to provide informed consent. Some may retain the capacity to provide informed 
consent for participation in a study, however, many may not, particularly in the later 
stages [267]. In order to improve dementia care and prevention, it may in many cases 
be necessary to include them in clinical trials. The effect of BLT on sleep in healthy 
adults and older people, for example, may not translate to people with dementia, due to 
dementia-related neuropathology [171]. When a potential participant is deemed not to 
have the capacity to provide informed consent, a legal guardian may provide presumed 
consent to participate on behalf of the patient [265], by asking them to consider what 
the person in question would have wanted. To respect the autonomy and dignity of the 
patient, researchers should additionally aim to adapt the information about the study, 
convey this, and seek consent from the individual with dementia [268]. Interventions 
that improve medical, behavioural, or psychological symptoms could have a 
significant impact on the quality of life of nursing home patients and on the burden of 
care taken on by family and nursing home staff.  
1.8 Rationale for this thesis 
Based on the evidence, as summarized above, the DEM.LIGHT trial and this thesis 
were based on the following: 
i) Sleep disruption is common among nursing home patients with dementia, and 
detecting and treating disrupted sleep should be a priority in the nursing home 
setting. 
ii) There is a need for easy-to-administer scales that can reliably identify sleep 
problems in nursing home patients with dementia.  
iii) Light exposure during the day is inherently important for optimal human 
functioning, including sleep-wake behaviour. 
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iv) Most nursing homes provide insufficient light exposure to sustain stable 
circadian rhythms, promote alertness during the day, and consolidate sleep 
during the night. Thus, sleep problems seen in dementia are hypothesized to, in 
part, be caused or exacerbated by the lack of a robust light input during the day.  
v) Reintroducing a robust photic zeitgeber during the day by means of ceiling-




2. Aims  
The overall aim of this thesis was to investigate whether BLT can improve sleep in 
nursing home patients with dementia. This entailed: i) an investigation of previous 
studies of BLT in dementia, highlighting methodological issues in the field (Paper 1), 
ii) an assessment of the validity of a proxy-rated sleep scale for use in nursing home 
patients with dementia (Paper 2), and finally, iii) an evaluation of the efficacy of a 
BLT intervention on sleep in nursing home patients with dementia (Paper 3).  
The aim of Paper 1 was to synthesize previous research on BLT in people with 
dementia in a systematic review of the literature. The aim was to provide a detailed 
overview of the research field, including non-RCT studies. The paper focused on the 
differences between studies in terms of population characteristics, intervention 
strategies (delivery method, timing, duration, light levels), study designs, and outcome 
measures, and aimed to explore how these differences might have influenced study 
results.  
The aim of Paper 2 was to validate the proxy-rated Sleep Disorder Inventory (SDI), a 
short-form questionnaire exclusively measuring sleep, against actigraphy.  
The aim of Paper 3 was to evaluate the effects of a ceiling-mounted dynamic ambient 
BLT solution on sleep in nursing home patients with dementia by means of a cluster-
randomized placebo-controlled trial, controlling for known confounding variables.  
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3. Methods 
Paper 1 was based on a systematic search of the literature (PROSPERO 
CRD42017051004). Paper 2 and 3 used data from the DEM.LIGHT trial (Therapy 
Light Rooms for Nursing Home Patients with Dementia – Designing Diurnal 
Conditions for Improved Sleep, Mood, and Behavioural Problems, ClinicalTrials.gov 
Identifier: NCT03357328). The trial was approved by the Regional Committee for 
Medical and Health Research Ethics South East Norway (REC 2016/2246).  
As the main study of this thesis was the DEM.LIGHT trial, the following section will 
present the methods of this trial, followed by the methods specific to each of the 
papers 1, 2, and 3.   
3.1 The DEM.LIGHT trial 
3.1.1 Design 
Paper 2 and 3 were based on the dataset from the DEM.LIGHT trial, which was a 24-
week cluster-randomized placebo-controlled trial. Data were collected at baseline and 
at follow-up at week 8, 16, and 24. The trial included eight nursing home units that 
constituted one cluster each.  
3.1.2 Participants and setting 
The DEM.LIGHT trial took place in Bergen, Norway between September 2017 and 
April 2018. Bergen municipality has 284,208 inhabitants (1st quarter, 2020, [269]), and 
the nursing homes are located across the city, suburbs, and more rural areas. In 
preparation of the study, the principal investigator had meetings with the Department 
of Health and Care, City of Bergen and the municipal agency for elderly and nursing 
homes, and presented the DEM.LIGHT trial on several occasions to the managers of 
the nursing homes in Bergen. The municipal agency provided a list of 14 eligible 
nursing homes (had a designated dementia unit, did not participate in other trials or 
quality of care projects), and the managers of these nursing homes were contacted 
directly by the research team via e-mail. The managers that were interested in 
participating in the study provided a candidate unit, and the researchers (Eirin Kolberg, 
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EK and Gunnhild Johnsen Hjetland, GJH) made on-site visits. A short presentation 
was given to the management, and staff and we assessed whether it was possible to 
install new light fixtures in the ceiling of the common room. When we had achieved 
the required number of nursing home units, we did not invite more units. One 
dementia unit had twice as many patients as the other units, and was excluded. Four 
units declined to participate, and one unit signalled their interest after we had finished 
recruitment. The eight recruited units were located in nursing homes in diverse 
locations (near the city centre or more rural areas) of different sizes (small and large 
nursing homes), and were located in old and new buildings. 
One of the units was included about six months before the study commenced. The 
intervention was piloted for four weeks and adapted in collaboration with the staff to 
optimize the intervention strategy. Following this, the LED light sources were 
programmed to deliver standard light for two months until the study started. In the 
remaining nursing home units in the intervention group, the LED units were installed 
during the months prior to baseline data collection. Until the baseline data collection 
was completed, the light was set to standard light levels of approximately 100 lux 
(measured vertically in the middle of the room 1,2 m above the floor) and 3,000 K 
during the day.   
When the units were included, we discussed the inclusion and exclusion criteria with 
the resident physician (see Table 3). The aim of the DEM.LIGHT trial was to assess 
the effect of BLT in nursing home patients with dementia. Although sleep and 
circadian rhythmicity were the primary outcomes, important secondary outcomes were 
BPSD and function. Therefore, we used wide inclusion criteria, where participants had 
to have either disrupted sleep, circadian disturbances, clinically significant BPSD, or 




Table 3: The inclusion and exclusion criteria of the DEM.LIGHT trial 
ADL=Activities of Daily Living, BPSD=Behavioural and Psychological Symptoms of Dementia, 
DSM-5=Diagnostic and Statistical Manual of Mental Disorders-5, NPI-NH=Neuropsychiatric 
Inventory-Nursing Home Version. 
GJH and EK performed the data collection while in continuous contact with the 
research group.  
3.1.3 The intervention 
The intervention consisted of a light-emitting diode (LED) ceiling-mounted bright 
light solution that was installed in the common rooms of four intervention units. The 
light setup was delivered by Glamox, using a number of square LED units (Glamox, 1 
x C95 48 CCT 6,500 K MP 47 W / 4,702 lm). Glamox engineers calculated the 
number of LED-units needed to provide the target light levels in each common room, 
accounting for the number and direction of windows. The LED units were 
programmed to provide 400 lux and 3,000 K (measured vertically) from 07:00-10:00, 
1,000 lux and 6,000 K from 10:00 to 15:00, 400 lux and 3,000 K from 15:00-18:00, 
and 100 lux and 2,500 K from 18:00-21:00 (Figure 3). Light values gradually changed 
across 30 minutes. Figure 4 illustrates the contrast between standard light levels and 
light of 6,000 K.  
Participants were eligible if they: Patients were not included in the study if they: 
- were ≥60 years and in long-term care (>4 
weeks) 
- had dementia in accordance with DSM-5  
- had either sleep/circadian rhythm 
disturbances, BPSD as identified by NPI-
NH, or severely reduced ADL function 
- provided written informed consent if the 
participant had capacity or, if not, a written 
proxy informed consent from a legally 
authorized representative  
- were blind or might otherwise not benefit from 
light 
- took part in another trial 
- had a condition contra-indicated to the 
intervention  
- had an advanced, severe medical disease/disorder 
and/or expected survival less of than 6 months or 
other aspects that could interfere with 
participation 
- were psychotic or had a severe mental disorder  
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Figure 3: An illustration of the intervention light sequence. The light changed gradually 
across 30 minutes between each condition. The staff at each unit could choose if they wanted 
to maintain the light at 100 lux and 2,500 K through the night or if they wanted it to turn off.  
 
Figure 4: An illustration of the contrast between the spectral composition of standard light 
(left, 3,000 K) and the spectral composition used in the intervention (right, 6,000 K). The 
photos show one of the units in the intervention group. Source: Photos provided by Glamox, 
reprinted with permission. 
Following the installation of the LED units and activation of the light sequence, we 
measured light levels in all eight units, using the GL Spectis 1.0 T Flicker 
spectrometer (GL Optic). Measurements were made at predetermined locations 
vertically 1,2 m above the floor. Illumination, CCT, and equivalent melanopic 
illuminance were calculated using the Lucas et al. 2014 toolbox [90]. Unfortunately, 
the maximum light level was too low in one of the units (mean 722 lux, range 641-
796; 5,641 K, range 5,478-5,723), however, still substantially higher than the control 
units (see Table S1 in Paper 3). The LED units were installed prior to the start of the 
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study and light levels were maintained at standard levels so that staff and participants 
could get used to the new light fittings. The intervention light sequence was switched 
on immediately following the baseline data collection. The control panel for the light 
was locked with a personal identification number only known to the researchers. The 
contact information of the researchers (GJH and EK) was provided in case of any 
problems with the light setup. 
3.1.4 The placebo condition 
The placebo control condition was created by replacing the light sources of the 
existing light fittings in all control common rooms with conventional light sources of 
3,000 K (CFL AURA UNIQUE-D/E LL 18W/830 G241-2 in three common rooms 
and CFL AURA UNIQUE-L LL 18W/830 2G11 in one). Light sources were replaced 
immediately following the baseline data collection. 
3.1.5 Estimating time spent in the common room 
At week 8, 16, and 24, we estimated when, and how long, each participant had been 
present in the common room (where the intervention/placebo was installed) during the 
preceding eight weeks. This was measured by means of a short questionnaire 
completed by the nursing staff. They were asked to estimate the approximate time the 
patient had spent in the living room in different epochs of the day during the preceding 
eight weeks. The epochs corresponded to the light cycle, so that the day was split into 
time epochs of 07:00-10:00, 10:00-15:00, 15:00-18:00, and “after 18:00”. The staff 
provided a time estimate for each epoch in hours and minutes. They were also 
instructed to report the number of days when the patient was not present in the 
common room, and that these days should not be included in the above-mentioned 
estimate.  
3.1.6 Assessments used in DEM.LIGHT 
The primary outcomes were sleep and circadian rhythmicity measured by actigraphy 
and a proxy-rated sleep scale. The secondary outcomes were neuropsychiatric 
symptoms, activities of daily living, quality of life, pain, cognitive impairment, clinical 
impression of change, and care demand. The patients received a thorough medical and 
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psychological examination and testing. Not all measurements were used in this thesis. 
See Table 4 for a complete overview of the assessment tools used in the DEM.LIGHT 
trial.  
Table 4: Assessment tools used in the DEM.LIGHT trial and how they are used in paper 2 
and 3. 
Assessment tool What the tool 
measures 
Characteristics How the instrument was used 
in this thesis 
Sleep assessments 
Actigraphy†: SE The percentage 
of time spent 
asleep in the rest 
interval  
The percentage of time spent 
asleep in the rest interval from 
22:00 to 06:00. Mean across a 
minimum of five days. 
Paper 2: Outcome. 
Paper 3: Outcome and baseline 
correlation. 
Actigraphy†: WASO Time spent 
awake after sleep 
onset 
The time (in minutes) spent 
awake after sleep onset. Mean 
across a minimum of five days. 
Paper 2: Outcome. 
Paper 3: Outcome and 
correlation analysis at 
baseline. 
Actigraphy†: TST in 
the rest interval 
Sleep duration 
during the night 
The time (in minutes) spent 
asleep in the rest interval. Mean 
across a minimum of five days. 
Paper 2: Outcome. 
Paper 3: Outcome. 
Actigraphy†: TST 24h The amount of 
sleep across 24 
hours 
The time (in minutes) spent 
asleep across 24 hours. Mean 
across a minimum of five days. 
Paper 2: Not used. 
Paper 3: Outcome and 
correlation analysis at 
baseline. 
Actigraphy†: TST in 
the daytime interval 
The amount of 
sleep during the 
day 
The time (in minutes) spent 
asleep during the day interval 
from 10:00 to 18:00. Mean 
across a minimum of five days. 
Paper 2: Not used. 
Paper 3: Outcome and 




A measure of 
sleep 
fragmentation 
across 24 hours 
A higher number represents a 
more severe fragmentation of 
the sleep-wake rhythm. Mean 
across a minimum of five days. 
Paper 2: Outcome. 
Paper 3: Not used. 
SDI*† [203] Sleep-wake 
behaviour 
Assesses seven sleep-related 
behaviours observed the 
preceding two weeks. A higher 
score (range 0-84) indicates 
poorer sleep.  
Paper 2: Outcome. 
Paper 3: Outcome and 




ADL*† [270] Activities of 
daily living 
Assesses the patient’s ability to 
perform six activities. A higher 
score (range 0-30) indicate 
poorer function.  
Paper 2: Not used. 
Paper 3: Patient characteristic 
at baseline and a potential 
covariate. 
CCI*† [271] Comorbid 
burden 
Seventeen comorbidities are 
weighted with a score from 1-6. 
A higher score indicates a higher 
comorbid burden.  
Paper 2: Patient characteristic 
at baseline. 
Paper 3: Patient characteristic 
at baseline, correlation 
analysis at baseline, and a 
potential covariate. 
CMAI*† [272] Agitation Assesses 29 behaviours. A 
higher score (range 29-203) 
indicate more agitation.  
Outcome in the DEM.LIGHT 
trial not used in this thesis. 
 
CSDD*† [273, 274] Depression Assesses 19 symptoms of 
depression. A higher score 
(range 0-38) indicate more 
depressive symptoms. 
Outcome in the DEM.LIGHT 
trial not used in this thesis. 
FAST*† [275] Severity of 
dementia 
Assesses the severity of 
dementia, rated in seven stages.  
Paper 2: Patient characteristic 
at baseline. 
Paper 3: Patient characteristic 
at baseline, correlation 
analysis at baseline, and a 
potential covariate. 
MMSE† [276] Cognitive 
impairment 
Assesses the level of cognitive 
impairment using 30 items. A 
lower score (range 0-30) 
indicates more severe 
impairment.  
Paper 2: Patient characteristic 
at baseline. 
Paper 3: Patient characteristic 
at baseline, correlation 




Pain in people 
with severe 
dementia 
Pain is scored according to the 
patient’s pain behaviour during 
standardized, guided movements 
and according to observed pain 
behaviours prior to assessment 
Outcome in the DEM.LIGHT 
trial not used in this thesis. 
NPI-NH*† [279, 280]  BPSD Assesses twelve symptoms 
observed in the preceding four 
weeks. A higher score (range 0-
144) indicates more severe 
symptoms. 
Paper 2: Patient characteristic 
at baseline. Sleep item used as 
outcome.  








A measure of circadian phase 
using core body temperature 
across 24 hours. An ingestible 
capsule measures temperature in 
1-minute intervals.  
Outcome in the DEM.LIGHT 
trial not used in this thesis. 
QUALID*† [282] Quality of life in 
late-stage 
dementia 
Assesses 11 observable 
behaviours and emotional 
expressions. A lower score 
(range 11-55) indicate a higher 
quality of life.   
Outcome in the DEM.LIGHT 
trial not used in this thesis. 
*Proxy rated instrument, † Validated for use in people with dementia.  
ADL= Activities of daily living, CCI= Charlson Comorbidity Index, CMAI= Cohen-Mansfield Agitation 
Inventory, CSDD= Cornell Scale of Depression in Dementia, FAST= Functional Assessment Staging, MMSE= 
Mini Mental Status Examination, MOBID-2= Mobilization-Observation-Behaviour-Intensity-Dementia-2, NPI-
NH= Neuropsychiatric Inventory- Nursing Home version, QUALID= Quality of Life in late-Stage Dementia 
Scale, SDI= Sleep Disorder Inventory, SE= sleep efficiency, TST= total sleep time, WASO= wake after sleep 
onset. 
In the following, the assessment tools used in this thesis are described.   
Sleep outcomes 
Actigraphy 
The Actiwatch II (Philips Respironics) was used for actigraphy measurement. In 
accordance with previous studies in this population [197, 283, 284], the actigraphs 
were placed on the dominant wrist. The staff were informed about the purpose of the 
actigraphs so that they could inform the patient if they had any questions while we 
were not present. The staff were instructed to help patients remove the actigraph if 
necessary (if a patient gave any sign of wanting to remove the device). 
The epoch length was set to 1 minute, and each epoch was scored as sleep or wake by 
the Actiware 6.0.9 (Philips Respironics) software. The threshold for wakefulness was 
set to medium. Epochs were scored based on the activity count of the epoch in 
question, in addition to the two preceding and to following epochs (Figure 5). The 
epoch was scored as sleep if the sum of the activity counts of these five epochs 
(weighted by .04 for the most distant epochs and .20 for the closest epochs) was at or 
below a threshold (medium= 40).  
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Figure 5: An epoch is scored as sleep if the sum of the activity counts are at or below the 
threshold. The activity counts of the epochs preceding and following the epoch is weighted 
by 1/25 or 1/5. Figure adapted from the Actiware user manual.  
Actiware requires the definition of a rest interval from where to estimate periods of 
sleep. In accordance with previous studies, the rest interval was set from 22:00 to 
06:00 [9, 18, 229, 284]. Relevant only to Paper 3, a fixed interval was also set for 
daytime, from 10:00 to 18:00, in line with another study on dementia [180]. Sleep 
intervals were automatically set by Actiware within the rest interval. After the start of 
each rest interval, the start of each sleep interval (sleep onset) was set to the first epoch 
of ten subsequent epochs (1 epoch=1 minute) where all except one epoch were scored 
as sleep. Before the end of each rest interval, the end of each sleep interval was set to 
the last epoch of ten subsequent epochs where all except one epoch were scored as 
sleep.  
The participants wore the actigraphs for seven days, with five nights as a required 
minimum to be included in the analyses. All actigraphy outcomes represent means 
across a minimum of five nights. In Paper 2, we used actigraphy as the reference 
against which a sleep scale was validated. In Paper 3, actigraphy was used as a 
primary outcome.  
Sleep Disorder Inventory (SDI) 
In addition to actigraphy, sleep was assessed by the staff. Because people with 
cognitive impairment may be unable to provide estimates of their own sleep or may 
provide unreliable estimates [181], nursing home staff served as proxy-raters, 
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assessing the patients’ sleep using the SDI [203]. Few proxy-rater tools for people with 
dementia exist, and the SDI was chosen because it is relatively short and 
straightforward. The SDI was developed and validated for the use in people with 
dementia living at home, using in-living relatives as proxy-raters [203]. The scale was 
adapted to the nursing home context and translated to Norwegian for the purpose of 
the DEM.LIGHT trial. 
The SDI evaluates sleep-related behaviour during the two weeks preceding test 
administration [203]. The SDI is based on the sleep item of the Neuropsychiatric 
Inventory (NPI) [279], which evaluates the frequency, severity, and caregiver distress 
of several BPSDs, including disturbed sleep. Each item of the NPI is elaborated with 
subquestions, and the SDI was developed by assigning a frequency (0-4), severity (0-
3), and caregiver distress (0-5) score to each subquestion of the NPI sleep item [203].  
In Paper 2, the SDI was validated against actigraphy. In Paper 3, the SDI was used as a 
primary outcome.  
Other outcomes 
Activities of Daily Living (ADL) 
To assess ADL, the instrument by Lawton and Brody was used [270]. This scale 
includes six items. The total score ranges from 0-30, where a lower value indicates 
better functioning and independence. In Paper 3, the ADL was used as a baseline 
patient characteristic and as a potential covariate. 
Charlson Comorbidity Index (CCI) 
The CCI [271] is a measure of comorbid burden, where 17 comorbidities are weighted 
with a score ranging from 1-6. A higher score indicates a higher risk of mortality and a 
total score of ≥5 has been associated with a 1-year mortality of 85% (63). The CCI 
was used as a baseline patient characteristic in Paper 2 and 3, and also as a potential 
covariate in Paper 3.  
Functional Assessment Staging (FAST) 
The FAST [275] is a measure of the severity of dementia, rated in seven stages. 
Patients receiving a score of 1-2 are considered to have normal cognition, 3 indicates 
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mild dementia, 4-5 moderate dementia, and 6-7 severe dementia. The FAST has 
documented good validity and reliability [275]. FAST was used as one of the measures 
for potential dementia while screening patients for the DEM.LIGHT trial, as a baseline 
patient characteristic in Paper 2 and Paper 3, and also as a potential covariate in Paper 
3.  
Medical records 
The research team had permission to extract data from a centralized journal system 
used in all nursing homes in Bergen. To limit the workload on the nursing home staff, 
information about blood pressure, heart rate, height, weight, registered diagnoses, and 
medications was extracted from the patients’ medical records prior to each visit. The 
total number of medications, number of psychotropic medications (all drugs coded as 
N in the ATC system), and the number of sedatives (N05C drugs, including z-
hypnotics) were used as baseline patient characteristics in Paper 2 and Paper 3, and the 
number of psychotropic medications was used as a potential covariate in Paper 3.  
Mini Mental Stage Examination (MMSE) 
The MMSE assesses the level of cognitive impairment [276]. The total score ranges 
from 0-30, where a low score indicates worse cognitive function [276]. The MMSE 
was used as one of the measures for potential dementia while screening patients for the 
DEM.LIGHT trial, and as a baseline patient characteristic in Paper 2 and Paper 3, and 
also as a potential covariate in Paper 3. 
Neuropsychiatric Inventory – Nursing Home Version (NPI-NH) 
The NPI-NH [279, 280] is a proxy-rated tool that assesses BPSD by assigning 
frequency and severity ratings to 12 symptoms (delusion, hallucination, agitation, 
depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor 
behaviour, night-time behaviour, and eating disturbance). The NPI-NH was used as a 
baseline patient characteristic in both Paper 2 and Paper 3. In Paper 2, the sleep item of 
the NPI-NH was used to assess the convergent validity of the SDI.   
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3.1.7 Data collection procedure 
On each unit, we established contact with one or two nurses, and scheduled our visits 
with them. All questionniares were completed by daytime staff, either the same week 
as the patients wore an actigraph or the following week. We assisted the nurses as they 
completed the questionnaires in order to aid them in completing the assessment tools. 
As the nurses became familiar with the questionnaires, they completed them 
independently, allowing them to complete the questionnaires at times most convenient 
to them.  
3.1.8 Sample size 
Using G-power [285, 286], the power-analysis showed that we needed 64 patients 
when including eight clusters in order to detect differences between conditions, 
expecting moderate effect sizes (Cohen’s d= .50) for the actigraphy outcomes, a .05 
alpha level (two-tailed), and the power set to .80. We expected a 20% dropout, and 
thus the aim was to recruit 80 participants from eight nursing home units (clusters).  
3.1.9 Randomization 
The clusters were randomized by EF and EK to the intervention condition (1) or the 
control condition (0) using random group assignment in SPSS for Windows, version 
25.0.   
3.1.10 Blinding 
The DEM.LIGHT trial was single-blinded, aiming to blind the participants and the 
nursing home staff to group allocation. However, staff and participants could not be 
kept completely blind to the intervention, as the light setup comprised an obvious 
change in the common room. Therefore, we installed new light sources in the control 
units, in order to mimic an intervention and to ensure similar lighting across the 
control units. All included units were located at different nursing homes to minimize 
threats to internal validity in terms of performance and detection bias [237]. 
3.1.11 Contributions 
Elisabeth Flo-Groeneboom was the PI for the DEM.LIGHT trial. The data-collection 
was organized and data were collected by PhD-fellow Eirin Kolberg (EK) and the 
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candidate (GJH), with guidance and support by the main supervisor (EF) and co-
supervisors (Ståle Pallesen, Inger Hilde Nordhus, and Eirunn Thun). Eirunn Thun also 
participated in parts of the data collection. Two research assistants, Kristin Stotesbury 
and Marianne Hvattum Løken, took part in the data collection and plotting of data at 
week 8 and 16.  
3.1.12 Ethics  
The DEM.LIGHT trial was planned and conducted in line with the Declaration of 
Helsinki [265]. The trial was approved by the Regional Committee for Medical and 
Health Research Ethics, Health Region South East (project no. 2016/2246). The trial 
was preregistered at clinicaltrials.gov (Identifier NCT03357328). 
At each nursing home, we conferred together with the resident physician regarding the 
individual patient’s capacity to provide informed consent. In most cases, the patients 
did not have the capacity to provide informed consent, and the legal guardians were 
thus contacted by phone and we explained the study protocol to them. Subsequently, 
they received a letter with comprehensive information about the study aims, 
proceedings, and time frame, and a presumed concent form to return with their 
signature. The legal guardians were asked to provide presumed consent if they thought 
that the patient would wish to participate in the study if they were able to give their 
own consent, in line with the Helsinki Declaration [265].  
Regardless of consent capacity, we endeavoured to inform all participants about the 
study, adapting the information accordingly. We made a close assessment of their 
ability to understand study information when talking with the patients and 
administering the MMSE. During the study period, the patients’ ability to provide 
active assent or dissent was respected. Thus, no patients were forced to complete any 
assessments that involved their active participation (MMSE, MOBID-2, actigraphy). 
The researchers were sensitive to any protests or expressions of discomfort from the 
participants; and considered this as withdrawal of consent to complete the assessment 
in question. Most of the data were collected using proxy-raters. 
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The data were stored using a solution for secure processing of sensitive personal data 
in research, offered by the University of Bergen (SAFE). Only the research team had 
access to the data, which were accessed via a secure desktop.  
3.2 Methods of Paper 1 
3.2.1 Systematic literature search 
Protocol and registration 
The protocol for the systematic review was pre-registered in PROSPERO (registration 
number CRD42017051004), which is an international prospective register of 
systematic reviews. 
Eligibility criteria 
Table 5 shows the inclusion and exclusion criteria used to select studies for the review. 
These criteria were applied to reduce the heterogeneity of the included studies, while 
including all studies of interest.  
Table 5: Listing the inclusion and exclusion criteria applied in the systematic review. 
Inclusion criteria Exclusion criteria 
- BLT was delivered as an enhanced indoor 
electrical light scheme 
- The intervention was aimed at impacting NIF 
responses, including mood, behaviour, sleep, 
and/or circadian rhythmicity 
- The interventions had to entail an increase in 
illumination (lux) and/or CCT compared to 
baseline or control conditions 
- Information about lux or equivalent unit 
- Studies had to implement BLT as an 
intervention using standard care group 
comparison, placebo group comparison, or a 
single group pre-post design 
- The included participants had dementia 
- Quantitative study design 
- Qualitative studies  
- Case studies, chronicles, guidelines, 
protocols, non-systematic reviews, legal 
documents, conference abstracts, and other 
grey literature 
- Not published in English 
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BLT= Bright Light Treatment, CCT= Correlated colour temperature, NIF= Non-image forming 
We defined BLT as an enhanced indoor electrical light scheme aimed at impacting 
NIF responses including mood, behaviour, sleep, and/or circadian rhythmicity. 
Further, the interventions had to entail an increase in illumination (lux) and/or CCT 
compared to baseline or control conditions. Studies using dawn-dusk simulation (low 
lux, low CCT) were excluded.  
We only included studies encompassing participants with presumed dementia. A 
presumed dementia diagnosis could be based on medical records, diagnosed 
specifically for the study according to the Diagnostic and Statistical Manual for Mental 
Disorder (DSM) or the International Classification of Disorders (ICD) system, or on a 
MMSE cut-off. When both people with and without a dementia diagnosis were 
included, the study was included only if the results from the dementia participants 
were reported separately.  
To provide a comprehensive description of the published research in the field and to 
capture important insights from all available studies, we chose to be inclusive with 
regard to study design. Thus, we did not restrict inclusion to RCTs. Included studies 
had to be quantitative and implement BLT as an intervention using standard care 
group comparison, placebo group comparison, or a single group pre-post design. 
Publications such as case studies, chronicles, guidelines, protocols, non-systematic 
reviews, legal documents, conference abstracts, and other grey literature, as well as 
non-English publications, were excluded. We also excluded studies where BLT was 
combined with other treatments. 
Information sources and search strategy 
In collaboration with a skilled university librarian, Regina Küfner Lein, systematic 
literature searches were conducted in relevant databases: CINAHL, Medline, 
PsychINFO, Embase, Web of Science, and Cochrane libraries. The initial systematic 
search was conducted in June 2016, with a follow up search in March 2019. The 
search covered MESH terms and free text phrases synonymous with “bright light 
treatment” (*phototherapy, *photo therap, dawn-dusk, dawn dusk, light*, illuminat*, 
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bright, therap*, treatment, box, visor*, exposure*, LED), “dementia” (alzheimer 
disease, frontotemporal lobar degeneration, lewy body disease, delirium, amnestic, 
cognitive disorders, dement*, Alzheimer*, lewy body disease), and “nursing home” 
(home* for the aged, hospice*). No time limit was set for the searches. A complete 
overview of the search strategy for each database is available as supplementary 
material to Paper 1.  
Study selection 
On the basis of the inclusion and exclusion criteria, potential manuscripts were 
screened at the abstract level by GJH and EF, after which the inclusion and exclusion 
criteria were used to assess selected full texts by GJH and EK. Any disagreements 
were discussed with the co-authors. The reference lists of the full-text publications 
were searched for potential additions to the review.  
Data extraction process 
The data extraction was a back-and-forth process involving the co-authors, following 
the PRISMA guidelines (“Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) [287]. We agreed on the information of interest and developed a 
standardized form, which was piloted on a few of the included publications and 
amended in meetings with the research group. The following data items were 
extracted: Full reference, publication year, country, inclusion and exclusion criteria, 
type of setting (nursing home or home-dwelling), number of participants, participant 
characteristics (age, percentage female, type of dementia, and information about 
dementia severity), study design, intervention strategy (delivery method, illumination, 
CCT, duration of daily exposure, timing of daily exposure, duration of intervention 
period, and time of year) and control condition, time to follow-up, study setting, 
outcome measures, and study results.  
Risk of bias in individual studies 
The study quality was assessed using the Oxford Quality Scoring System [288], where 
quality is assessed in terms of randomization, descriptions of randomization 
procedures, double-blinding, descriptions of blinding procedure, and descriptions of 
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dropout. Studies were graded from zero to five, where a higher score reflects a more 
rigorous study. The included studies were rated independently by GJH and EK and 
subsequently compared. Any disagreements were discussed with EF and a consensus 
was reached.  
Risk of bias in the review 
In order to reduce risk of bias in terms of including publications in the review, 
potential manuscripts were screened at the abstract level by two authors (GJH and 
Elisabeth Flo-Groeneboom, EF), after which the inclusion and exclusion criteria were 
used to assess selected full texts by two authors (GJH and EK). Any disagreements 
were discussed in group meetings.  
3.2.2 Synthesis of results 
The included studies were systematized according to the PICO system (Population, 
Intervention, Comparison, and Outcome). The synthesis started with creating a 
descriptive summary of each included study, in the form of a table containing the 
extracted data items. Through discussions of this preliminary summary, we decided to 
group the studies according to which outcomes they had measured and according to 
the intervention strategy. To synthesize outcomes, the studies were systematized 
according to: 1) behavioural and psychological symptoms of dementia, 2) function and 
dementia severity, 3) sleep, and 4) circadian rhythmicity. To differentiate between 
types of interventions, BLT interventions with 1,000 lux or above, where the CCT was 
not manipulated, were categorized as “high illumination”. Interventions with high 
CCT compared to standard warm-white light, i.e., 5,000 K or more, were defined as 
“high CCT”. These categories were used to describe the different interventions.  
Under each category of outcomes, we first summarized all results, and then the results 
from the high illumination studies and the high CCT studies separately. Important 
study characteristics were highlighted in the text, while more details were available in 
a supplementary table. The goal of the synthesis was to collate the findings of the 
included studies while considering the strength of the evidence, exploring if there were 
any consistent effects across studies, and exploring relationship between the 
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characteristics of single studies (study design, population characteristics, intervention 
strategy) and the reported findings. Potential confounders, and recommendations for 
futures studies were discussed.  
3.3 Methods of Paper 2 
3.3.1 Procedures  
Paper 2 was a validation study of the SDI. This paper was based on baseline data from 
the DEM.LIGHT trial.  
The SDI was adapted to the nursing home setting and translated to Norwegian. Item 4 
(“awakening you during the night”) was replaced with “awakening at night”, in order 
to capture wake time during the night, but where the patient did not engage in the 
behaviours covered in the other items (e.g., getting out of bed or wandering). The 
translation process adhered to standard guidelines [289]. EF translated the SDI to 
Norwegian. GJH and EK back-translated the Norwegian version to english, and the 
back-translated version was compared to the original version by Inger Hilde Nordhus 
(IHN). Further refinements were made in a meeting between EF, EK, GH, and IHN. 
As some of the wording of the SDI was similar to the sleep item from the NPI-NH, 
which was already translated to Norwegian [280], we used existing translations when 
possible. Thus, five out of seven items were based on the Norwegian version of the 
NPI-NH. 
Actigraphy was used as a reference standard in order to validate the SDI. The 
following outputs were extracted from Actiware: Sleep efficiency (SE; the percentage 
of time spent asleep in the rest interval), total sleep time (TST) in the rest interval, 
wake-after-sleep-onset (WASO; the time spent awake after sleep onset), and the 24 
hour fragmentation index (indicates the overall disturbance of the sleep-wake rhythm 
across 24 hours, a higher score indicates a higher fragmentation). In addition to the 
SDI, the sleep item from the NPI-NH was also included in this study.  
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3.3.2 Statistical analyses  
The statistical analyses for Paper 2 were conducted using SPSS for Windows, version 
25.0. The analyses were performed by GJH, in close collaboration with the co-authors.  
For the SDI, missing data were imputed using Expectation Maximization when 
questionnaires were missing <20% of items. In total 31 items from 11 patients (2.3% 
of all items) were imputed, while three participants were missing ≥20% and were 
excluded from the analyses. Normality of the data was assessed and non-normal data 
were analysed using non-parametric tests.  
The internal consistency of the SDI was assessed using Cronbach’s alpha. Internal 
consistency is one of the main aspects of the reliability of a scale and refers to inter-
item correlations. This reflects if the items are measuring the same construct [290]. A 
Cronbach’s alpha of above 0.7 is normally considered acceptable, but is also 
dependent on the number of items, where more items results in a higher alpha [291].  
Convergent validity refers to how closely the scale in question is related to other 
measures of the same construct [292]. We assessed convergent validity by evaluating 
the strength of the relationship between the SDI and the NPI-NH sleep item and 
between the SDI and actigraphy outcomes, calculating Spearman correlation 
coefficients. To further evaluate the clinical utility of the SDI, receiver operating 
characteristic (ROC) curves were calculated. ROC curves require a dichotomous “gold 
standard” outcome of which the test in question is compared to [293]. An actigraphy-
based cut-off defining the presence of disrupted sleep was set to sleeping less than six 
hours in the fixed rest interval. The ROC analysis produces an “area under the curve” 
(AUC) score, which reflects the discriminatory ability of the test (here the SDI). A test 
with a high rate of true positives and a low rate of false positives, yields a high AUC 
score. An AUC score of .75 or more is considered clinically useful [293].  
The next step was to identify which total score on the SDI should be used as cut-off to 
represent clinically significant sleep problems. Thus, sensitivity (the rate of true 
positives), specificity (the rate of true negatives), and predictive values were calculated 
for different cut-offs on the SDI. In this context, the positive predictive value is the 
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probability that a person scoring on or above the SDI cut-off (i.e., a positive test) 
actually has disrupted sleep (as defined by the actigraphy reference), and the negative 
predictive value is the probability that a person scoring below the cut-off (i.e., a 
negative test) actually do not have disrupted sleep. Figure 6 shows how sensitivity, 
specificity, and positive and negative predictive values are calculated. The Youden’s 
index (sensitivity + specificity - 1) is a common summary measure for ROC curve 
data, incorporating sensitivity and specificity, which may be used to determine the 
most appropriate cut-off value for a scale [294–296]. The cut-off that results in the 
highest Youden’s index value is regarded as the “optimal/best” threshold value. 
 
Figure 6: A schematic overview of how sensitivity, specificity, positive predictive value, 
negative predictive value, and accuracy of a test are calculated. Sick= Disrupted sleep 
according to actigraphy. Healthy= Not disrupted sleep according to actigraphy.  
3.4 Methods of Paper 3 
Paper 3 was based on sleep data (actigraphy and the SDI) from the DEM.LIGHT trial. 
The following actigraphy outputs were extracted: SE, WASO, TST in the rest interval, 
TST during the day, and 24 h TST. The SDI total score was calculated as the sum of 




3.4.1 Statistical analyses 
The statistical analyses for Paper 3 were partially conducted using SPSS for Windows, 
version 25.0. Baseline data were presented as means (standard deviation; SD) for 
normally distributed continuous data, medians (25th-75th percentile) for non-normal 
continuous data, and number of participants (%) for categorical variables.  
The relationships between sleep outcomes and age, gender, eye disease, total number 
of drugs, number of psychotropic drugs, number of sedatives, MMSE, FAST, and CCI 
were assessed using correlation analysis for continuous data and by comparing groups 
for categorical data. Student’s t-test was used for normally distributed data and Mann-
Whitney U test for skewed data.  
To compare the light levels of the intervention condition and the control condition, 
differences in light levels between the intervention and the placebo condition were 
evaluated using Mann-Whitney U test. 
The effect of the intervention on sleep outcomes was analysed using multilevel 
regression modelling in “R” [297]. These analyses were completed by EK in close 
collaboration with GJH and the rest of the research group. Treatment effects on the 
primary outcomes were evaluated using linear mixed models, which incorporate the 
assessments from all time points (baseline, week 8, week 16, and week 24). There 
were some missing data because patients passed away or moved to another facility 
during the study (see Figure 2 in Paper 3). Mixed linear models use all available data 
while performing well in the presence of missing data. This model also estimates fixed 
effects while adjusting for correlation caused by repeated measurements of the same 
individuals [298, 299]. 
Linear mixed models using restricted maximum likelihood estimation were used to 
assess all outcomes for the impact of group (intervention and placebo), time (treated as 
categorical with levels baseline, 8 weeks, 16 weeks, and 24 weeks), and the group-by-
time interaction. Fixed effects for time, the intervention, and their interaction were 
included in the models. The models were fitted with random intercepts at the 
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participant level to allow each participant to vary at baseline, and random slope was 
included if it improved model fit. 
Covariates were also selected based on model fit. The Akaike information criterion 
(AIC) and Bayesian information criterion (BIC) were examined, and log likelihood 
values were compared using analysis of variance (ANOVA). Covariates that improved 
the fit were added to the model. The following list of covariates were tested: Age, 
gender, number of psychotropic medications, CCI, FAST, MMSE, eye disease, 
whether the participants passed away or moved during the study (drop-out), and 
average time in the living room during the day (between 10:00 and 15:00). Because 
there was some variation in light levels within the intervention group and within the 
control group, the measured melanopic illuminance of each unit was also tested as a 
covariate.  
The SDI data were transformed to achieve normal distribution, as preliminary analyses 
showed that the SDI data were highly skewed. The scores were transformed to achieve 
normal distribution by adding a constant of 0.5 and using a Box Cox transformation 
resulting in a lambda of 0.6.    
 
 72 
4. Summary of results 
4.1 Paper 1 
• The systematic review included 31 publications from 24 studies.  
• The results of the included studies were inconsistent, with a mixture of 
significant improvements, non-significant findings, and even negative results in 
terms of circadian rhythmicity, sleep, BPSD, function, and quality of life.  
• The included studies varied widely regarding intervention characteristics, 
designs, outcome measures, and population characteristics, which may have 
affected the outcomes.  
• Most of the studies had small samples with time-limited treatment durations. 
Longer treatment durations (≥eight weeks) appeared to be more effective on 
BPSD than shorter treatment durations (two weeks or less).  
• No pattern emerged in terms of timing (time of day) of treatment. It might be 
that timing is less important than a general increase in light exposure, as this 
population is notoriously under-exposed to daylight. 
• Studies using too intense placebo conditions (>400 lux) might have nullified 
potential differences between intervention and control conditions.  
• Considering the long-lasting effects on sleep found in one study for up to 12 
weeks post-treatment, there may have been carry-over effects in the studies 
using a cross-over design and with no wash-out or a short wash-out. 
• There was some evidence that studies including only people with Alzheimer’s 
disease had more favourable outcomes than studies including patients with 
multiple diagnoses, and that men might be more sensitive to light exposure than 
women.  
• The review did not support the notion that light of higher illumination (above 
2,500 lux) is more effective.  
• Several studies reported that high-CCT ambient light (from 6,500 K and 1,200 
lux to 13,000 K and 400 lux) had a negative impact on some outcomes, 
including depression and agitation. Keeping the light below 6,500K and 1,200 
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lux (measured vertically), but still as high as possible, could represent a viable 
solution.  
4.2 Paper 2 
• The internal consistency of the SDI was high, with a Cronbach’s Alpha of .82 
for the frequency ratings and .87 for the severity ratings.  
• The SDI was tested using three different ways of calculating a total score. All 
three total scores had a high convergent validity, with moderate significant 
correlations with the actigraphy-based outcomes of TST in the rest interval 
(Spearman’s rho, all correlations >.4, all p’s <.01), and WASO in the rest 
interval (all correlations -.4). The SDI did not correlate significantly with the 
fragmentation index (p=.10). 
• The ROC analyses showed that all three SDI total scores yielded an AUC score 
of .77 (95% CI about 65%-90%), using actigraphy as the reference standard 
(sleep disturbance defined as SE<75%). AUC scores of more than .75 are 
considered to be “clinically useful”.  
• The SDI summed product score (summarizing all item products, i.e., each scale 
item’s frequency multiplied with its severity), using a cut-off of five or more, 
yielded the best sensitivity, specificity, and predictive values for predicting 
sleep disturbance. This total score and cut-off also had the highest Youden’s 
Index of 0.49. 
• The results indicate that even though the SDI was developed for home-dwelling 
people with dementia and their caregivers, the SDI may be used to identify of 
sleep disturbances when administered by daytime staff in a nursing home 
context. However, clinicians should be vigilant to any signs of poor sleep, as 
there is a risk of missing up to 30% of potential cases using the SDI. 
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4.3 Paper 3 
• The intervention delivered significantly higher lux and CCT in the four 
intervention units (mean vertical lux 1,039 (SD 225); mean CCT 5,369 K (SD 
275)) compared to the four control units (mean vertical lux 242 (SD 102), 
p=.001; mean CCT 3049 K (SD 470), p=.000), as measured at predetermined 
locations using a standardized protocol. 
• The linear mixed model analyses for actigraphically measured sleep showed no 
statistically significant changes in the intervention group compared to the 
control group from baseline to week 8, 16, or 24. 
• The linear mixed model analysis for sleep measured by the SDI showed a 
significant improvement in the intervention group compared to the control 
group from baseline to week 16 (regression coefficient -.06, p=.02) and from 
baseline to week 24 (regression coefficient -.05, p=.03).  
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5. Discussion 
The overall aim of this thesis was to investigate whether BLT can improve sleep in 
nursing home patients with dementia and to highlight important methodological 
challenges in this field of research. Paper 1 reviewed previous studies on the effect of 
BLT in people with dementia, with a focus on the methodology of the included 
studies. Paper 1 demonstrated the diversity of the field, highlighting important 
methodological challenges that should be addressed in future studies. One of the 
findings was that the variety of measurement tools and operationalizations of 
outcomes (e.g., SE was calculated differently across studies), may explain some of the 
inconsistency of results across the included studies. Paper 2 complemented this finding 
by validating the proxy-rated sleep scale SDI against actigraphy, using baseline data 
from the DEM.LIGHT trial. The results showed that the SDI may be clinically useful 
to identify patients with potentially disrupted sleep in the nursing home context. 
Finally, Paper 3 reported on the sleep outcomes of the DEM.LIGHT trial, evaluating 
the effect of a dynamic ambient BLT intervention in nursing home patients with 
dementia. Here, we found that proxy-rated sleep measured by the SDI, improved in the 
intervention group compared to the control group from baseline to week 16 and from 
baseline to week 24. There were, however, no improvements in sleep measured by 
actigraphy.  
5.1 Discussion of the results 
In the following, the main aim of this thesis, i.e., whether BLT may represent an 
effective non-pharmacological treatment for sleep problems in nursing home patients 
with dementia, will be discussed. In order to do so, the findings from Paper 3 will be 
discussed first, followed by an overall discussion of this question. Subsequently, the 
use of the SDI as a measurement of sleep in the nursing home context will be 
discussed.  
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5.1.1 The findings from Paper 3  
The discrepancy between actigraphy and the SDI outcomes reported in Paper 3 may 
have been caused by the most important difference between these outcome measures; 
namely that actigraphy measure activity, while the SDI taps into the observations 
made by the staff. As discussed in Paper 2, over 80% of the variability in the SDI 
score was not explained by TST measured by actigraphy. There is a lot more 
complexity to sleep than is measured by actigraphy, which ultimately is a measure of 
mobility/immobility. There was a high use of psychotropic drugs among the 
participants in the DEM.LIGHT trial. As reported in Paper 3, 97% were prescribed at 
least one psychotropic drug, which is higher than the numbers reported in other 
Norwegian studies [300, 301]. The mean number of psychotropic drugs was 2.7, which 
may have resulted in sedation [302]. The potentially high occurrence of quiet 
wakefulness as a result of sedation may have confounded the actigraphy outcomes, as 
quiet wakefulness is recorded as sleep by the actigraphs. Conversely, staff 
observations may capture a more comprehensive impression of the patients’ sleep-
wake behaviour and is not subject to these limitations. Although, as discussed in the 
discussion of the methods, proxy-rated instruments include other methodological 
issues which may have biased the results. 
The findings of Paper 3 are similar to those in a recent study by Figueiro et al. [252], 
also using ambient light. In this RCT with a cross-over, they tailored a light 
intervention to each participant, according to where they spent the most time during 
the day. Light was administered for four weeks using floor luminaires (600 lux and 
5,000 K or 550 lux and 7,000 K at eye level), light boxes (350 lux, 6,000 K), and light 
tables (750 lux and 5,000 K). Similar to the findings reported in Paper 3, the 
intervention resulted in improved proxy-rated sleep (using the Pittsburg Sleep Quality 
Index), compared to the placebo condition, but not sleep parameters measured by 
actigraphy. Three other RCTs also found no effect on sleep measured by actigraphy 
[229, 230, 244].  
Meanwhile, the finding of paper 3 are in contrast to the findings by McCurry et al. 
[19], who reported an improvement of sleep measured by actigraphy, but not sleep 
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measured by the SDI, following two months of evening BLT using light boxes (2,500 
lux). Also, Ancoli-Israel et al. [20] found improvements of sleep measured by 
actigraphy following only 10 days of BLT delivered using light boxes (2,500 lux), 
both when administered during the morning and when administered during the 
evening. Further, a recent open clinical trial by Van Lieshout-van Dal et al. [251], 
where they administered ambient light using floor-lamps, reported improvements of 
sleep (estimated based on an activity sensor in the participants’ beds) during the 
intervention compared to standard light. The intervention comprised 1,100 lux and 
6,500 K vertically at eye level from 10:00-14:00, and 600 lux and 1,800 K in the 
morning and evening, for three weeks.  
There is a possibility that the lack of a robust effect of the intervention on sleep as 
reported in Paper 3 is related to issues regarding actual light exposure. Although we 
asked the nursing home staff to estimate the time each participant on average spent in 
the common room, these estimates may have been inaccurate. In addition, corneal light 
exposure is reduced when the observer is facing the floor or closing their eyes, which 
was not recorded. Thus, actual light exposure may have been lower than intended. This 
issue was exemplified in a recent study by Münch and colleagues [257]. Here, they 
used ceiling-mounted light and administered approximately 1,000 lux and 6,500 K 
from 11:00 to 16:00, with a gradual increase from 2,700 K in the morning and that 
reversed back to 2,700 K and below 200 lux in the evening. They found no effect of 
the intervention on sleep measured by actigraphy compared to the control group, 
however, found significant improvements in sleep when comparing groups based on 
individual light exposure (high vs. low light exposure), measured by light sensors on 
the actigraphs. It was not possible to evaluate individual light exposure based on light 
information from the actigraphs in the DEM.LIGHT trial, as the participants 
frequentlty wore clothing covering the device.  
5.1.2 Is BLT an effective non-pharmacological treatment for sleep 
problems in nursing home patients with dementia? 
Based on the findings from Paper 1 and Paper 3, the effectiveness of BLT in 
ameliorating sleep problems among nursing home patients with dementia is uncertain. 
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However, positive effects have been demonstrated, including our findings reported in 
Paper 3. As reported in Paper 1, we found that overall, the majority of studies 
assessing sleep and circadian rhythmicity using actigraphy found improvements in 
some of the parameters, but also several non-significant results. The lack of a robust 
effect may be explained by several factors. As will be elaborated in the discussion of 
the methods, both actigraphy and proxy-rated scales have some important weaknesses 
that may obscure the effect of BLT on sleep. Beyond the challenges of measuring 
sleep, other issues are relevant to discuss. First, effects of BLT may take a long time to 
manifest. Second, the response to BLT may depend on dementia diagnosis and/or 
severity. Third, polypharmacy and other factors associated with nursing home 
placement might counteract effects of BLT. Finally, the intervention strategy used in 
the studies included in Paper 1 and the DEM.LIGHT trial intervention might not have 
been optimal.  
Long-term effects 
One of the findings from Paper 1 was that 9 out of 23 included studies had short 
treatment durations of around 2 weeks, 11 studies had a treatment duration of 3-4 
week, and a longer treatment duration (eight weeks or more) was recommended based 
findings regarding BPSD. The same conclusion may pertain to sleep, although one 
RCT found improvements of sleep following only 10 days of treatment, using 2,500 
lux light boxes [20], and Figueiro et al. [252] found and improvement of proxy-rated 
sleep after four weeks of treatment. In contrast, the improvement in the SDI reported 
in Paper 3 was not seen until week 16 (and not in week 8), indicating that several 
weeks of exposure may be necessary to elicit a beneficial effect of BLT on sleep in 
people with severe dementia.  
The effect may depend on diagnosis and/or severity of dementia 
As highlighted in Paper 1, the included studies varied in terms of population 
characteristics. Some included people with Alzheimer’s disease only, while others 
included people with different diagnoses. Ancoli-Israel et al. [20] repeated the protocol 
used in a study of people with different dementia diagnoses [229], including 
participants with Alzheimer’s disease only. In the second study, they found within-
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group improvements of sleep following BLT, while there were no significant effects 
on sleep when including people with different diagnoses [229]. Similarly, in their 
review of the literature, Mitolo et al. [303] suggested that people with mild to 
moderate Alzheimer’s disease might benefit more from BLT than people with severe 
Alzheimer’s disease and other dementias.  
In the DEM.LIGHT trial, we included patients with different dementia diagnoses who 
on average had severe dementia. Ideally, we should have had enough participants to 
perform subgroup analyses based on dementia severity and diagnosis. However, the 
majority of the participants had severe dementia, as indicated by the median MMSE 
score of 4, prohibiting a separation of patients based on severity. Further, studies have 
shown that it is common for one patient to have several types of neuropathology 
corresponding to several types of dementia [161, 162]. This is increasingly common 
with higher age [304, 305], complicating a separation of patients based on dementia 
subtype in our population. 
There is also a possibility that some people with dementia have too widespread 
neuropathology to benefit from BLT, where areas involved in sleep-wake regulation 
are affected to the point that efforts to improve sleep are ineffective. Alternatively, 
age- and dementia-related changes of eye physiology [306] may have progressed to the 
stage that the BLT was unable to adequately stimulate NIF responses in some patients, 
and consequently had no effect on sleep measured by actigraphy. In line with this, van 
Someren et al. [245] found an improvement of circadian rhythmicity only in 
participants with no eye pathology. Whether or not a participant had a diagnosed eye 
condition was a significant covariate for SE in Paper 3, indicating that eye disease 
affected the response to BLT. However, eye disease was not a significant covariate for 
the other sleep outcomes. Importantly, it is unlikely that extensive eye examinations 
aiming to assess light sensitivity are performed upon nursing home admission, and 
information regarding eye pathology may not have been accurate. Some previous 
studies have assessed eye health in relation to BLT [e.g., 244], and future studies 
should aim to implement such assessments.  
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Improving sleep in the nursing home context 
Importantly, the are multiple causes of sleep disruption, and although light exposure is 
pivotal for a stable sleep-wake rhythm, other factors may significantly impact sleep. 
One obvious challenge related to nursing home patients is that they often spend a 
significant amount of time in bed, often more than 12 hours from bedtime to rise-time, 
excluding daytime naps [146, 197, 198]. Paradoxically, the first-line treatment for 
insomnia in otherwise healthy adults entail behavioural approaches such as restricting 
time in bed [307]. Although people with dementia may need more rest than otherwise 
healthy adults, spending more than 12 hours in bed and frequent daytime naps [146, 
197, 198] will normally increase the risk of fragmented sleep significantly [308]. 
Similarly, other factors that are prevalent in nursing homes, such as reduced daytime 
activity [199] and/or a high sedative load resulting from polypharmacy [144] may 
counteract effects of BLT. Attempting to improve sleep in this context is perhaps 
futile, and it is perhaps not possible to fully delineate the effect of BLT on sleep unless 
the aforementioned practical issues are resolved.  
Dementia is progressive in nature and as a consequence, deterioration in sleep quantity 
and quality over time is to be expected in this population. In Paper 3, the observed 
means and standard deviations of the SDI for the groups at each time point indicate 
that the significant treatment effect in week 16 and 24, as shown in the mixed linear 
model analysis, was caused by an improvement in the intervention group in 
combination with a worsening in the control group (see Table 6 in Paper 3). 
Importantly, the observed means do not account for drop-out during the course of the 
study. Thus, improving sleep in people with dementia may largely entail preventing or 
counteracting deterioration of sleep over time. This highlights the necessity of 
including a control group.  
Was the intervention strategy optimal? 
Several previous studies have provided the participants with BLT from 7:00 or 8:00 in 
the morning. This is appropriate if the aim is to advance the sleep-wake rhythm (i.e., 
wake up earlier, go to sleep earlier), and if the person has a normal circadian rhythm. 
However, nursing home patients may vary in the timing of their circadian phase [257]. 
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Providing BLT early in the morning might actually delay the rhythm, as people might 
be exposed to light prior to nadir for core body temperature. Ideally, BLT should be 
tailored to each patients’ circadian phase. However, when using ambient light in 
common rooms, this is not possible. By providing light from 10:00, we were confident 
that the light occurred after nadir for most patients. Importantly, people with dementia 
often struggle with sleep fragmentation (i.e., multiple sleep and wake episodes across 
the day and night) [174], rather than a delay or advance of the rhythm. Thus, the aim 
of the intervention was to consolidate sleep to the night and promote 
wakefulness/alertness during the day, both through the circadian effects and the acute 
alerting effects of light [13, 111]. Circadian effects occur even when bright light is 
provided several hours after wake-up [81, 83, 84]. Also, exposure to bright light 
during the day seem to protect against circadian disruption and alerting effects caused 
by evening/night-time light exposure [106]. 
It is possible that the light levels (lux and CCT) and duration of daily exposure used in 
the DEM.LIGHT trial were not sufficient to stimulate NIF responses due to age- and 
dementia-related deterioration of eye physiology. The optimal light levels to employ 
when delivering BLT as ambient light has not been established, as reflected in the 
wide variety of intervention strategies employed in previous studies, as summarized in 
Paper 1. Recently, knowledge regarding the light characteristics needed for optimal 
physiological and psychological well-being for people in general was also highlighted 
as a gap in the literature by Münch et al. [78], thus expanding beyond dementia 
research. In the DEM.LIGHT trial, we decided to use a peak light level of 1,000 lux 
and 6,000 K from 10:00 to 15:00, with lower light levels in the morning and 
afternoon/evening (see section 3.1.3). This strategy was based on previous studies, 
discussions with experts in the field, and on feedback from nursing home staff. In the 
DEM.LIGHT trial, we completed a pilot including one nursing home unit, where 
nursing home staff had the opportunity to provide feedback on the light settings. 
Following feedback from staff, we reduced the duration of the interval with the highest 
light levels (1,000 lux and 6,000 K), and reduced the illumination in the evening. 
There is a possibility that people with severe dementia may require much higher light 
levels in order to stimulate NIF responses than people without dementia.  
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Conversely, too high CCT and/or lux may have undesirable effects. As reported in 
Paper 1, three studies using ambient light reported negative outcomes following BLT 
with high CCT values. Van Hoof et al. [247] reported increased anxious and 
depressive behaviour using light with a CCT level of about 12,500 K, and a vertical 
lux level of 400-500, for the whole day. Another study reported increased apathetic 
behaviour following light of 6,500 K and 1,200 vertical lux delivered for the whole 
day [246]. One study used light of 6,500 K and 2,500 horizontal lux (corresponding to 
a somewhat lower vertical lux) and reported increased depression among men after 
morning BLT (07:00-11:00) compared to the control condition [309], and also that 
evening BLT (16:00-20:00) was associated with increased daytime sleepiness in one 
of the two participating nursing homes [243].  
Potential negative effects of BLT are important to consider. Van Hoof et al. [247] 
suggested that the light was uncomfortable for the participants and that they expressed 
discomfort through worsened behaviour. This is an important point that is largely 
overlooked in BLT research. Few studies have investigated which light levels people 
prefer in their environment [310, 311], and none have investigated this in relation to 
dementia. Here, it is also important to consider different preferences related to “focus 
lighting” in work environments and lighting in settings where people live. While short-
wavelength light may be more efficient in terms of stimulating NIF-functions, light 
levels with a CCT that outperforms sunlight (5,700-7,700 K [103]), is perhaps not a 
viable solution in peoples everyday environment. We recommended in Paper 1 that 
studies should not use light levels of more than 6,500 K and 1,200 lux (measured 
vertically), particularly when delivered as ambient light in people’s living 
environment. Although this recommendation was based on the existing literature, there 
is a clear need for studies that investigates preferences and light comfort in different 
indoor settings. More clinical studies should look into how light sensitivity is reduced 
with age and dementia, and identify the minimum light levels required to stimulate 
NIF responses in this population, as well as the upper limit in terms of negative effects 
and/or subjective preferences and comfort. When available, it is possible that we 
should harvest natural daylight (i.e., light emitted by the sun), as people seem to prefer 
natural light over electric light [312]. 
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Beyond ensuring sufficient light exposure during the day, darkness at night is also an 
important aspect to consider, as a stable circadian rhythm depends on both daytime 
light exposure and nocturnal darkness [99]. Several of the more recent studies have 
employed light of low lux and CCT during the evening and night [106, 250, 251]. In 
the DEM.LIGHT trial, we reduced the light to 400 lux and 3,000 K at 15:00, and then 
further to 100 lux and 2,500 K at 18:00. However, we did not control the light outside 
the common room, and thus patients may have been exposed to light late in the 
evening and during the night. Although daytime light exposure reduce the sensitivity 
to nocturnal light exposure, this is an important weakness. More favourable results 
could have been achieved from securing low light levels and darkness during night, 
and future studies should endeavor to control the light environment also in patients’ 
rooms.  
5.1.3 Is the SDI a valid outcome measure of disrupted sleep in 
nursing home patients with dementia?  
Few proxy-rater tools for assessing sleep in the nursing home are available. The SDI is 
a relatively short and easy-to-administer tool that has been validated for home-
dwelling people with dementia, using in-living relatives as proxy-raters [203]. In Paper 
2, we reported that the SDI adapted to the nursing home corresponded well to sleep 
measured by actigraphy in nursing home patients with dementia, using staff as proxy-
raters. However, some important issues need to be considered. 
Nursing homes are short-staffed at night and thus some sleep-related events may go 
unnoticed. In particular, wake time at night is often underestimated [264]. Still, the 
SDI performed quite well compared to actigraphy, in contrast to commonly used 
questionnaires assessing sleep using one or a few items [197]. In their study, Blytt et 
al. [197] found a specificity (correctly identified negative cases) of the sleep item of 
the Neuropsychiatric Inventory (Nursing Home Version) of 89%, and a sensitivity 
(correctly identified positive cases) of only 22%. Similar results were found for the 
sleep items of the Cornell Scale for Depression in Dementia. Thus, the SDI is more 
accurate in detecting sleep disturbances in nursing home patients with dementia, with a 
specificity of 78% and sensitivity of 70%, and may thus contribute to detection and 
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subsequent treatment of sleep problems in this population. Importantly, while the SDI 
may indicate if a patient has clinically significant sleep disruption, more deliberate 
approaches would be needed to identify the underlying cause of the sleep disturbances, 
such as obstructive sleep apnea, periodic limb movements, nocturia, or pain. Thus, the 
SDI may serve as a screening tool, but may not be used as a diagnostic tool. Further, 
we did not assess test-retest reliability or the responsiveness of the SDI over time to 
detect clinical change, which are weaknesses of Paper 2. Future studies should assess 
these aspects of the SDI.    
Using the SDI to detect possible sleep disturbances 
In Paper 2, we used the Youden’s index to identify the best cut-off for defining 
disrupted sleep, where the cut-off that yields the highest Youden’s index is regarded 
most “optimal” cut-off [294, 296]. The analyses revealed that a definition of sleep 
disturbances as a SDI total score of five or more yielded the highest Youden’s index, 
and a sensitivity of 70%, a specificity of 78%, a positive predictive value of 73%, and 
a negative predictive value of 76%. Although clinically useful according to the AUC 
score of .78, these values are not great. The sensitivity of 70% means that the SDI will 
detect 70% of patients that have sleep problems (as defined by the actigraphy 
reference), and thus fail to detect almost a third of the cases. We could have chosen a 
lower cut-off, with a higher sensitivity and thus detecting more of those with disrupted 
sleep. However, this would also entail decreasing the specificity and producing more 
“false positives”, i.e., categorizing patients who sleep well as having disrupted sleep.  
An instrument with even higher sensitivity and specificity than found in Paper 2 would 
be ideal. This may not be possible without adding an element of systematic 
observation. Unless patients get out of bed or otherwise attract the attention of the 
night-time staff, patients may be awake or exhibit symptoms of sleep apnea, periodic 
limb movements, or other conditions, without the staff noticing. Because continuous 
observation is extremely labour-intensive and time-consuming, most approaches rely 
on intermediate observation, for example every 15 minutes or every hour [259, 313]. 
But, as nursing home patients with dementia often experience extremely fragmented 
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sleep, these approaches risk missing the occurrence of sleep and wakefulness in 
between observations. It may also disrupt the patients’ sleep.  
Future efforts to developing methods of detecting sleep disturbances that are feasible 
to use in nursing homes would greatly benefit the research field as well as clinical 
practice. Recent developments of a non-invasive radar-based sleep detector represent a 
promising solution [314]. In the meantime, the SDI may serve as a practically feasible 
tool with higher accuracy than many of the tools which are now commonly used in the 
nursing home context.  
5.2 Discussion of the methods 
5.2.1 Discussion of the methods used in Paper 1 
Paper 1 was a systematic review providing an overview of studies assessing the effect 
of BLT in people with dementia. We used a systematic approach to the identification 
and selection of relevant studies to include in the review, and extracted predetermined 
data. To ensure transparency of the review, data were reported in line with the 
PRISMA Statement and the study protocol was preregistered in the PROSPERO 
database.  
Originally, one of the aims of Paper 1 was to perform a systematic review with a meta-
analysis, adding to the findings by Forbes et al. [226] and van Maanen et al. [227]. 
Meta-analyses combine data from multiple studies and provide a quantitative estimate 
of the combined effect [315]. Following the systematic identification and inclusion of 
relevant literature, however, it became apparent that a meta-analysis would require the 
exclusion of several of the identified studies. Overall study quality was low, with few 
RCTs, and many studies included relatively few participants. We aimed to provide a 
detailed overview of the field and thus to include as many studies as possible. Further, 
the studies were quite heterogenous, and they varied widely in terms of intervention 
characteristics, i.e., the timing and duration of treatment, illumination level, the 
spectral composition of the light, and the method of delivery (light box, ambient light), 
and also in terms of outcomes. Hence, pooling the data from heterogeneous studies 
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may not be appropriate [316]. In order to provide a broad overview of the field, we 
decided to pursue a narrative synthesis of the data.  
Systematic reviews where a meta-analysis is not conducted has been referred to as 
“qualitative meta-analyses” [317]. Qualitative meta-analyses summarize the results 
from studies that have been identified using a systematic approach, but does not 
combine the data in a statistical analysis. Thus, conclusions about effects may not be 
established. Instead, we aimed to delve into the heterogeneity of the studies and 
mapped out the different approaches to delivering BLT, providing a comprehensive 
background for those searching to gain insight into the field. We also attempted to 
evaluate how differences across studies in terms of intervention strategies, population 
characteristics, or design could potentially have affected the results, in order to point 
out potential covariates, and also to provide some recommendations for future 
research.  
Risk of bias 
Systematic reviews entail a systematic search of the literature to minimize bias in the 
selection of studies [317]. The purpose of a systematic review is to provide a complete 
overview of the existing research on a topic, using a systematic approach to identify all 
available scientific evidence, and securing that the evidence accurately reflects the 
research that has been carried out [315]. In Paper 1, we used a predefined protocol-
based search method, searched multiple relevant search engines, and selected studies 
for inclusion using predetermined criteria.  
We did not, however, include grey literature, i.e., literature that is not published in 
peer-reviewed journals. Examples are conference abstracts, reports, and dissertations. 
Thus, we may have missed relevant research, and importantly, may have introduced 
publication bias. Publication bias arises when the publication of research depend on 
the results, where significant or positive results are more likely to be published than 
non-significant or negative results [318]. However, retrievable unpublished papers are 
not representative of unpublished literature in general [319].   
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To assess risk of bias in each of the included studies, we assessed study quality using a 
quality assessment instrument [288]. We chose to use a relatively simple scale because 
the review in itself aimed to address methodological issues in the included papers in 
great detail. However, more comprehensive quality scales such as the GRADE 
approach [320] are commonly used in systematic reviews, and could have increased 
the comparability across reviews in dementia research.  
Study selection 
As mentioned above, a systematic literature review summarize and analyse all the 
available research literature on a topic [315]. But what is considered “all the literature” 
in BLT research is not straightforward. Unlike previous systematic reviews [226, 227, 
255, 303], we focused on studies using indoor electrical light interventions delivering 
bright light, thus excluding dawn-dusk simulation and outdoor light. Dawn-dusk 
simulation does not exceed standard light levels [321], as it entails a gradual increase 
of the light level from darkness to typically 200-300 lux, starting prior to wake-up. 
While Gasio et al. [321] found beneficial effects of this intervention, it deviates from 
what we defined as bright light, as it does not entail an increase in light exposure, but 
rather a change in the timing of exposure. Further, we did not include studies that had 
utilized outdoor daylight as an intervention [322, 323], obtained by taking the patients 
outside. This inevitably entail social interaction and physical activity. These activities 
may themselves have therapeutic effects [221], and may complicate the interpretation 
of results. Also, there is a potentially beneficial effect of exposure to the natural world 
[324]. While increased physical activity, social interaction, and outdoor environments, 
in addition to increased light exposure, could possibly represent an effective 
intervention in terms of mood, behaviour, sleep, and circadian rhythmicity in people 
with dementia, the goal of the systematic review was to synthesize studies that used 
indoor illumination alone. Paper 1 was therefore intended to be more relevant to 
researchers studying or planning to study the effect of indoor electrical lighting 
systems than previous reviews.  
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5.2.2 Discussion of the methods used in Paper 2 and 3 
This section will discuss central methodological aspects pertaining to Paper 2 and 3: i) 
the placebo condition, ii) estimating light exposure, iii) challenges pertaining to 
actigraphy and to the SDI, iv) sleep as one of several outcomes, v) the analytic strategy 
of Paper 3, vi) sources of bias and internal validity, and vii) external validity.  
The light characteristics of the placebo condition 
In DEM.LIGHT, we used a placebo condition consisting of standard light values. 
Ideally, the control units should also have had new light fixtures installed, which could 
be programmed to deliver almost any light values. Unfortunately, this was not 
economically feasible. The best alternative was to replace the light sources of the 
existing light fixtures, with sources of identical light characteristics in all control units. 
As a result, the lux in the control units varied, as the number and placement of light 
fixtures and number and placement of windows varied. However, we secured that none 
of the control units used blue-enriched light sources of high CCT. The light levels in 
the control units were significantly lower than the light levels in the intervention units, 
as reported in Paper 3. Importantly, all control units had the lighting changed in the 
common room in their unit.  
Estimating light exposure 
In BLT studies using light boxes, participants sit in front of the light box for a 
restricted period of time, thus securing the target light exposure. When using ambient 
light, participants move freely in the BLT room/area, and may come and go as they 
please. Thus, individual light exposure is likely to vary across participants. In the 
DEM.LIGHT trial, we estimated individual exposure based on reports from the staff. 
As the staff had to approximate the average time spent in the living room each day for 
the last eight weeks for each patient, these estimates likely deviated somewhat from 
true exposure. Further, the participants may have sat with their face downwards or 
with their eyes closed, reducing the amount of light entering the eye. Future studies 
could benefit from improved accuracy of estimating light exposure by monitoring time 
spent in treatment areas, for example using wearable tracking devices. Accurately 
measuring light exposure was recently listed as one of the main goals of daylight 
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research in a report by Münch and colleagues [78]. Hopefully, future technological 
advances will result in accurate measures of light exposure that are also feasible to use 
in the nursing home context.  
Another aspect of estimating light exposure pertain to the light metrics used in Paper 
3. To increase comparability with other studies, we reported the illumination (lux) and 
CCT (K) of the intervention and placebo conditions. In addition, melanopic 
illuminance was reported, calculated using the toolbox developed by Lucas et la. [90]. 
It is a weakness of Paper 3 that we did not calculate light levels using the CIE toolbox 
[91], as this represents the most recent and updated standard. However, the CIE 
standard is based on the toolbox developed by Lucas et al., and produces an output that 
is marginally different from the Lucas et al. toolbox. Hence, there is little reason to 
believe that using the melanopic EDI, as opposed to the equicalent melanopic 
illuminance provided by Lucas et al., would significantly impact the results of Paper 3. 
Challenges pertaining to actigraphy 
In the DEM.LIGTH trial, actigraphy was used as an objective measure of sleep. Some 
specific challenges pertain to the use of this equipment. 
Using actigraphy as a reference standard 
The first issue related to actigraphy is the use of this measurement method as a 
reference standard in Paper 2.  
To determine the accuracy of a test, the same people are subjected to the test as well as 
to a “gold standard” test (i.e., the reference standard), indicating the true presence of a 
disease or condition [325]. Then, test results are classified as either true positive, false 
positive, true negative, or false negative, compared to the reference standard. In the 
DEM.LIGHT trial, actigraphy was considered the most feasible option serving as an 
objective measurement of sleep and as the reference standard [283, 326]. The 
actigraphs are small and light, and are generally well tolerated, and thus actigraphy is 
widely used in sleep research involving people with dementia [283]. Actigraphy 
allows measuring sleep over a prolonged period of time and does not limit the patient 
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in his/her daily activities. However, actigraphy have some caveats that need to be 
considered.  
Actigraphy may overestimate sleep [262, 263]. Research has shown that compared to 
PSG, the accuracy of actigraphy to detect sleep and wake declines with lower sleep 
efficiency, i.e., the accuracy is lower in populations with low sleep quality [262]. This 
is mostly due to a decline in specificity, i.e., the ability of the actigraphs to detect 
wake. Actigraphy is solely based on motor activity, and thus quiet wakefulness, when 
subjects are awake but not moving, may be interpreted as sleep [262]. This is 
particularly relevant for immobile nursing home patients. Sivertsen et al. [263] found 
that in older individuals, the specificity of actigraphy was only 36%, and that 
actigraphy overestimated sleep and underestimated sleep onset latency and total wake 
time compared to PSG. In a group of older women with insomnia, Taibi et al. [327] 
found a SE of 84% from actigraphy recordings, compared to only 67% when measured 
by PSG. A potentially low specificity of actigraphy might have caused measurement 
error, which would impact the convergence between the SDI and actigraphic 
parameters in Paper 2. The results of that study should be interpreted with these 
caveats in mind. Importantly, if total sleep time, which was used to define disrupted 
sleep (TST<6 h), was over-estimated, then the suggested cut-off on the SDI may be 
too high.  
Using a fixed rest interval for actigraphy outcomes 
To estimate sleep outcomes, Actiware requires a defined rest interval, either set 
automatically by the software, or defined by the user. Several protocols for defining 
the rest interval have been proposed [e.g., 197, 328]. These protocols rely heavily on 
the participants (or the nurses on duty) pressing the event button on the actigraphs at 
“lights out” in the evening and “lights on” in the morning, which results in marker set 
times in the actigraphy output. In the DEM.LIGHT trial, we encouraged the nursing 
home staff, through oral and written messages, to push the event marker to indicate 
bedtime and rise time. Unfortunately, the event markers were used in <50% of the 
intervals in the actograms.  
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Protocols for defining rest intervals often use activity and light exposure information 
to determine bedtime and wake-time when event markers are not available. We 
initially aimed to manually set the rest intervals for each individual night using a 
predetermined protocol. However, nursing home patients spend a significant amount 
of time in bed [197, 198], and determining a true bedtime and wake-time was thus 
challenging. The pattern of activity and light exposure was extremely irregular, 
complicating the definition of bedtime and wake-time. For these reasons, it is common 
to use a fixed rest interval in studies involving participants with dementia, and we 
decided to use a fixed rest interval from 22:00 to 06:00 in Paper 2 and Paper 3. This 
interval was based on previous studies including people with dementia [9, 18, 229, 
243, 284, 329]. Although nursing home patients may spend more than 12 hours in bed 
[197, 198], bed time and wake time varies across nursing homes and across 
individuals. The interval from 22:00 to 06:00 was considered likely to capture the 
main sleep episode of the majority of patients, without including a significant amount 
of time spent out of bed.  
One important drawback of using fixed rest intervals is that individual variations in 
sleep patterns [33] may be interpreted as poor sleep. Some patients might have a 
delayed circadian phase and prefer to go to bed later and get up later. For example, 
even though a person slept well from 24:00 to 08:00, the sleep efficiency would still be 
only 75% using a rest interval from 22:00 to 06:00. Further, if a participant slept from 
22:30-06:00 at baseline and then shifted his or her sleep episode to 23:30-07:00 at 
follow-up, this would be interpreted as a deterioration of sleep in terms of TST and SE 
(as illustrated in Figure 7). Conversely, shifting the sleep episode to earlier hours 
would also be interpreted as a deterioration of sleep. However, such shifts in the sleep 
episode may not represent a deterioration of sleep in the perspective of the patient or 
the staff. A reliable way to determine each individual’s bedtime and wake-time would 
therefore be ideal, however, this could not be achieved in the DEM.LIGHT trial.   
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Figure 7: A demonstration of how the sleep efficiency declines if the timing of the sleep 
episode is shifted. SE= Sleep efficiency 
Choosing an actigraphy-based cut-off to define sleep problems 
In Paper 2, “disrupted sleep” was defined as a TST in the rest interval of below six 
hours, as measured by the actigraphs. This corresponds to a SE of 75% in the fixed rest 
interval. In otherwise healthy adults, disrupted sleep is often defined as having a sleep 
efficiency of below 85% [330, 331], and this cut-off was also used in a study including 
people with dementia by Blytt et al. [197]. The six hour cut-off used in Paper 2 was 
based on Yesavage et al. [332], and also on the original publication on the SDI by 
Tractenberg et al. [203]. However, different fixed rest intervals were used in the two 
publications, from 21:00-06:00 and 20:00-08:00, respectively. Thus, the cut-off from 
Yesavage et al. [332] correspond to a SE of 67% and the one from Tractenberg et al. 
[203] to 50%. Ju et al. [333] used a sleep efficiency of 75% as a cut-off in a study of 
people with Alzheimer’s disease, although based on individually defined rest intervals. 
As elaborated in the background chapter, sleep often becomes more fragmented as we 
age, and dementia is associated with a further deterioration of sleep. Therefore, using a 
definition for sleep disturbances that is normally used in otherwise healthy adults 
(SE<85%) would perhaps be too inclusive, in terms of defining people as sleep 
disturbed while they actually slept quite well given the circumstances. Conversely, 
using a cut-off of a SE<67% or <50% seemed too lenient, in terms of defining people 
as not sleep disturbed and who actually only slept somewhat more than half of the time 
in bed. Using a cut-off corresponding to a SE<75% was all in all considered a golden 
middle ground.  
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Duration of actigraphy recording 
In the DEM.LIGHT trial, patients wore the actigraphs for approximately seven days. 
There are some indications that actigraphs should ideally be used for 14 days, as this 
results in the highest stability coefficients [262, 334]. Due to night-to-night variability 
in sleep, sleep estimates based on only one or a few nights may not reflect the average 
sleep of a person, and measurements made a few days later may provide estimates that 
deviate greatly from the initial estimate (i.e., the sleep estimate has low stability, and 
thus reliability) [334]. By increasing the number of consecutive nights of measuring 
activity, the difference between the average sleep estimates calculated at two time 
points is reduced and the stability is increased. Although van Someren [334] 
recommended two weeks of recording, estimates based on seven days of recording had 
adequate reliability. Similarly, Rowe et al. [335] found that the aggregated means for 
TST, SE, SOL, and WASO were consistent across 3, 7, and 14 days of measurements. 
Using actigraphs for seven days is common in sleep research [262, 283], and was also 
the most practically feasible option in the DEM.LIGHT trial.  
Challenges pertaining to the SDI 
Daytime staff rating nocturnal behaviour 
The SDI was completed by daytime staff. It is possible that the SDI completed by 
night-time staff would have reflected the sleep of the patients more accurately, as 
daytime staff did not directly observe the patients during the night. 
The SDI was only one out of multiple scales the staff completed. We aimed to have 
one rater complete all questionnaires for the same patient to secure consistency across 
the proxy-rated scales. Further, the night shifts are generally poorly manned, where 
one nurse is often responsible for many patients [143], and where the night-time staff 
may not know the patients as well as the daytime staff. As argued in Paper 2, clinical 
decisions are often made by the nursing home physician in collaboration with daytime 
staff. Night-time staff convey information to the daytime staff orally and/or in written 
form in the patients’ journals. Thus, daytime staff are normally well informed about 
how the night has passed and if there were any clinically relevant events during the 
night. However, these “distal” estimates may have introduced measurement error and 
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should inform he interpretation of the results. This is particularly relevant for Paper 2, 
as we compared the SDI completed by daytime staff with night-time actigraphy 
recordings. The fact that there was satisfactory correspondence between the SDI and 
actigraphy is uplifting as it suggests that the usual procedure for administering tests 
during the day is possible also with the SDI, given an adequate communication 
between the night and day shift.  
However, it is possible that the correspondence between the SDI and actigraphy (Paper 
2) would have been better if the former was completed by night-time staff, and future 
studies should address this issue. Importantly, errors stemming from the daytime staff 
rating sleep is ‘non-differential’, i.e., is not different for the intervention group and the 
control group [336]. 
Lack of temporal overlap between actigraphy and the SDI 
Another limitation is the lack of a temporal overlap between the actigraphy recordings 
and the SDI, which is particularly relevant to Paper 2. The SDI asked about the last 
two weeks, while the actigraphy outcomes were summaries of at least five days of 
measurement (mean duration of measurement 7.7 days). The actigraphy recordings 
were made during the same week as the SDI was completed, hence, the SDI included 
time when the patients were not wearing an actigraph.  
In relation to Paper 2, there is a possibility that the correspondence between the SDI 
and the actigraphy recordings would have been higher if there was complete temporal 
overlap between the two measurements.  
Sleep as one of several outcomes in the DEM.LIGHT trial 
The aim of the DEM.LIGHT trial was to assess the effect of BLT in nursing home 
patients with dementia. Due to the comprehensive effect of light on human 
functioning, including effects on circadian rhythmicity, alertness, and mood, the 
response to treatment can potentially be detected by many different oucomes. Thus, 
although sleep and circadian rhythmicity were the primary outcomes, important 
secondary outcomes were BPSD and functional status. Therefore, we used wide 
inclusion criteria, where participants had to have either disrupted sleep, clinically 
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significant BPSD, or significantly reduced function (ADL). Consequently, we included 
participants both with and without sleep disturbances. Ideally, we should have 
included enough patients to run subgroup analyses and thus be able to evaluate the 
effect in only those with sleep disturbances at baseline. We did, nevertheless, account 
for individual baseline values on the primary outcome including a random intercept in 
the mixed linear models.  
Methodological issues relating to the analysis of data in Paper 3 
In RCTs, known and unknown confounding factors are balanced between groups by 
using randomization [237]. The goal is to create a control group that is as similar as 
possible to the intervention group, so that differences in outcomes can be assigned to 
the intervention and not to baseline differences between the groups. Due to the nature 
of the BLT intervention in the DEM.LIGHT trial, namely an ambient light intervention 
in the common room of each nursing home unit, the patients living in the same unit 
had to belong to the same group. Thus, each unit represented one out of eight clusters 
that were randomized to either the intervention group or the control group. Cluster-
randomized trials are subject to some specific challenges.  
Sample size and power 
The power-analysis showed that we needed 64 patients when including eight clusters. 
As we expected some drop-out, the aim was to recruit 80 participants from eight 
clusters. Because not all of the patients living in the included units could be included 
in the trial (were not eligible or declined to participate), we only achieved 69 
participants at baseline. Further, participants died or moved (mostly to a somatic unit 
due to deterioration of physical health) during the study, and some were excluded from 
the analyses due to non-compliance. Thus, we might not have had sufficient power to 
detect effects. As the patient group had severe dementia and several medical 
comorbidities, a large improvement in sleep could not be expected. Ideally, the trial 
should have included more patients.  
Beyond the total number of participants, the number of clusters was a weakness of the 
DEM.LIGHT trial. Although we accounted for cluster-effects when calculating the 
minimum number of participants needed, we did not calculate the optimal number of 
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clusters. In cluster-randomized longitudinal studies, data are clustered both within each 
individual (several measurements of one individual are likely to correlate) and within 
the cluster. Outcomes from subjects from the same cluster are likely to correlate more 
strongly than with the outcomes of subjects from other clusters [337]. In the 
DEM.LIGHT trial, routines or other characteristics of the different nursing home units 
may have deviated, representing cluster-specific influences on the patients in each 
unit. Importantly, statistical power increases with the number of clusters [338]. 
During the course of the trial, we changed the analytical strategy from analysis of 
variance (ANOVA), to linear mixed modelling. Linear mixed models use all available 
data, perform better when there are missing data, and adjust for correlation due to 
repeated measures [298, 299], and was therefore regarded superior to ANOVA. 
Unfortunately, in order to account for cluster-specific effects using linear mixed 
modelling, at least 10-15 clusters are needed [339]. Thus, the trial should ideally have 
included more clusters. Meanwhile, each cluster represented a significant economic 
cost related to the purchase and instalment of the LED units, and including more than 
the minimum number of required clusters was not possible. 
Accounting for confounding variables 
Confounding variables refer to other factors beyond the intervention that affect the 
outcome and distort the measured effect of the intervention [237]. Nursing home 
patients with dementia are characterized by several factors that are likely to affect the 
outcome, such as high age, multimorbidity, high use of medications, or eye disease. 
Hence, confounding variables were likely in the present study. In order to control for 
confounding variables, we agreed on potential covariates a priori. Variables were 
considered relevant based on the literature and we included them in the models if they 
improved model fit. For example, for the SDI, the average number of psychotropic 
drugs improved model fit and was thus included as a covariate. This implied that the 
model became better at predicting the observed outcomes when we controlled for 
psychotropic drugs, and that those with fewer psychotropic drugs had a larger 
improvement of sleep than those who received more drugs. This strategy was thus both 
theoretically and empirically founded [340]. 
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Accounting for baseline differences 
If the intervention group and the control group are very dissimilar regarding the 
primary outcome and confounding variables at baseline, the estimated treatment effect 
of an intervention may be biased [341]. Systematic baseline differences between the 
groups are minimized by randomization [342]. Some researchers test for significant 
differences between the groups at baseline, to evaluate if the randomization was 
“successful” [343]. However, using an alpha of .05, approximately one in twenty 
significance tests are bound to show a significant result [343]. Therefore, we did not 
test for baseline differences in Paper 3, but rather provided the baseline levels of 
relevant confounding variables (in addition to the primary outcomes) separately for the 
control group and the intervention group.  
Sources of bias 
In relation to Paper 2 and 3, some important threats to internal and external validity 
need to be considered. In the context of intervention studies, internal validity can be 
defined as the extent to which the differences between the intervention group and the 
control group can be correctly attributed to the intervention, while external validity 
refers to the generalizability of the results to other clinical contexts [237]. In the 
following, threats to internal validity, i.e., sources of bias, will be discussed, followed 
by a discussion of external validity. 
Internal validity is threatened by systematic error. Systematic error, or bias, refers to 
systematic deviations of the results from the truth, caused by how the study was 
designed, conducted, or reported [237]. Relevant to Paper 3, bias can lead to an 
overestimation or underestimation of the true effect of an intervention. Bias may also 
have been operating in Paper 2, affecting the correspondence between the SDI and 
actigraphy.  
Selection bias 
Selection bias refers to systematic differences between the intervention group and the 
control group resulting from the way participants have been assigned to the groups 
[344]. In some cluster-randomized studies, individual participants are recruited after 
the clusters are randomized to either the treatment group or the control group. Then, 
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selection bias may be introduced because the researcher is aware which patients will 
end up in the intervention group or the control group, and may potentially recruit 
specific types of participants to the clusters [345]. In the DEM.LIGHT trial, 
randomization and recruitment of the participants of the included units happened 
simultaneously, as light installation needed to be planned and carried out in time 
before the study commenced. The patients already lived in the nursing home units that 
were randomized, i.e., we had no impact on which group (intervention or control) each 
patient ended up in. Participants were excluded from the trial only if they fulfilled the 
exclusion criteria (after discussion with the nursing home physician and nursing staff), 
or if the patient or the legal guardians declined participation. 
Selection bias related to specific outcomes should be considered. For example, some 
patients refused to wear the actigraphs in one or several of the data collections. Those 
that did not want to wear the actigraph may have been more agitated, anxious, or 
confused than those agreeing to wearing them. Thus, the actigraphy outcomes should 
be considered with this in mind. The same issue applies to the MMSE, where several 
patient did not complete the instrument due to agitation or confusion, or because they 
did not want to.    
Attrition bias 
While randomization balance known and unknown confounding factors across the 
intervention and control group, attrition bias may arise if patients are lost to follow-up 
unequally between the groups [237, 346]. During the 24-week follow-up in the 
DEM.LIGHT trial, six patients were lost to follow-up in the intervention group (four 
passed away, two moved), while ten patients were lost to follow-up in the control 
group (nine passed away, one moved). The majority of those that moved, moved due 
to a deterioration of somatic health. Importantly, there is no reason to believe that the 
difference in attrition between the groups was related to the intervention, i.e., that the 
attrition was not random. The nurses did not report adverse events related to the 
intervention.  
 99 
To avoid bias stemming from attrition, we used linear mixed modelling, which uses all 
available data and does not require that participants have completed all four data 
collections. In addition, whether or not a patient was lost to follow-up during the study 
was included as a covariate in the analyses.  
Performance bias and information bias 
Performance bias refers to systematic differences in how the intervention group and 
the control group are treated, other than the intervention [237]. For example, the 
people around a patient (clinicians, family members) may think that a treatment is 
working. This may create a more supportive and optimistic environment around the 
patient, which in turn could cause behavioural change [347]. Performance bias may 
significantly impact the effect estimates of a trial.  
Information bias (or measurement bias) refers to bias arising from how data are 
collected or measured [344]. Information bias is relevant to discuss in relation to the 
SDI and other proxy-rated instruments, which may be subject to bias when the 
response of the proxy-rater is influenced by knowledge of the intervention received 
[348]. If blinding was not successful in the DEM.LIGHT trial, the proxy-raters in the 
intervention group may have reported more favourable outcomes than the raters in the 
control group.   
To reduce performance bias and information bias, we created a placebo condition in 
the nursing home units in the control group by replacing the existing light sources. The 
participants and nursing home staff were blinded to which condition they had been 
assigned to. To prevent any effects of light in the control group, however, the placebo 
condition had standard light levels. To minimize the chance that nursing staff from 
different units could compare the light levels, the intervention and control units were at 
separate nursing homes. However, as lighting is inherently visible, it is challenging to 
blind participants completely to group allocation in BLT studies. The intervention light 
setup required that we installed new light fixtures and the light they emitted was much 
brighter than the lights in the rest of the unit, and thus the intervention may have been 
apparent to the staff. The patients did not seem very concerned about the new light 
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setup, but to the staff, the light might have constituted a constant reminder that they 
were participating in a clinical trial and consequently led to performance bias [347]. In 
contrast, many of the staff in the control units (those not involved in data collection) 
may not have been aware that they were participating in a trial. As a consequence, the 
staff in the intervention group and the control group may have behaved differently 
towards the patients and thus introducing performance bias.  
At the end of the trial, we asked the staff to complete a short questionnaire asking 
about whether they believed they were in the intervention group or in the control 
group. Here, we asked all available staff, not limited to the outcome assessors. Five of 
the 19 staff members in the intervention group who returned the questionnaire believed 
that they were in the control group, while the remaining 14 respondents correctly 
thought that they were in the intervention group (not published). Similarly, two of the 
staff members, out of 12 respondents, in the control group thought that they were in 
the intervention group. Thus, most staff correctly guessed which group they were in 
when prompted, however, the blinding can be argued to have been somewhat 
successful as several wrongly guessed which group they were allocated to. 
Nevertheless, performance bias and information bias may not be ruled out and the 
results should be interpreted with this in mind.   
External validity 
External validity refers to the generalizability of the study results to other settings 
[237]. In the DEM.LIGHT trial, we recruited participants from nursing homes located 
in both urban and rural areas in and around the city of Bergen, and from nursing 
homes of different sizes. We only included dementia units, and thus the participants on 
average probably had more severe dementia than in other nursing home units. Thus, 
the results of Paper 2 and 3 may not be generalized to the general nursing home 
population. However, as approximately 80% of patients in Norwegian nursing homes 
have dementia, and approximately 47% have moderate and severe dementia [125, 139, 
140], it can be argued that the findings may be generalized to a large part of the 
nursing home population in Norway. The generalizability to other countries depends 
on how comparable the nursing home populations are. Due to an extensive expansion 
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of the home-based services for older people in Norway, there has been a reduction in 
the proportion of people living in nursing homes since the 1990s [138]. As a 
consequence, more people live at home for a longer time, and those who are admitted 
to nursing homes are sicker than before. In 2011, 80% of nursing home residents in 
Norway had an extensive need for assistance in performing activities of daily living 
[138]. The circumstances are similar in countries such as Sweden, the Netherlands, 
and the United Kingdom [349], but generalizing to other countries should be done with 
caution. Overall, the findings in Paper 2 and 3 should be considered in light of the 
specific characteristics of the populations, such as high age, severe dementia, and 
multimorbidity. The suggested cut-off for identifying disrupted sleep using the SDI is 
based on this population, which may not translate to other populations. Further, the 
effect of BLT found in Paper 3, i.e., an improvement of the SDI and not actigraphy, 
should also be considered in light of the population. It is, for example, possible that 
more beneficial effects would be found including people with less severe dementia and 
a more intact nervous systems.  
5.3 Ethical considerations 
As the world’s population ages, the challenges of dementia care will dramatically 
increase [152]. Thus, research on dementia care is of both public and academic 
importance. Informed consent represents one of the most important ethical challenges 
pertaining to clinical trials including people with dementia, as outlined in section 1.7.4 
of the background chapter. As we elaborated in the methods section (section 3.1.12), 
the majority of patients did not have the capacity to consent to participate in the 
DEM.LIGHT trial. Thus, their legal guardians provided presumed consent, and the 
participants were informed about the study in an adapted manner. This means that we 
may have included people that would not themselves have agreed to participate. 
Considering this, it may be argued that people with severe dementia should never be 
included in clinical trials. Conversely, one can argue that the potential value of 
effective interventions for this population is of utmost importance.  
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Importantly, the burden on the patients can be argued to have been modest in the 
DEM.LIGHT trial. We used a non-invasive intervention and the majority of outcome 
measures involved the staff as proxy-raters rather than the patients. Three of the 
outcomes, however, involved the participants, namely the actigraphs, the cognitive 
testing (MMSE), and the pain assessmend (MOBID-2). These were only completed if 
the participant agreed to complete the assessment and were discontinued if the 
participant expressed any sign of not wanting to continue. Another important issue 
pertaining to the intervention is that everyone residing in the room where the 
intervention was installed are inevitably exposed to the intervention. In the 
DEM.LIGHT trial, we only installed BLT in the common room of each intervention 
unit, and patients had alternative spaces to socialize, and their private room had 
standard light. That said, the intervention entailed light levels far below outdoor light 
levels, and unwanted effects from the intervention were unlikely. Importantly, nursing 
home staff were asked to report any negative effects that were likely to be caused by 
the intervention.  
5.3.1 Retinal safety 
In healthy adults, light of 17,000 K and 2,500 lux has been determined to be safe in 
terms of retinal damage [101]. Sloane and colleagues [244] assessed the potential 
retinal adverse effects specifically in people with dementia. A retina specialist 
evaluated each participant before and after the study, and also evaluated the potential 
for retinal damage in those who had underwent cataract surgery (and thus lost the 
native yellow “blue blocking” lens). They found no eye changes following the 
intervention of six weeks of ambient light of 13,000 K and 400 lux, delivered from 
wake-up to 18:00. Although no eye examinations were conducted in relation to 






Paper 1 showed that there are promising results regarding the effect of BLT on sleep, 
circadian rhythmicity, and also BPSD. However, large heterogeneity in terms of 
interventions, study designs, and population characteristics may explain the current 
inconsistency of results across studies. Studies also varied in terms of which sleep 
outcomes they measured and how they operationalized actigraphy outputs. Several 
potential moderating factors emerged as we reviewed the study designs and 
procedures.  
Paper 2 showed a satisfactory internal consistency of the SDI and convergent validity 
between the SDI and actigraphy. The ROC analysis showed that the SDI was clinically 
useful, and based on calculations of the Youden’s Index, we suggested a cut-off score 
on the SDI of five or more as defining disrupted sleep. These results should be 
interpreted keeping in mind that actigraphy have some important weaknesses, such as 
underestimating wake time. Also, proxy-rated tools may be vulnerable to bias. 
However, the SDI may represent a useful a screening tool to identify patients in the 
nursing home context with probable sleep problems.  
Paper 3 showed that the SDI of the intervention group improved significantly from 
baseline to week 16 and baseline to week 24, compared to the control group, using an 
ambient BLT solution with a maximum of 1,000 lux and 6,000 K (10:00-15:00). 
However, these findings were not corroborated by actigraphy. Although these results 
are not conclusive about the effect of BLT on sleep in nursing home patients with 
dementia, it adds to the understanding of the potential value of BLT in this population.  
In summary, the evidence for an effect of BLT on sleep in nursing home patients with 
dementia is equivocal. Importantly, clinical trials in the nursing home context face 
some important challenges in terms of measuring sleep in a multimorbid population 
with a range of potential confounding variables.  
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7. Implications and future perspectives 
Based on the systematic review in Paper 1 and the results from the DEM.LIGHT trial 
reported in Paper 3, firm conclusions about the effect of BLT in nursing home patients 
with dementia cannot be drawn. However, some previous RCTs have found positive 
effects on sleep [19, 20, 252], and an improvement in proxy-rated sleep using an 
ambient BLT solution was reported in Paper 3. Importantly, the lack of a robust effect 
of BLT on sleep in dementia may be partly explained by methodological issues (e.g., 
intervention strategy and detecting changes in sleep) and characteristics of the 
population and setting (e.g., various neurodegenerative conditions, polypharmacy, and 
nursing home routines), and future studies should aim to address these issues. 
As reported in Paper 2, the SDI may represent an improvement of the evaluation of 
sleep in the nursing home context. However, the SDI should be validated in a larger 
sample. Importantly, some patients suffering from disturbed sleep, for example sleep 
apnea, may go undetected using the SDI, and further improvements of sleep 
assessment in the nursing home are welcome. Similarly, BLT research involving 
people with dementia would greatly benefit from objective measurements of sleep that 
overcome the weaknesses of actigraphy.  
Although Paper 3 showed an improvement in the SDI in the intervention group, these 
findings were not corroborated by actigraphy. Importantly, the participants recruited to 
the DEM.LIGHT trial had severe dementia. There is a possibility that BLT at this 
stage is less effective, as the patients may have severe neurodegeneration and eye 
pathology that prevent an effect of light on sleep. Future studies should assess the 
effect of BLT earlier in the course of the disease, e.g., among people with mild to 
moderate dementia.  
The DEM.LIGHT trial demonstrated that it is possible to implement ambient BLT in 
nursing homes. A strength of the study was that we completed a pilot and adjusted the 
intervention strategy according to feedback from the staff. The BLT field would 
greatly benefit from more studies evaluating light preferences in the living 
environment, in order to strike a balance between sufficient light exposure to stimulate 
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NIF responses in people with dementia, while also providing a light setting that is 
comfortable for those who live there and are exposed to it. Light preference is 
understudied, and to my knowledge, no studies have evaluated light preference among 
nursing home patients and/or staff.  
The low light levels reported in several studies measuring illumination in nursing 
homes indicate that optimizing indoor light levels in terms of non-visual effects is not 
prioritized in the health sector. In the future, the importance of daylight in sleep-wake 
regulation should be implemented more heavily in nursing homes. In addition to the 
potential of enhanced indoor electrical light/BLT, building nursing homes that allow 
for easy access to areas with ample daylight and facilitating light-orienting behaviour 
in patients might reduce the prevalence of sleep problems in this population. 
Particularly in high-latitude countries such as Norway, exposure to sufficient light 
during the day is challenging during winter. Then, BLT may offer a non-
pharmacological intervention to improve or prohibit a deterioration of sleep among 
nursing home patients. However, more research is needed to identify the optimal 
treatment strategy.  
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Behavioral and psychological symptoms of
dementia
s u m m a r y
Dementia is a devastating disease with a global impact, and there is an urgent need for effective in-
terventions to alleviate the accompanying disturbances in behavior, mood, sleep, and circadian rhythms.
Bright light treatment (BLT) is a promising non-pharmacological intervention; however, studies have
yielded conflicting results. This systematic review provides a comprehensive overview of the effect of BLT
in dementia, with a specific focus on how study characteristics might have affected the available results.
The included studies were small and comprised time-limited interventions and follow-ups. Light values,
adherence to treatment, and time of year were not consistently reported. Varying designs, methods, and
population characteristics such as age, gender, dementia diagnosis, circadian phase, and baseline
symptoms may have moderated the outcomes and affected review results. The use of crossover designs
and too high illumination as placebo lights might have nullified positive effects of BLT. Because some
studies had negative outcomes after ambient BLT with high amounts of short wavelengths, more modest
light levels should be further investigated. Employing rigorous designs and detailed reporting of inter-
vention characteristics, i.e., the illumination, correlated color temperature, timing, and duration of light
utilized, are of utmost importance to establish the optimal treatment approach in this population.
Systematic review registration number: PROSPERO CRD42017051004.
© 2020 Elsevier Ltd. All rights reserved.
Introduction
Approximately 50 million people worldwide are affected by
dementia, and the number is estimated to exceed 150 million by
2050 [1]. Dementia is characterized by impaired cognition, and
“behavioral and psychological symptoms of dementia” (BPSD), such
as sleep problems, agitation, depression, and psychosis [2].
Approximately 90% develop one or more BPSD during the course of
their disease [3,4] and over 70% experience disrupted sleep already
in the early stages of dementia [5]. BPSD and sleep problems result
in distress for the patient and family members [2] and are often the
main causes of institutionalization [6,7]. Thus, effective in-
terventions for BPSD and sleep problems are of great individual and
societal importance.
People with dementia often show circadian dysregulation, with
several sleep and wake periods occurring throughout the 24-h day
[8,9]. Some patients exhibit a diurnal rhythm in BPSD, with
increased agitation, confusion, and wandering in the afternoon and
evening. This phenomenon is referred to as “sundowning” and is
thought to reflect a breakdown of circadian rhythmicity [10e12].
Circadian dysregulation has further pervasive effects on neural and
Abbreviations: AD, Alzheimer's disease; BLT, Bright light treatment; BPSD,
Behavioral and psychological symptoms of dementia; CCT, Correlated color tem-
perature; CMAI, Cohen-Mansfield Agitation Inventory; K, Kelvin; MMSE, Mini-
Mental State Examination; NIF, Non-image forming; RCT, Randomized controlled
trial.
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neuroendocrine systems, including cognitive and emotional func-
tioning [13].
Daylight, our most important “zeitgeber”, entrains circadian
rhythms, and directly affects wakefulness, mood, and cognition,
phenomena referred to as non-image forming (NIF) functions [e.g.,
Ref. [14]]. The physiological response to light depends on duration
and timing of exposure, the amount of light, in terms of illuminance
(lux) and spectral composition, as well as on previous light expo-
sure [15]. The NIF system is maximally sensitive to short wave-
lengths (~460 nm), corresponding to blue light [16,17]. Generally,
by increasing the amount of short wavelengths emitted by light
sources, i.e., increasing the correlated color temperature (CCT),
lower illumination is sufficient to stimulate NIF responses. For
example, 100 lux at the cornea with 4100 K was shown to cause a
mean melatonin suppression of 10%, whereas 100 lux at the cornea
with 8000 K caused a mean melatonin suppression of 32% [18].
With increasing age, the amount of light reaching the retina is
reduced due to lens yellowing and pupil constriction [19,20]. While
compensatory mechanisms may preserve light sensitivity to some
degree [21], lens yellowing has been associated with self-reported
sleep disturbances [22]. Alzheimer's disease (AD) is associated with
pathological changes in the retina and the optic nerve. Importantly,
these include the loss of intrinsically photosensitive melanopsin-
containing retinal ganglion cells, which are largely responsible for
NIF responses [23]. Other ocular changes associated with AD that
may disrupt circadian regulation entail among others glaucoma,
macular degeneration, pupillary dysfunction, and reduction in op-
tical nerve fiber thickness [24]. Further, dementia care institutions
generally appear to have low levels of illumination [25e27], and
home-dwelling dementia sufferers are often exposed to lower light
levels than healthy older adults [28]. In a study of seven nursing
homes in the Netherlands, vertical illuminances in common rooms
fell significantly below the 750 lux reference (based on an age-
adjustment of standard EN 12464-1:2011 [27]) in at least 65% of
the measurements [29]. In addition, the median color temperature
was below the reference value of 5000 K set for daylight. Taken
together, these factors imply that older people suffering from de-
mentia are commonly exposed to insufficient light levels, in turn
contributing to sleep problems and circadian disruption [25,28].
Increasing light exposure, in terms of illumination and/or CCT,
i.e., bright light treatment (BLT), has therefore been suggested to be
a promising non-pharmacological intervention for sleep distur-
bances and BPSD [30]. Typically, BLT has been delivered as high
illumination white light using table-mounted “light boxes”. Recent
technological developments allow for manipulation of both the
illumination levels and CCT, often delivered as ambient light in
common rooms.
BLT has been shown to have positive effects on BPSD [31,32],
sleep [32], and circadian rhythms [33] in dementia. However, a
Cochrane meta-analysis from 2014 concluded that it was “prema-
ture to recommend the use of light therapy in practice” [34]. Other
meta-analyses have reported more encouraging results, with
moderate effect sizes in terms of behavioral disturbances and
depression [35], but small effect sizes regarding sleep [34,36].
These meta-analyses only included randomized-controlled trials
(RCTs), thus many studies were excluded. The mixed study results
andmediocre effects inmeta-analysesmay partly be a consequence
of differences in the design of interventions, such as the timing,
duration, and spectral composition of light. Also, dementia diag-
nosis and severity varied across studies.
Against this backdrop, the present review aimed to synthesize
results from BLT studies including people with dementia, focusing
on identifying methodological characteristics that may have
moderated the outcomes. Specifically, the aims of this review were
to: 1) provide an overview of how light treatment has been
administered (delivery method, timing, duration, illumination and
CCT), 2) describe experimental study designs and outcome mea-
sures, 3) evaluate how study results might have been influenced by
methodological factors.
Method
Systematic literature searches were conducted in relevant da-
tabases: CINAHL, Medline, PsychINFO, Embase, Web of Science, and
Cochrane libraries. The systematic search was conducted in March
2019 covering MESH terms and free text phrases synonymous with
“bright light treatment”, “dementia”, and “nursing home”. A com-
plete overview of the different MESH terms and free text is avail-
able as an online resource (Table S1). No time limit was set for the
searches. We defined BLT as an enhanced indoor electrical light
scheme aimed at impacting NIF responses including mood,
behavior, sleep, and/or circadian rhythmicity. The interventions had
to entail an increase in illumination (lux) and/or CCT compared to
baseline or control conditions. BLT using outdoor daylight often
involves physical and social activity, which have therapeutic effects
[37]. Dawn-dusk simulation does not exceed standard light levels
[38], and did not coincide with how BLT was defined in the present
study. Hence, studies on such interventions were also excluded. The
studies had to inform about lux or equivalent unit. Included studies
had to implement BLT as an intervention using standard care group
comparison, placebo group comparison, or a single group pre-post
design. We only included studies with participants with dementia,
based on medical records, diagnosed specifically for the study ac-
cording to the Diagnostic and Statistical Manual for Mental Disor-
der (DSM) or the International Classification of Disorders (ICD)
system, or by using a Mini-Mental State Examination (MMSE) cut-
off. When both people with and without dementia were included,
the study was included only if the results from the dementia par-
ticipants were reported separately. Only quantitative study designs
were included, excluding publications such as case studies,
chronicles, guidelines, protocols, non-systematic reviews, legal
documents, conference abstracts, and other grey literature, as well
as non-English publications. We also excluded studies where BLT
was combined with other treatments. Based on these criteria, the
authors screened potential manuscripts at the abstract level (E.F.
and G.H.) and subsequently applied the inclusion and exclusion
criteria to selected full texts (G.H. and E.K., see Fig. 1). The reference
lists of the full-text publications were searched for any relevant
publications that were not identified in the systematic search.
All authors agreed on the information of interest, and one
author (G.H.) extracted the content based on a standardized form.
The following information was extracted: full reference, number of
participants, participant characteristics, study design, type of
intervention and control condition, time to follow-up, study
setting, outcome measures, and results. To differentiate between
types of interventions, BLT interventions using 1000 lux or more,
withoutmanipulating CCT, were categorized as “high illumination”,
as this threshold has been used as a definition of bright light in
previous studies [39,40]. Interventions with a CCT of 5000 kelvin
(K) or morewere, for the purpose of this study and in linewith [29],
classified as “high CCT” interventions. In the case of a combination
of high CCT and an illumination of 1000 lux or more, the study was
classified as “high CCT”.
The study quality was assessed using the Oxford Quality Scoring
System [41], in terms of randomization, blinding procedure, and
descriptions of withdrawals. Studies were graded from zero to five,
where a higher score reflected a more rigorous study. The studies
were evaluated by two authors (G.H. and E.K.), and any disagree-
ments were discussed in a group meeting with a third author (E.F.)
to reach consensus.
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Results
The articles included in the review are presented in Table 1. A
comprehensive overview of methodological characteristics of the
included studies are available as a supplement (Table S2). The
systematic search generated 1421 unique hits after duplicates were
excluded (Fig. 1), 73 papers were identified for full-text evaluation,
and of these 31 publications based on 24 studies met the inclusion
criteria. Three publications by Fetveit et al. [42e44] reported from
the same study, two publications by Ancoli-Israel et al. [33,45] re-
ported from the same study, two publications by Onega et al.
[46,47] reported from the same study, and Sloane et al. [48],
Hickman et al. [49], and Barrick et al. [50] reported from the same
study. Lovell et al. [51] reported on a sub-population from a second
study by Ancoli-Israel et al. [52].
Population characteristics
The sample size ranged from 6 to 92. In all, 21 studies included
institutionalized patients, and three studies included home-
dwelling participants. Mean age ranged from 70.1 to 88.2 years. On
average, the sample comprised 63% women. The mean MMSE score
ranged from 0.6 to 22.1 (Table S2). Eight studies reported a specific
symptom or diagnosis, e.g., depression, as an inclusion criterion
[31,32,43,51,53e56]. Four studies excluded participants if they had
sleep-wake disturbances [52,57], or depression [58,59].
Light therapy intervention
The interventions varied in terms of method of delivery, timing,
duration, illumination, and CCT. A total of 16 studies provided BLT
with high illumination (1000 lux or higher). Out of these studies, 14
employed light boxes [31,33,43,47,52,54e62] and one used ceiling-
mounted white light [63]. Target light values of the light boxes
ranged from 2500 to 10,000 lux at eye level from a distance of
0.3 me1.0 m [31,43,45,47,51,52,54e62], as measured at eye level
[33,52,55,61] or provided by the manufacturer. The ceiling-
mounted light provided about 1100 lux measured at eye level
[63]. Only one study reported if the measurement was done hori-
zontally or vertically [63].
Unique hits a er excluding duplicates, 
systema cally evaluated at tle or abstract level 
(n = 1421)
2083 studies iden fied from: Medline = 
335; CINAHL = 166, EMBASE = 652, 
Web of Science = 596, PsychINFO = 164, 
Cochrane reviews = 44, Cochrane other 
reviews = 3, Cochrane Trials = 123
Studies excluded (n = 1348), due to:
- Mee ng abstract (42)
- Cita on (1)
- No relevance (478)
- Not relevant par cipants (104)
- Not bright light treatment (282)
- Not English (65)
- Not original studies (349)
- Not only BLT (6)
- Clinicaltrials.gov (18)
- Cochrane central (3)
Studies considered in full 
text for inclusion
(n =  73)
Full-text studies excluded (n = 42), 
due to:
- Case report (8)
- Grey literature (3)
- Not relevant par cipants (12)
- Not electrical light (4)
- Not only BLT (7)
- Not BLT (1)
- Not original study (7)
Included publica ons 
(n = 31)
Studies iden fied through 
reference list search (n = 0)
Fig. 1. PRISMA based flowchart of the systematic search and review process.
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Eight studies provided BLT by high CCT light, either by ceiling-
mounted light [48,64e66] or by a customized set-up of lumi-
naires [32,53,67,68]. Two studies used lights providing 17,000 K and
6,500 K, but the on-site measurements revealed much lower CCT
values of 7300e8300 K [65] and 4400 K [69], respectively, and with
considerable spread. The remaining studies reported the CCT of the
manufacturer; 6500 Ke13,000 K [32,48,53,66e68]. Illumination
ranged from ~300 lux to ~2500 lux measured at eye level
[32,53,64e67] or at pre-determined locations [48,68]. Five studies
reported if the measurements were done horizontally or vertically
[32,48,64e66]. While the studies using very high CCT
(9000e13,000 K) had modest illumination levels (300e400 lux)
[32,53,65,67], three studies had both high CCT and high illumina-
tion (~1000e2500 lux and ~6500 K) [48,64,66]. A study by
Wahnschaffe et al. achieved quite low light values [69], and with
~4400 K and 400 lux, the daytime illumination was comparable to
the placebo condition in two other studies [48,53]. Notably,
Wahnschaffe and colleagues measured their light vertically. Other
included studies measured their light horizontally, which yielded
higher illumination levels (see Table S2 for overview of light
measuring methods).
Eight studies delivered BLT in the morning (between 07:00 and
12:00) [31,43,55e58,61,62], three studies in the evening (between
16:00 and 20:00) [54,59,60], and nine studies delivered BLT for the
whole day (between 07:00 and 20:00) [32,53,63e69]. Three studies
compared morning, evening, and all-day treatment [45,48,52], and
one administered light both in the morning and evening [47].
Adherence to treatment was addressed in 22 of 24 studies (see
Table S2). Adherence was assessed in different ways (distance to
light source and time spent in relevant area) and only 13 studies
reported the actual light received during treatment and/or time
spent in BLT [32,45,48,52e54,61,63e67,69]. Hence, standardization
concerning assessment and reporting of this in the future seems
necessary.
Study designs and methods
Nine studies were RCTs comparing one or more active condi-
tions to a control condition [45,47,52e54,56,57,59,61], of which
three included a crossover [53,57,61] (Table 1). Two studies used a
non-randomized crossover design [48,65], two had a non-
randomized parallel group design [64,66], and 12 had a pre-post
design [31,32,43,51,55,58,60,62,63,67e69]. Twelve studies had a
placebo condition with lower illumination or lower CCT compared
to the intervention [45,47,48,52,53,56,57,59,61,64e66]. Studies
with a non-comparable control group were treated as pre-post
designs in this review [55,67]. Nine studies attempted to blind
staff and/or raters, four by concealing the study hypothesis
[33,48,51,66] and five by using naïve outcome raters
[47,54,56,57,59]. The study quality ranged from 0 to 3, with a me-
dian of 1 (M ¼ 1.33, SD ¼ 1.13) (Table 1).
Outcomes
Behavioral and psychological symptoms of dementia
BPSD outcomes were reported in 17 studies
[31,32,45,47,49,51,53,55e58,60,64e67,69]. Eight studies measured
depression, where three studies found improvements [32,47,53],
three studies found no change [56,57,67], and two studies found
exacerbated depressive symptoms [49,65]. Season was reported
and accounted for in all but one study of depression [57]. Twelve
studies measured agitation, of which seven studies found reduced
agitation after therapy [31,32,47,51,55,58,69], three reported no
significant effects [56,60,66], and two had some negative results
[45,50]. Six studies used scales assessing a range of dementia-
related behaviors and psychological symptoms [31,56,57,64e66],
where one study had positive results [31], three had no significant
results [56,57,66], two had mixed results, including negative out-
comes [64,65] (Table S2).
Nine of the studies investigating BPSD used high illumination
light, where five had positive outcomes [31,47,51,55,58], three had
no significant findings [56,57,60], and one had negative outcomes
[45]. This latter study reported more observed agitation following
evening BLT of 2500 lux delivered by light box [45]. One RCT using
light boxes of 10,000 lux for eight weeks found improved depres-
sion and agitation, while two other RCTs reported no change using
the same illumination but shorter intervention periods.
Seven studies used high CCT light [32,53,64e67], none of which
were large RCTs, and with mixed results. A randomized crossover
study [53] found decreased depression compared to baseline using
13,000 K light. However, there was no significant difference be-
tween the high CCT intervention and the low-CCTcontrol (both 400
lux), indicating that the decrease in depression may reflect a pla-
cebo effect. Alternatively, the relatively high illumination of 400 lux
at eye level in the placebo condition may have attenuated the
depressive symptoms. That study also investigated carry-over ef-
fects and found no significant carry-over effect on depression after
a four-week washout. Interestingly, three studies found negative
effects of high CCT light [49,50,64,65]. Van Hoof et al. [65] found
increased depressive and anxious behavior after a high CCT con-
dition (aiming at 17,000 K, however achieving a maximum of
12,500 K, and 400e500 lux vertically at eye level) compared to a
low CCT condition. The other study combined high CCT and illu-
mination (6500 K and 1200 lux vertically at eye level) and reported
increased apathetic behavior, but also decreased restlessness. One
study found a negative impact of BLT in men only [49] and a
negative impact in patients with mild to moderate dementia [50],
suggesting that dementia severity and gender may be moderators.
This study used 2500 lux and 6500 K, measured horizontally.
Wahnschaffe et al. found reduced agitation at post-intervention
compared to baseline using more moderate values of 400 lux and
4400 K (measured vertically at eye level) [69].
Thus, eight [31,32,47,51,53,55,58,69] out of 17 studies found
positive effects of BLT on BPSD, and four studies reported negative
effects. Three of these used high CCT ceiling-mounted light, from
6500 K combined with 1200 lux [49,50,64] to a maximum of
12,500 K combined with 400e500 lux [65]. One of nine studies
using high illumination light boxes had negative outcomes [45].
Gender and dementia severity might moderate the effect of BLT on
BPSD. Treatment periods of eight weeks or more might be more
effective.
Functioning and dementia severity
Effects of BLT on functioning and cognition have not been
extensively studied. Only three studies investigated cognitive
function and dementia severity [56,59,62], and three investigated
activities of daily living [32,53,66]. Using high illumination BLT, two
studies found improved MMSE scores [59,62], while one study
found no change in MMSE score in the intervention group
compared to the controls [56]. All of the studies investigating ac-
tivities of daily living delivered high CCT light [32,53,66], and none
reported positive effects. One study [53] found a worsening in
instrumental activities of daily living after high CCT light compared
to low CCT light.
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Sleep
Sleep was assessed with actigraphy in 15 studies (wrist-worn or
bed installed); nine found improvements on some sleep outcomes
[32,33,43,54,60e62,67,68], one reported both positive and negative
outcomes [48], and five found no effect [31,52,53,56,66]. Nine of the
15 studies also measured sleep by questionnaires or observations
[31,32,43,48,53,54,56,58,60]. These results were largely in concor-
dance with actigraphy outcomes. One study measured sleep by
observation only [55] (Table S2).
Nine studies used high illumination light
[33,43,52,54e56,60e62]. Two of these reported positive effects
compared to the control group on wakefulness at night [54] and
duration of sleep bouts [33]. In contrast, Ancoli-Israel et al. [52] and
Burns et al. [56] found no differences in sleep or activity levels
between treatment and control groups using light boxes with 2500
lux and 10,000 lux, respectively. However, the treatment periods
lasted for 10 and 14 days only. Interestingly, two of the controlled
studies with significant effects included exclusively AD patients
[33,54], while the non-significant studies included participants
with different dementias [52,56]. One pre-post study found that
sleep onset latency and sleep efficiency improvedwith BLT [43] and
these effects remained significant at four and 12-week washout
[44].
Six studies on sleep used high CCT light [32,48,53,66e68], of
which two pre-post studies reported significant improvements in
sleep duration and efficiency [32,67]. One study found positive
effects compared to the control group on sleep duration and the
number of sleep bouts [48]. One study reported increased time in
bed and less wandering at night [68]. These improvements were
not reflected in two of the studies with placebo conditions [53,66].
However, when stratifying participants by the light exposure data
from the actigraphs, Münch et al. found that those with higher light
exposure (above the median of 417 lux) had higher activity, less
time in bed, later bed times, and sleep onset, compared to those
with lower light exposure (below 417 lux), regardless of group
allocation [66]. Sloane et al. investigated intervention carry-over
effects and found a significant carry-over effect on proxy-rated
sleep [53].
In summary, the majority of studies reported improvements in
sleep parameters following BLT. The two RCTs with improvements
in sleep included AD patients only [33,54]. The non-significant
studies included all dementia diagnoses and had short treatment
durations [52,56]. Two studies found that the BLT effects lasted
beyond washout periods of up to 12 weeks [44,53].
Circadian rhythm
Twelve studies investigated circadian parameters from acti-
graphs [31e33,48,52,53,56,60,63,66,67,69]; nine reported signifi-
cant effects [31e33,48,52,56,60,63,67], while three found no effects
[53,66,69]. The majority of these outcomes reflect improved
circadian rhythmicity, expressed as higher phasor magnitude
[32,67], higher amplitude [60], reduced intradaily variability
[60,63], increased interdaily stability [63], and a five-parameter
model, encompassing a combination of rhythm indicators [33].
Two studies found effects on activity level [52,56] and three found
effects on circadian phase [31,48,52], which is difficult to interpret
clinically.
Six studies used high illumination light, and all reported some
significant, but sometimes opposing, effects [31,33,52,56,60,63]. For
example, Ancoli-Israel et al. found awithin-group delay of the peak
of the activity rhythm (acrophase) and an increase in the mean
activity level (mesor) in the morning light treatment group [52]. In
contrast, Skjerve et al. found an advance in acrophase [31] and
Burns et al. found a reduction in activity level in the intervention
compared to the placebo group [56].
Five studies investigated the effect of high CCT light on circadian
rhythmicity, measured by actigraphy [32,48,53,66,67]; two
combining high CCT and high illumination [48,66]. The two pre-
post studies found improvements in phasor magnitude, a circa-
dian rhythmicity variable reflecting the correspondence between
light exposure and activity, after four weeks of BLT [32,67]. Im-
provements in circadian rhythmicity were not reflected in the
studies with control groups [48,53,66]. However, one study found
an advance in acrophase during morning BLT compared to the
control condition [48].
Circadian parameters measured by other means than actigraphy
have rarely been investigated. Two studies measured melatonin
[55,66], and three studies measured body temperature under the
arm [59] or in the ear [64,65]. Münch et al. found that participants
with lower light exposure (<417 lux; n ¼ 5) obtained an earlier
melatonin onset than participants with higher exposure (>417 lux;
n ¼ 4) [66]. One study found a delay of the temperature minimum
(nadir) after high illumination BLT in the evening [59], and one
study found a within-group increase in individual temperature
range after all-day high CCT light and a decrease after low CCT light
[64].
The majority of studies on circadian rhythmicity found an effect
of BLT on at least one outcome, combined with several non-
significant outcomes (Table S2). Studies administering BLT in the
morning found opposing results in terms of acrophase [31,48,52].
Discussion
The aim of this paper was to provide a comprehensive overview
of studies investigating the effect of BLT in dementia, focusing on
methodological characteristics. Overall, the results of the included
studies are inconsistent. However, the studies varied widely in terms
of intervention characteristics, designs, outcome measures, and
population characteristics, which may have moderated the out-
comes [31,32,47,51,53,55,58,69]. In addition, most of the studies had
small sample sizes, with time-limited treatment durations of less
than eight weeks, which alsomay have affected the results. Only five
out of the 24 studies reported effect sizes [47,48,54,67,68]. As sta-
tistical significance is highly dependent on sample size, authors
should in the future provide effect sizes in order to ease comparisons
of results across studies.While themajority of studies found positive
effects of BLT [31e33,43,47,48,52e55,58e64,67e69], a few of the
included studies found negative effects of ambient high CCT light on
BPSD [49,50,64,65], activities of daily living [53], and sleep [48].
While these studies had some methodological limitations, such as a
short [53,64] or no [48,65] washout period before crossover, other
possible reasons for the negative results should be considered. In one
study, the CCT levels were very high, and the authors hypothesized
that the light was perceived as unnatural and uncomfortable, and
therefore led to negative behavioral outcomes [65]. Studies have
shown that preference for different CCT levels depend on the type of
activity or the task to be performed [70,71]. One study evaluated the
preference of CCT levels ranging from2000 K to 100,000 K and found
a U-shaped curve, where the subjective preference and visual
comfort was highest for a CCT ranging from 4400 to 6200 K,
depending on the task (relaxing vs working) [71]. The maximum
“acceptable range” spanned only up to 7600 K. Dementia patients
may not have the capacity to express dissatisfaction with their light
environment which may instead be expressed through disrupted
behavior [72]. This impact might apply to all studies using high CCT
ambient light.
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The association between intervention characteristics and outcomes
Duration and timing
While three studies used high illumination light boxes and the
same outcome measures [45,47,56], only the study with a long
(eight-week) treatment period found improvements in BPSD as
compared to treatment durations of ten [45] and 14 [56] days. It
may be that changes in BPSD take longer than two weeks to
manifest, and that longer treatment durations are warranted.
In terms of timing, no clear pattern emerges, corresponding
with other reviews [34e36]. Three studies found more nocturnal
sleep [48] and less nocturnal activity [43,55] with morning and all-
day BLT, but so did one study using evening BLT [60]. Another study
found increased agitation in response to evening BLT [45]. Two
other studies also found similar effects of BLT irrespective of timing
[33,50]. It might be that timing is less important than a general
increase in light exposure, as this population is notoriously under-
exposed to daylight [25,28,29,64].
Illumination and CCT
A moderator analysis in the meta-analysis by Chiu et al. showed
that illumination levels of 2500 lux or higher produced stronger
effects on depression than lower levels [35]. In the present review,
only one of four studies using 2500 lux or higher had significant
positive effects on depression [47], and one had negative outcomes
[49]. Importantly, Chui et al. only included six of the studies
covered in the present review [35]. Overall, it is challenging to
delineate a relationship between illumination, CCT and outcomes
based on the included studies. All high CCT studies used ambient
light, and exposed the participants to all-day light, in contrast to the
restricted duration of BLT by light boxes. Additionally, light levels
weremeasured and reported differently across studies. The present
results indicate that using light boxes delivering from 1500 to
10,000 lux for 30 min to two hours have negligible negative out-
comes, but unclear effectiveness. Meanwhile, several studies re-
ported that high CCT ambient light (from 6500 K and 1200 lux to
13,000 K and 400 lux) had a negative impact on some outcomes
[48e50,53,64,65]. Indeed, Wulff and Foster suggested that there is
a doseeresponse relationship between light exposure and health,
where too little and too much light is aversive [73]. Thus, the effect
of moremoderate light levels should be explored. Positive effects of
ambient light on depression and agitation were found using more
moderate light levels of 400 vertically measured lux and 4400 K
[69]. Those values exceed most indoor light levels [25,74], and may
be sufficient in treating BPSD. However, higher light levels are
probably more effective, considering the impaired light absorption
associated with old age. Thus, when using ambient light, keeping
the light below 6500 K and 1200 lux (measured vertically), but still
as high as possible, could represent a viable solution. Keeping the
CCT about 6000 K makes sense from an evolutionary perspective,
because sunlight have a CCT of around 6000 K [75].
Adherence
In recent years, researchers have provided BLT by manipulating
the ambient light setting. This has reduced the strain on caregivers
to secure treatment compliance and may be more practically
feasible than light boxes. One caveat however, is the challenge of
measuring adherence to treatment. This was demonstrated in the
study by Münch et al., who found no difference in daily light
exposure between the intervention and the control group [66].
When they split the participants into a “high exposure” (above
median of 417 lux) and “low exposure” group (below median), 40%
of the original intervention group had low light exposure. Thus, lack
of effects may be due to adherence issues.
Related to this, light at eye level was not consistently reported,
and only five of 24 studies specified if light was measured vertically
or horizontally [48,63e66]. Lux values vary substantially depend-
ing on the direction of measurement [64,65], and light should thus
be measured vertically at eye level [64]. Another concern is the lack
of standard light quantifiers. In addition to the contribution of rods
and cones, NIF functions are heavily dependent on stimulation of
melanopsin-expressing retinal ganglion cells. The sensitivity of
these cells is not accounted for by lux, which is based on cone cell
sensitivity [see e.g., Ref. [76]].
Choice of placebo/control condition
There is also no consensus on the most appropriate placebo
condition, and choice of placebo might have nullified potential
differences between intervention and control conditions. One
study found no difference in sleep between the high CCT condition
and the low CCT placebo condition [53]. Importantly, the placebo
condition had an illumination of 400 lux and was delivered from
wake-up until 18:00. Wahnschaffe et al. [69] found improved
agitation using 400 lux, suggesting that placebo condition with
such high illuminationmay improve symptoms. Meanwhile, Sloane
et al. used a placebo condition of 500e600 lux, and found signifi-
cant improvements in the intervention compared to the placebo
[48].
Season
Although none of the studies accounting for day length found
any association with depression scores [49,56,67], two studies
found an effect on agitation [56,58]. Thorpe et al. reported lower
agitation during the summer [58]. Meanwhile, Burns et al. reported
that improvement in agitation was negatively associated with day
length, in the intervention as compared to the control group [56].
Indeed, Burns et al. recommended that BLT should only be used
during winter. Seasonwas not consistently reported in the included
studies, precluding analyses of the relationship between outcomes
and season.
The association between study design and outcomes
Five studies had a crossover design; two had no washout before
crossover [48,65], and three had only one to four weeks washout
[53,57,61]. Considering the long-lasting effects of BLT reported by
Fetveit and Bjorvatn [44] and the carry-over effects reported by
Sloane et al. [53], carry-over effects might have attenuated differ-
ences between conditions in studies with cross-over designs. Pos-
itive results from pre-post studies (without control condition) may
reflect well-known non-experimental confounders (e.g., time,
regression towards the mean). In line with this, improvements in
both intervention and placebo conditions were found in some
studies [45,53,56]. To ensure adherence to treatment by light boxes,
NH staff did in some cases interact with and motivate patients.
Hence, it cannot be ruled out that this could have influenced out-
comes beyond the effect of BLT. Lack of blinding may also have
influenced the results in some studies, as some assessors were not
blinded to group allocation. Unblinded studies may show biases
related to placebo-by-proxy [77] and the Hawthorne effect [78,79].
Outcome measures
Choice of measurement tools might partially explain incon-
sistent results across studies. For example, Ancoli-Israel et al.
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[45] and Barrick et al. [50] found no changes in agitation when
using the proxy-rated Cohen-Mansfield Agitation Inventory
(CMAI). Meanwhile, both studies found a worsening of agitation
assessed by observation. The CMAI requires nurses to recall
behavior over the past week and details may thus be lost.
Temporal variations in behavior, such as sundowning, are not
assessed by the CMAI.
Using self-report becomes increasingly challenging with
advancing dementia. When using proxy-rated scales, raters may
be influenced by factors such as information processing,
educational level, and their relationship with the patient. The
responses from self- and proxy raters often diverge, especially
when the construct is latent [80]. NH staff and family members
have different perspectives and may provide different answers.
In addition, outcome measures may have low sensitivity to
change and scales with different psychometric properties may
yield different outcomes.
Sleep outcomes were defined differently across studies, and
seemingly similar actigraphic outcomes were operationalized
divergently. For example, sleep efficiency was sometimes calcu-
lated from individual bedtime and rise time [32,43,66,67], while
other authors set fixed night intervals and calculated sleep effi-
ciency based on these [53]. The use of different actigraphy equip-
ment and software to compute outcome variables, as well as
different durations of actigraph registration, may have influenced
the results [81].
The association between population characteristics and outcomes
In their review, Mitolo et al. suggested that patients with
mild to moderate AD might respond better to BLT than those
with severe AD [82]. Barrick et al. found more agitation with BLT
only among those with mild to moderate dementia, suggesting
that individuals in the earlier stages of dementia are more
sensitive to light exposure [50]. Onega et al. reported however,
that BLT was equally effective on depression in all stages of
dementia, and even more effective in severe dementia on some
subscales [46]. Although the response to BLT might be moder-
ated by dementia severity, the direction is not clear. It is also
unclear whether type of dementia affects the response to BLT.
For example, of two studies using the same protocol [33,52],
only the one that exclusively included AD patients found
improved sleep. Similarly, van Someren et al. reported that
increased circadian rhythm amplitude was associated with AD
[63]. Meanwhile, Mishima et al. found reduced night activity in
patients with vascular dementia, not in AD patients [61].
Lastly, gender may affect BLT responses. Münch et al. found that
higher light exposure was associated with a higher circadian
rhythm amplitude in men only [66]. Hickman et al. reported higher
depression scores in men during morning BLT compared to stan-
dard light [49]. Men may thus be more sensitive to changes in light.
The circadian response to light exposure depends on the circa-
dian phase. Münch et al. found incommensurable melatonin pro-
files in patients with severe dementia [66]. Providing BLT at the
same times to individuals with different rhythms will probably
have diverging effects. For example, Skjerve et al. found that
morning BLTadvanced the acrophase of the activity rhythm only for
patients that had an acrophase after 15:00 at baseline [31]. Studies
investigating the circadian response to BLT should account for
baseline rhythms.
Symptoms at baseline often had a wide range in the study
populations and were sometimes subclinical. For example, Burns
et al. found no effect on sleep [56]; however, the participants had a
mean sleep duration within healthy parameters (8.3 h) at baseline.
Although Van der Ploeg et al. recommended that target symptoms
should be at clinical levels at baseline [83], this is not always
possible in studies that measure a range of symptoms associated
with dementia. Other patient characteristics that may have
moderated study outcomes are medications, multi-morbidity, and
pain. Such factors are difficult to control for, particularly with small
study samples.
Conclusions
Overall, there are promising results regarding the effect of BLT
on BPSD, sleep, and circadian rhythmicity. However, large hetero-
geneity in terms of interventions, study designs, and population
characteristics occlude final conclusions. Outcomes are inconsis-
tent and several potential moderating factors emerged as we took a
closer look at study designs and procedures. Thus, the inconsis-
tency of results should not be interpreted as a lack of effect of BLT in
dementia, but can rather be ascribed to the heterogeneity of the
studies.
To resolve the inconsistencies in this field, future BLT studies
should use a randomized placebo-controlled design with a treat-
ment period lasting for a minimum of two months. Cross-over
designs should account for the potential long-lasting effects of
BLT. Trials should have sufficient statistical power to allow for
subgroup analyses regarding potential moderators such as de-
mentia severity and diagnosis, gender, individual circadian phase,
and level of baseline symptoms. Light levels should be measured
vertically at eye level.
Because BLT has caused negative effects in some studies, the
light delivered should stay within acceptable levels. The ability
of light to produce NIF responses can be ensured by increasing
both illumination and CCT over a prolonged period of time,
without increasing the levels to uncomfortable levels. Ambient
high CCT light of 6500 K combined with 1200 vertically
measures lux, was associated with some negative outcomes. The
effect of ambient light using lower CCT values should be inves-
tigated, i.e., 6000 K in combination with a maximum of 1200 lux.
Bright light is relatively invasive in people's environment, and
the physiological effect on the circadian system, alertness, and
more cannot be disentangled from subjective experiences and
preferences. Developing light solutions that are effective, as well
as being comfortable and aesthetically pleasant, should be a
priority.
Practice points
The majority of studies on bright light treatment in de-
mentia have reported positive effects on sleep, circadian
rhythm, and behavioral and psychological symptoms,
however:
 Beneficial effects were found following BLT administered
at different times, from early morning to early evening.
Hence, the optimal timing of BLT is unclear, but is likely to
depend on the circadian phase of the individual.
 Longer exposure duration, for months instead of days or
weeks, is associated with better responses.
 Light with high amounts of short wavelengths might
cause negative effects on mood and function.
 The use of crossover designs and too intense placebo
lights in some studies might have nullified the positive
effects of bright light treatment.
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Table S1: The search strategy of the systematic database search 12.mars 2019 
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
<1946 to March 11, 2019> 
12. March 2019 
1     dementia/ or alzheimer disease/ or frontotemporal lobar degeneration/ or lewy body disease/ (127103) 
2     Delirium, Dementia, Amnestic, Cognitive Disorders/ (8918) 
3     (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease").tw. (196117) 
4     1 or 2 or 3 (221121) 
5     homes for the aged/ or exp nursing homes/ (42142) 
6     Hospices/ (4858) 
7     (nursing home* or "home* for the aged" or hospice*).tw. (39709) 
8     5 or 6 or 7 (64296) 
9     4 or 8 (277930) 
10     phototherapy/ or color therapy/ or heliotherapy/ or intense pulsed light therapy/ (8483) 
11     (Phototherap* or Photo Therap* or dawn-dusk or dawn dusk).ti,ab. (8235) 
12     ((light* or illuminat*) adj2 (bright or therap* or treatment or box or visor* or exposure* or LED)).ti,ab. 
(19226) 
13     10 or 11 or 12 (31221) 
14     9 and 13 (335) 
Ovid Embase <1974 to 2019 March 11> 
12. March 2019 
1     health care facility/ or hospice/ or nursing home/ (121516) 
2     home for the aged/ (10518) 
3     (nursing home* or "home* for the aged" or hospice*).tw. (52566) 
4     1 or 2 or 3 (143100) 
5     dementia/ or alzheimer disease/ or diffuse lewy body disease/ or frontotemporal dementia/ or "mixed 
depression and dementia"/ or exp senile dementia/ (268195) 
6     (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease").tw. (272239) 
7     5 or 6 (323024) 
8     4 or 7 (455269) 
9     phototherapy/ or color therapy/ or intense pulsed light therapy/ (22235) 
10     (Phototherap* or Photo Therap* or dawn-dusk or dawn dusk).ti,ab. (11289) 
11     ((light* or illuminat*) adj2 (bright or therap* or treatment or box or visor* or exposure* or LED)).ti,ab. 
(22485) 
12     9 or 10 or 11 (44953) 
13     8 and 12 (652) 
Ovid PsycINFO <1806 to March Week 1 2019> 
12. March 2019 
1     residential care institutions/ or nursing homes/ (17932) 
2     hospice/ (3093) 
3     (nursing home* or "home* for the aged" or hospice*).tw. (16824) 
4     1 or 2 or 3 (27148) 
5     dementia/ or dementia with lewy bodies/ or exp senile dementia/ or vascular dementia/ or alzheimer's 
disease/ or senile plaques/ (69929) 
6     (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease").tw. (96382) 
7     5 or 6 (97149) 
8     4 or 7 (119755) 
9     phototherapy/ (911) 
10     (Phototherap* or Photo Therap* or dawn-dusk or dawn dusk).ti,ab. (329) 
11     ((light* or illuminat*) adj2 (bright or therap* or treatment or box or visor* or exposure* or LED)).ti,ab. 
(3923) 
12     9 or 10 or 11 (4233) 
13     8 and 12 (164) 
Cochrane library (Wiley) 
12. March 2019 
#1 dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease":ti,ab,kw 
(Word variations have been searched) 21360 
 
 
#2 MeSH descriptor: [Nursing Homes] explode all trees 1228 
#3 nursing home* or "home* for the aged" or hospice*:ti,ab,kw (Word variations have been searched)
 8991 
#4 #1 or #2 or #3 26997 
#5 "color therapy" or heliotherapy:ti,ab,kw (Word variations have been searched) 53 
#6 Phototherap* or Photo Therap* or dawn-dusk or "dawn dusk":ti,ab,kw (Word variations have been 
searched) 2862 
#7 (light* or illuminat*) near/2 (bright or therap* or treatment or box or visor* or exposure* or 
LED):ti,ab,kw (Word variations have been searched) 2770 
#8 #5 or #6 or #7 4801 
#9 #4 and #8 176 
CINAHL (Ebsco) 1981 – now 
12. March 2019 
S1 (MH "Nursing Homes+") OR (MH "Nursing Home Patients")   (32,103) 
S2 (MH "Hospices") OR (MH "Hospice Patients")   (3,335) 
S3 TI ( (nursing home* or "home* for the aged" or hospice*) ) OR AB ( (nursing home* or "home* for 
the aged" or hospice*) )   (32,778) 
S4 S1 OR S2 OR S3   (52,401) 
S5 (MH "Dementia") OR (MH "Dementia, Senile+") OR (MH "Lewy Body Disease") OR (MH 
"Dementia, Multi-Infarct")   (58,765) 
S6 (MH "Delirium, Dementia, Amnestic, Cognitive Disorders")   (118) 
S7 TI ( (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease") ) OR 
AB ( (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body disease") )   
(61,437) 
S8 S5 OR S6 OR S7   (75,726) 
S9 S4 OR S8   (121,526) 
S10 (MH "Phototherapy")   (2,865) 
S11 TI ( Phototherap* OR "Photo Therap*" OR dawn-dusk OR "dawn dusk" ) OR AB ( Phototherap* OR 
"Photo Therap*" OR dawn-dusk OR "dawn dusk" )   (1,340) 
S12 TI ( (light* or illuminat*) N2 (bright or therap* or treatment or box or visor* or exposure* or LED) ) 
OR AB ( (light* or illuminat*) N2 (bright or therap* or treatment or box or visor* or exposure* or LED) ) 
  (2,770) 
S13 S10 OR S11 OR S12   (5,689) 
S14 S9 AND S13  (166) 
Web of Science (Thomson & Reuters), Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All 
years    
12.March 2019 
# 8 596  - #7 AND #3 
# 7 58,559   - #6 OR #5 OR #4 
# 6 48,261   - TOPIC: ((light* or illuminat*) near/2 (bright or therap* or treatment or box or visor* or 
exposure* or LED)) 
# 5 11,225   - TOPIC: (Phototherap* or "Photo Therap*" or dawn-dusk or "dawn dusk") 
# 4 108  - TOPIC: ("color therapy" or heliotherapy) 
# 3 334,628  - #2 OR #1 
# 2 45,583  - TOPIC: ("nursing home*" or "home* for the aged" or hospice*) 
# 1 298,621  - TOPIC: (dement* or alzheimer* or "Frontotemporal lobar degeneration" or "Lewy Body 
disease") 
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Background: Disrupted sleep is common among nursing home patients with dementia
and is associated with increased agitation, depression, and cognitive impairment.
Detecting and treating sleep problems in this population are therefore of great
importance, albeit challenging. Systematic observation and objective recordings of sleep
are time-consuming and resource intensive and self-report is often unreliable. Commonly
used proxy-rated scales contain few sleep items, which affects the reliability of the raters’
reports. The present study aimed to adapt the proxy-rated Sleep Disorder Inventory (SDI)
to a nursing home context and validate it against actigraphy.
Methods: Cross-sectional study of 69 nursing home patients, 68% women, mean
age 83.5 (SD 7.1). Sleep was assessed with the SDI, completed by nursing home
staff, and with actigraphy (Actiwatch II, Philips Respironics). The SDI evaluates the
frequency, severity, and distress of seven sleep-related behaviors. Internal consistency
of the SDI was evaluated by Cronbach’s alpha. Spearman correlations were used to
evaluate the convergent validity between actigraphy and the SDI. Test performance was
assessed by calculating the sensitivity, specificity, and predictive values, and by ROC
curve analyses. The Youden’s Index was used to determine the most appropriate cut-off
against objectively measured sleep disturbance defined as <6 h nocturnal total sleep
time (TST) during 8 h nocturnal bed rest (corresponding to SE <75%).
Results: The SDI had high internal consistency and convergent validity. Three SDI
summary scores correlated moderately and significantly with actigraphically measured
TST and wake-after-sleep-onset. A cut-off score of five or more on the SDI summed
product score (sum of the products of the frequency and severity of each item) yielded
the best sensitivity, specificity, predictive values, and Youden’s Index.
Hjetland et al. Sleep Disorder Inventory Validation
Conclusion: We suggest a clinical cut-off for the presence of disturbed sleep in
institutionalized dementia patients to be a SDI summed product score of five or more.
The results suggest that the SDI can be clinically useful for the identification of disrupted
sleep when administered by daytime staff in a nursing home context.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03357328.
Keywords: dementia, sleep, proxy-rating, actigraphy, nursing home
INTRODUCTION
Sleep problems and disturbed nocturnal behavior constitute
important aspects of the behavioral and psychological symptoms
of dementia (BPSD) (1). In nursing homes, night-time
wandering, confusion, and related behaviors can increase
the risk of patient injuries, e.g., falling (2), and may cause
disturbances for other residents. Such behaviors are also
distressing and resource demanding for the staff (3).
As part of normal aging, characteristic changes in sleep and
circadian rhythmicity take place. These entail a reduction in sleep
duration and the proportion of slow wave sleep, as well as sleep
fragmentation and an increase in the frequency and duration
of daytime naps (4). Commonly, the sleep phase is advanced,
implying that older people tend to experience sleepiness earlier
in the evening and wake up earlier in the morning than desired.
Also, the prevalence of some primary sleep disorders, such as
sleep-disordered breathing, increases with age (5).
Sleep and circadian alterations are more frequent in patients
suffering from dementia than in normal aging, and studies
have provided estimates of disturbed sleep from 24% (6, 7) to
70% in dementia populations (8, 9). Brain systems involved
in sleep and wakefulness are often increasingly affected as
neurodegeneration progresses (10). Moreover, the causes of
disturbed sleep in dementia are multiple, and factors such
as inactivity, medications, and reduced exposure to social
interaction and reduced daylight exposure are all associated with
disturbed sleep (11–13).
Disruption of sleep and circadian rhythmicity have been
associated with increased agitation (14), depressive symptoms
(15–17), and cognitive impairment (15, 18) in people with
dementia. In addition, disturbed sleep has been identified
as an important cause of caregiver distress (19, 20) and of
institutionalization of patients suffering from dementia (21–23).
Detecting and treating disturbed sleep is of crucial importance
in relation to improving behavioral and mood related symptoms,
enhancing well-being, and reducing caregiver distress.
Assessing disturbed sleep in people with dementia is
challenging, as self-report may be unreliable and, in many cases,
unfeasible. Most et al. (24) demonstrated that even in the early
and middle stages of Alzheimer’s disease (AD), patients had
more objectively measured sleep problems compared to healthy
age-matched controls, however, the former group self-reported
fewer sleep problems. Hence, clinicians and researchers often
rely on proxy-rater instruments, where nurses or relatives answer
on behalf of the patient. Unfortunately, research suggests that
nursing home staff often provide unreliable and inaccurate
reports of their patients’ sleep when not using adequate
instruments (25–27). For example, using the sleep items of
the Cornell Scale of Depression in Dementia (CSDD) and the
Neuropsychiatric Inventory (NPI) in a nursing home population,
Blytt et al. (25) found that staff reported significantly fewer sleep
problems than measured by actigraphy. Their study suggested
that disturbed sleep may go largely undetected in the nursing
home population when measured by staff rated instruments with
only one or a few items. Meanwhile, using the comprehensive
21-items Circadian Sleep Inventory for Normal and Pathological
States (CSINAPS), completed by nursing home nurses, Hoekert
et al. (27) found only small-to-medium associations between
actigraphy parameters and scale items and subscales. However,
systematic observation of sleep behavior often requires that staff
frequently or continuously observe each patient across several
days (28, 29). Such time consuming and resource intensive
assessments are not necessarily feasible in a nursing home
context. Further, objective measures of sleep such as actigraphy
are rarely used in clinical contexts due to the cost of the
equipment and the time and skill needed to interpret the output.
Thus, identifying a relatively short questionnaire that more
accurately detect sleep problems in dementia populations has the
potential of providing caregiving staff with a clinically important
and more feasible tool.
To the authors’ knowledge, the Sleep Disorder Inventory
(SDI) (30) is the only short-form scale that exclusively focuses
on evaluating sleep in dementia populations. Tractenberg
and colleagues (30) have demonstrated appropriate convergent
validity (i.e., significant correlations with actigraphy) in a group
of home-dwelling participants suffering from AD. To date, the
SDI has not been validated for use in the nursing home context,
despite the need for clinically relevant and easy-to administer
sleep assessment tools in these settings.
Accordingly, the aim of the current study was to evaluate the
SDI in the nursing home context after adapting item wording
accordingly. Specifically, we aimed to: (i) assess the adapted SDI’s
internal consistency, (ii) investigate the convergent validity of the
adapted SDI against actigraphy, (iii) and suggest a clinical cut-off
for disturbed sleep in nursing home patients with dementia.
MATERIALS AND METHODS
Sample and Setting
This study used baseline data from a 6-months cluster-
randomized placebo-controlled trial, evaluating the effectiveness
of bright light treatment in people with dementia (the
DEM.LIGHT trial, ClinicalTrials.gov Identifier: NCT03357328).
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TABLE 1 | List of sample inclusion and exclusion criteria.
Participants were eligible if they: Patients were not included in the
study if they:
- were ≥60 years and in long-term
care (>4 weeks)
- had dementia in accordance with
DSM-5
- had either sleep/circadian rhythm
disturbances, BPSD as identified by
NPI-NH, or severely reduced ADL
function
- provided written informed consent if
the participant had capacity or, if
not, a written proxy informed
consent from a legally
authorized representative
- were blind or may otherwise not
benefit from light
- took part in another trial
- had a condition contra-indicated to
the intervention
- had an advanced, severe medical
disease/disorder and/or expected
survival less of than 6 months or
other aspects that could interfere
with participation
- were psychotic or had a severe
mental disorder
ADL, Activities of Daily Living; BPSD, Behavioral and Psychological Symptoms
of Dementia; DSM-5=Diagnostic and Statistical Manual of Mental Disorders-5;
FAST, Functional Assessment Staging; NPI-NH, Neuropsychiatric Inventory-Nursing
Home Version.
The trial was conducted in Norway from September 2017 to April
2018. We invited the Department of Health and Care, City of
Bergen, Norway, to participate in the study with eight eligible
nursing home dementia units (e.g., nursing homes that were not
involved in other trials or quality of care projects and that had
an architecture that allowed for ceiling light installment). See
Table 1 for inclusion and exclusion criteria.
Measurements
Researchers involved in the DEM.LIGHT trial supervised nurses
in the use of assessment tools. Only staff that knew the
patients well, i.e., the regular nursing staff, working directly with
the patients, completed the questionnaires. Daytime personnel
completed the questionnaires used in the present study, as
part of a larger data collection. The daytime nurses usually
convey information about patients to the attending physician
and are normally well-informed about nocturnal behavior of
the patients. In the present study, the questionnaires were
administered either the same week as the patients wore an
actigraph or the following week. The questionnaires were
completed once. Sociodemographic characteristics, medication
status, and diagnoses were collected from medical records.
The Mini-Mental State Examination (MMSE) (31) was used
to evaluate cognitive impairment at baseline. The total score
ranges from 0 to 30; zero to ten points corresponds to severe
dementia, 11–20 to moderate, 21–25 to mild dementia, 26–29
to questionable dementia, and 30 to no dementia (32). The
MMSE was administered the same week as the patients wore
the actigraph.
Sleep disturbance symptoms were assessed with the SDI,
which evaluates nocturnal behavior for the last 2 weeks (30).
The SDI is derived from the sleep item and its follow-up-
questions of the Neuropsychiatric Inventory (NPI) (33). The
NPI evaluates the frequency, severity, and caregiver distress
of several behavioral and psychological disturbances which
commonly occur in dementia, including disturbed sleep. The
questions pertain to the previous 4 weeks. Each item (e.g.,
agitation/aggression, anxiety, sleep) has a description to aid
determining whether and to what extent a disturbance occurs.
For the sleep item the description includes: “Does the patient
have difficulty sleeping? Is he/she up at night? Does he/she
wander at night, get dressed, or disturb your sleep?” Endorsement
of any of these behaviors elicits seven follow-up questions. The
NPI sleep item score is based on a single frequency and severity
rating for all the sleep disruption-related behaviors. The SDI was
developed by assigning a frequency (0–4), severity (0–3), and
caregiver distress (0–5) score to each of the follow-up questions
of the NPI sleep item (30).
The SDI was developed to be rated by the live-in caregivers
of home-dwelling seniors suffering from dementia. For the
DEM.LIGHT trial, the SDI was translated to Norwegian and
adapted to the nursing home context. Item 4 (“awakening you
during the night”) was changed into (“awakening at night”), in
order to take into account that patients may be awake at night
without engaging in any of the behaviors covered by other items
(e.g., wandering, getting out of bed). The translation process
adhered to standard guidelines to reach a cultural equivalence of
instruments (34). As some of the wording in the SDI was identical
to the NPI, which had already been translated to Norwegian (35),
we used the existing translations when possible. The SDI contains
eight items (see Supplementary Material), where the eighth item
asks about any additional information not captured by items 1–7.
Only items 1–7 were included in the total score.
In the original paper, Tractenberg et al. (30) calculated the
total SDI score as the average frequency multiplied by the
average severity. This total score has been used by other authors
adopting the scale (36, 37). When using this calculation, the total
score may however vary greatly depending on the distribution
of frequency and severity scores across items. For example,
having three frequently occurring symptoms (frequency = 4)
of mild severity (severity = 1) produces a higher total score
(=0.74, calculations provided in the Supplementary Material)
than having one frequently (frequency = 4) occurring symptom
of marked severity (severity = 3; = 0.25). Other authors have
therefore calculated the total score as the sum of the products of
the frequency and severity of each of the single items of the scale
(38, 39). This way of calculating the total score provides the same
total score for both of the scenarios outlined above (both = 12).
In the present study, both approaches to total score calculation
were investigated, where the former is referred to as the “SDI
average total score” and the latter is referred to as the “SDI
summed product score.” We also calculated summed frequency
as a general indicator of “overall disturbance” (referred to as the
“SDI summed frequency score”). Higher values on all of these
composite scores represent “worse sleep disturbance,” although
as noted above, these summaries are not linearly comparable. In
line with the original paper (30), mean frequency, severity, and
caregiver distress were also calculated.
The single sleep item from the nursing home version of
the NPI (NPI-NH) (35, 40) was investigated in relation to the
SDI. The NPI-NH asks about the previous 4 weeks. The NPI-
NH sleep item comes with a description similar to the NPI,
followed by six follow-up questions (including “other nighttime
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behaviors”). Previous studies have suggested a cut-off product
score of frequency (1–4) multiplied by severity (1–3) of ≥4 to
define the presence of sleep disturbance on this single item from
the NPI-NH (25, 41). In contrast to the SDI, the NPI-NH follow-
up questions do not ask about excessive daytime sleep (SDI item
7) or if the patient wake up during the night without engaging in
any specific behaviors (SDI item 4).
Sleep was objectively measured using the Actiwatch II (Philips
Respironics). Actigraphs are wrist-worn devices that can measure
activity across several days, and even weeks (42). The actigraphs
were placed on the dominant wrist, in accordance with previous
studies in this population (8, 25). Each 1-min epoch was scored
as either sleep or wake by the Actiware 6.0.9 (Philips Respironics)
software, based on activity from the two epochs immediately
preceding and following the relevant epoch. The threshold for
wakefulness was set to medium. Activity data were collected
for 7 days and patients had to complete at least five nights of
recordings to be included in the analyses. We initially planned
to score the actigraphic recordings manually, in line with a
premediated scoring protocol (25). However, it was challenging
to determine the start and end of the rest intervals. The event
buttons were not consistently pressed by the nursing home staff.
Additionally, many dementia patients have severely fragmented
sleep, thus, there were rarely clear indications of bedtime and
rise time in the actograms, normally indicated by a marked and
sustained decrease/increase in activity and/or light levels (25, 43).
These challenges are common in this population, and researchers
have typically solved these issues by setting a fixed rest interval
[e.g., (8, 14, 44–53)]. A range of rest intervals have been used
earlier and a fixed rest interval from 22:00 to 06:00 was chosen
for the present study, as it represents a sensible intermediate
of these. It was expected that the majority of patients would
be in bed by 22:00 and that the aforementioned interval would
overlap with the main sleep episode of most of the participants.
When using a fixed rest interval, some commonly reported
actigraphy outcomes become invalid, such as sleep onset latency
and early morning awakenings. Thus, the following actigraphy
outputs were extracted from the rest interval: Sleep efficiency
(SE, the percentage of time spent asleep in the rest interval),
total sleep time (TST), and wake-after-sleep-onset (WASO, the
time spent awake after sleep onset). While TST is a quantitative
measure of sleep, SE and WASO reflect mainly sleep quality,
although the latter parameters do not necessarily correspond
with subjectively reported sleep quality (54). The scores used for
SE, TST, and WASO were calculated as the mean value for all
nights of recorded actigraphy. These outputs are largely linear
in a fixed rest interval. In addition, the 24 h fragmentation index
was extracted, as an indication of the overall disturbance of the
sleep-wake rhythm across the day and night.
Having a SE of below 85% is often used as a cut-off for
identifying disrupted sleep in otherwise healthy populations
(55, 56). This corresponds to a TST of 6 h and 48min in the
fixed rest interval, which is close to the 7 h that is considered
normal in healthy populations (57). Dementia patients frequently
sleep during the day and some stay in bed for 12–13 h per
day (25), and it was therefore considered too strict to use
a cut-off of 6 h and 48min TST in the present study. Thus,
in agreement with Yesavage et al. (52), we used TST as the
indicator of overall sleep disturbance and TST values<6.0 h were
characterized as “disturbed” sleep, while those sleeping 6 h or
more were characterized as having “not disturbed” sleep. This
cutoff corresponds to a SE of 75% in the fixed rest interval
(22:00–06:00), a cutoff that has previously been used in dementia
populations (58).
Statistical Analyses
Statistical analyses were performed in SPSS for Windows, version
25.0. All data were analyzed for normality and non-normal data
were analyzed using non-parametric tests. Confidence intervals
(CIs) for medians were calculated using the Ratio Statistic in
SPSS. Due to the lack of distributional assumptions, the 95% CIs
for the Ratio Statistic represent approximations.
Missing Data and Imputation
There were some missing data on the SDI at baseline. Little’s
MCAR test was not significant (p =0.151), meaning that data
were missing completely at random (59). Imputations were thus
made by Expectation Maximization (EM) when questionnaires
were missing <20% of items (31 items from 11 patients, 2.2%
of all items). Three questionnaires were missing ≥20% and data
from these were excluded altogether from the analyses.
Internal Consistency
Internal consistency of the adapted SDI was evaluated using
Cronbach’s alpha (60), estimated as item-total correlations. A
Cronbach’s alpha of 0.7 and above is normally considered
acceptable (61). The internal consistency analyses were computed
separately for the frequency and severity ratings.
Convergent Validity
The strength of the relationships between the three different SDI
total scores, the single NPI sleep item (frequency × severity),
and actigraphic parameters were explored using Spearman
correlations. As TST and SE are perfect linear functions of each
other in a fixed rest interval, only TST,WASO, and fragmentation
index were included in this analysis.
Test Accuracy
Receiver operating characteristic (ROC) curves were calculated
for the actigraphy-based cut-off (“disturbed sleep” defined as a
TST of<6 h) against the SDI outcomes, in order to investigate the
diagnostic performance of each of the SDI composite scores (SDI
average total score, SDI summed product score, and SDI summed
frequency).We defined “disturbed sleep” as an average actigraphy
TST value of <6 h; this dichotomous variable was the outcome
in the ROC curve analysis (30, 52). The “area under the curve”
(AUC) score reflects the discriminatory ability of the test (62) or
SDI summary, in this case, for the outcome (disturbed sleep as
defined by TST). A high AUC score implies that the rate of true
positives is high and that the rate of false positives is low. AnAUC
score below 0.75 is not considered clinically useful (62).
Sensitivity, specificity, predictive values, and the rate of true
positives, false positives, true negatives, and false negatives were
calculated for the SDI summaries, to investigate which outcome
and which cut-off was the most clinically useful. Sensitivity refers
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to the proportion with the condition that get a positive test
result (true positives), while specificity refers to those who do
not suffer from the condition and that get a negative test result
(true negatives) (63). The positive predictive value refers to the
proportion of positive results that are true positives, while the
negative predictive value refers to the proportion of negative
results that are true negatives.
Youden’s Index
The Youden’s index (sensitivity + specificity-1) is a common
summary measure for the ROC curve and is used to determine
the most appropriate cut-off value for a scale (64–66). This index
incorporates sensitivity and specificity and the cut-off that yields
the highest Youden’s index value is regarded as the “optimal”
threshold value. The Youden’s Index was calculated for the SDI
summed product score and the SDI summed frequency score.
Ethical Approval and Consent to
Participate
Through conversations with the physician at each nursing
home, patients who were most likely able to provide informed
consent were identified. The researchers endeavored to inform all
participants about the study in an adapted way, and continuously
evaluated the capacity to provide consent. Most patients were not
able to provide consent. In these cases, the patient’s legal guardian
was contacted directly. After being approached by a phone call,
they received a letter by postal mail containing all relevant
information about the aims, proceedings, and ethical approval of
the trial, after which they gave a presumed informed consent on
behalf of the patient. In giving a presumed consent, the patient’s
guardian was instructed to consider what the patient would have
wished for in this situation, not what they themselves believed
was most pertinent. Across the study period, the researchers were
sensitive to any expressions of discomfort or protests from the
participants; and considered this as withdrawal of consent. The
study was approved by the Regional Ethics Committee (REC
South East 2016/2246).
RESULTS
A total of 69 participants were enrolled, of whom 68% were
women, mean age was 83.5 (SD 7.1), and mean MMSE was 6.4
(SD 6.7). Descriptive statistics and diagnoses are provided in
Table 2. Figure 1 shows the full inclusion and exclusion of study
participants leaving 62 with actigraphy recordings over at least 5
days and 65 with completed SDIs. A total of 59 patients had both
completed SDI and had sufficient actigraphy recordings.
Sleep Assessed With SDI
The SDI scores were not normally distributed, with the majority
of patients obtaining low scores. Therefore, the median was used
to summarize the group, instead of the mean (Table 3). In all,
19 patients (32%) had a total score of 0. The median of the SDI
average total score was 0.06 and the median of the SDI summed
product score and the SDI summed frequency score was 3.00.
Mean frequency was 0.43, mean intensity was 0.14, and mean
TABLE 2 | Descriptive statistics for the 69 patients.
Age (mean, SD) 83.5 (7.1)
Female (%) 68.0%
Mini mental state examination sum score,
mean (SD) (n = 56)
6.4 (6.7), median
4.0
Dementia diagnoses, n (%)
Alzheimer’s disease (AD) 38 (55.1)
Mixed AD and vascular dementia 0
Lewy body dementia 1 (1.4)
Other dementia 2 (2.9)
Vascular dementia 4 (5.8)
Frontotemporal dementia 0
Parkinson’s dementia 0
Unknown dementia 21 (30.4)
No diagnosis¤ 3 (4.4)
Neuropsychiatric inventory (NPI) (n = 69)
NPI total score, median (25th−75th percentile) 21.0 (6.0–42.0)
Sleep item score, median (25th−75th percentile) 0.0 (0.0–4.0)
Sleep item score ≥ 4, n (%) 18 (26.1)
Sleep item score 0, n (%) 38 (55.1)
Total number of medications (mean, SD) 6.7 (2.8)
Number of psychotropic medications* (mean, SD) 2.9 (1.3)




*All medications with an ATC code starting with N.
§All medications with an ATC code starting with N05C.
¤These patients were still included as their scores on the Mini Mental State Examination
and the Functional Assessment Staging suggest moderate and severe dementia. In
addition, clinically trained researchers concluded that they with high probability suffered
from dementia according to the DSM-5 criteria.
staff distress was 0.29. All SDI-based scores had a wide range,
reflecting heterogeneity in the sample.
The most frequent behavior was waking up at night,
happening at least once a week (i.e., endorsed by the staff) for
46% of the patients (Table 4). Getting up during the night was
endorsed for 34% of the patients and 31% engaged in wandering
or inappropriate activities during the night. The three items
reflecting these behaviors were also the most distressing to the
nursing personnel. One third of the patients were reported to
sleep excessively during the day at least once a week, but this
behavior caused less distress among staff.
Sleep Assessed With Actigraphy
The actigraph results were based on recordings including a mean
of 7.6 (SD 1.4, range 5–14) nights. The median sleep length (TST)
within the rest interval (i.e., at night) was 6 h 19min (95% CI 5 h
23 min−6 h 41min) and the median SE was 79% (95% CI 69–
84) (Table 5). The time spent awake after sleep onset (WASO)
was normally distributed and had a mean of 1 h 9min (95% CI
57 min−1 h 20min). The 24 h fragmentation index had a mean
of 93.2 (95% CI 88.0–98.3). All actigraphy outcomes had a wide
range, reflecting heterogeneity in the population.
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FIGURE 1 | A flow chart of the inclusion process. Allocation to intervention group and placebo group omitted here as only baseline data are used in present study.
TABLE 3 | Median values for the SDI outcomes for the 59 patients that had both SDI and actigraphy data, all of which had non-normal distributions.
SDI outcome (possible min-max score) Median 25th percentile 75th percentile Min-max 95% CI of median*
SDI average total (0–12) 0.06 0.00 1.84 0.00–6.12 0.04–0.57
SDI summed product (0–84) 3.00 0.00 18.00 0–60 2.00–9.00
SDI summed frequency (0–28) 3.00 0.00 11.00 0–22 2.00–7.00
SDI mean frequency (0–4) 0.43 0.00 1.57 0–3 0.29–1.00
SDI mean severity (0–3) 0.14 0.00 0.86 0–2 0.14–0.57
SDI mean distress (0–5) 0.29 0.00 1.43 0–4 0.00–0.86
SDI, Sleep Disorder Inventory.
*CI for medians were calculated with the Ratio Statistic in SPSS, which provide varying coverage, but always more than 95%.
Internal Consistency of the SDI
Cronbach’s alpha for the adapted SDI was 0.82 for the
frequency ratings and 0.87 for the severity ratings. The item-
total correlations varied across items and were below 0.3
for the frequency of item 7 (excessive sleep during the
day;0.22), the severity of item 6 (wake up too early;0.23) and
the severity of item 7 (excessive sleep during the day;0.25).
Removing these items caused only negligible increases of
alpha. Daytime sleep propensity became more severe with
increasing AD severity (67), hence the daytime sleep item
(item 7) provided relevant clinical information; thus even if
item-total correlations are lowest for these items/ratings, they
are a clinically-essential component of the instrument and
its scores.
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TABLE 4 | The endorsement of each SDI item (frequency ≥2), percentage rated
as being moderately to markedly severe (severity ≥2), and percentage rated as
moderately to extremely distressing (staff distress ≥3), in accordance with











Difficulty falling asleep 25.43 16.95 13.56
Getting up during the night 33.90 27.12 25.42
Wandering, pacing or getting involved
in inappropriate activities at night
30.51 23.73 25.42
Awakening at night 45.76 30.51 23.73
Awakening at night, dressing, and
planning to go out, thinking that it is
morning and time to start the day
11.86 8.48 6.78
Awakening too early in the morning
(earlier than is his/her habit)
8.48 3.39 1.70
Sleeping excessively during the day 33.90 13.56 3.39
SDI, Sleep Disorder Inventory.
Frequency ratings: 0 = not present; 1 = less than once per week; 2 = 1–2 times per
week; 3 = several times per week but less than every day; 4 = once or more per day
(every night). Severity ratings: 0 = not present; 1 = mild; 2 = moderate; 3 = marked.
Staff distress ratings: 0 = not at all; 1 = minimally; 2 = mildly; 3 = moderately; 4 =
severely; 5 = very severely/extremely (30).
TABLE 5 | Actigraphy variables for the 59 participants with complete SDI and
actigraphic recordings based on a mean of 7.6 days.
Mean (SD) Range 95 % CI§
TST night 379.10 (290.86–423.00)* 123.00–463.40 323.57–401.00
SE 79.00(60.60–88.13)* 25.63–96.54 68.59–83.54
WASO 68.47 (43.72) 3.00–212.71 57.08–79.87
24 h fragmentation
index
93.15 (19.58) 61.03–141.63 88.04–98.25
SE, sleep efficiency; TST, total sleep time; WASO, wake after sleep onset.
*Non-normal data presented as medians with the 25th and 75th percentile in parentheses.
§CI for medians were calculated with the Ratio Statistic in SPSS, which provide varying
coverage, but always more than 95%.
Convergent Validity: SDI Compared to
Actigraphy and NPI-NH
Table 6 shows the Spearman correlation coefficients between
different SDI variables and the actigraphy parameters. For
TST at night, all SDI outcomes had a significant and
moderate correlation (minimum −0.40 and maximum −0.44).
As expected, greater SDI scores were associated with lower TST
(resulting in a negative correlation), higher WASO, and higher
scores on the single NPI-NH sleep item (positive correlations).
The SDI summaries did not correlate significantly with the 24 h
fragmentation index.
Test Accuracy
As noted, we defined “disturbed sleep” to be actigraphy-derived
TST of <6 h for the ROC curve analysis (1 = TST at night <6 h,
0 = TST at night ≥6 h). Twenty-seven patients had a TST below
TABLE 6 | The correlation coefficients (Spearman’s rho) for the SDI outcomes
against actigraphy outcomes and the NPI-NH sleep item.








SDI average total −0.431* 0.389* 0.216 0.746*
SDI summed
product
−0.432* 0.402* 0.216 0.751*
SDI summed
frequency
−0.436* 0.395* 0.213 0.754*
Mean frequency −0.436* 0.395* 0.213 0.754*
Mean severity −0.403* 0.369* 0.195 0.749*
Mean distress −0.408* 0.372* 0.160 0.755*
NPI-NH, Neuropsychiatric Inventory—nursing home version; SDI, Sleep Disorder
Inventory; TST, total sleep time; WASO, wake after sleep onset.
*Correlations were significant at the 0.01 level (2-tailed).
TABLE 7 | The ROC output for the SDI summaries against the 6 h actigraphy
TST cut-off.
95% CI






Total SDI average total 0.771 0.064 0.000 0.646 0.895
Total SDI summed
product
0.777 0.063 0.000 0.653 0.900
Total SDI summed
frequency
0.780 0.062 0.000 0.659 0.901
CI, confidence interval; ROC, Receiver operating characteristic; SDI, Sleep Disorder
Inventory; TST, Total sleep time.
6 h, and 32 patients had a TST of 6 h or more. We evaluated
how the three SDI summaries performed against this standard
(Table 7). The AUC scores were above 0.75 for all three SDI
summaries, indicating that all are clinically useful. The scores
were almost equivalent, however, the SDI summed product score
and the SDI summed frequency score both had slightly higher
AUC scores than the SDI average total score, with AUC scores
of 0.78, 0.78, and 0.77, respectively.
The sensitivity, specificity, predictive values, and ratios of true
positives, false positives, true negatives, and false negatives were
calculated for each level of the SDI summed product score (range
1–84) (Table 8) and the SDI summed frequency score (range 1–
28) (Table 9). For both the SDI summed product score and the
SDI summed frequency score, Youden’s index peaked at cut-off
scores of 5–6 and the results are presented for values 1–10. The
sensitivity, specificity, and Youden’s Index of the SDI average
total score (not shown) were all worse than the two best AUC
performing summaries.
Comparing the SDI summed product score and the SDI
summed frequency score, the former achieved the highest
Youden’s index (0.485 compared to 0.480). These values were
obtained for both a cut-off of ≥5 and a cut-off ≥6, for both the
SDI summed product score and the SDI summed frequency score.
For the SDI summed product score, these cut-offs had a sensitivity
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TABLE 8 | The sensitivity, specificity, positive and negative predictive values, and the rate of true positives, false positives, true negatives, false negatives, and the
Youden’s Index for each value of the SDI summed product score (sum of frequency × severity).
SDI summed product score Sensitivity (%) Specificity (%) PPV (%) NPV(%) TP FP TN FN Youden’s Index
≥1 85 47 58 79 23 17 15 4 0.321
≥2 85 47 61 81 23 15 17 4 0.321
≥3 78 63 64 77 21 12 20 6 0.403
≥4 74 72 69 77 20 9 23 7 0.460
≥5 70 78 73 76 19 7 25 8 0.485
≥6 70 78 73 76 19 7 25 8 0.485
≥7 63 81 74 72 17 6 26 10 0.443
≥8 63 81 74 72 17 6 26 10 0.443
≥9 63 81 74 72 17 6 26 10 0.443
≥10 59 84 76 71 16 5 27 11 0.437
Total n = 59. FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; SDI, Sleep Disorder Inventory; TN, true negative; TP, true positive.
TABLE 9 | The sensitivity, specificity, positive, and negative predictive values, and the rate of true positives, false positives, true negatives, false negatives, and the
Youden’s Index for each value of the SDI summed frequency score.
SDI summed frequency score Sensitivity (%) Specificity (%) PPV (%) NPV (%) TP FP TN FN Youden’s Index
≥1 85 47 58 78 23 17 15 4 0.321
≥2 85 53 61 81 23 15 17 4 0.383
≥3 78 63 64 77 21 12 20 6 0.403
≥4 70 75 70 75 19 8 24 8 0.454
≥5 67 81 75 74 18 6 26 9 0.480
≥6 67 81 75 74 18 6 26 9 0.480
≥7 63 84 77 73 17 5 27 10 0.474
≥8 59 84 76 71 16 5 27 11 0.477
≥9 56 84 75 69 15 5 27 12 0.400
≥10 48 88 77 67 13 4 28 14 0.357
Total n = 59. FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; SDI, Sleep Disorder Inventory; TN, true negative; TP, true positive.
of 70%, a specificity of 78%, a positive predictive value (PPV)
of 73% and a negative predictive value (NPV) of 76%. For the
SDI summed frequency score, these cut-offs yielded a sensitivity
of 67%, a specificity of 81%, a PPV of 75%, and a NPV of 74%.
DISCUSSION
The aim of the present study was to validate the SDI in a nursing
home context and to determine a clinically useful cut-off score
on the SDI to identify sleep disturbance in this population. The
analyses showed that the SDI had high internal consistency and
convergent validity.
Even though two items had low item-total correlation,
they were not excluded because they minimally affected the
overall internal consistency and thus may provide important
clinical information. Three different ways of summarizing
the SDI correlated significantly with the actigraphy outcomes
TST at night and WASO, with medium-strength associations.
Considering frequency, severity, and staff distress separately,
frequency had the strongest association to these actigraphy sleep
variables. The SDI summaries did not correlate with 24 h sleep
fragmentation. Although the SDI contains one item pertaining
to daytime sleep, the total score did not seem to reflect the
fragmentation of the sleep-wake rhythm across the day and
night. The ROC curve analyses indicated that the SDI average
total score, the SDI summed product score, and the SDI total
frequency score led to correct predictions of disrupted sleep (yes
and no) about 78% of the time (95% CI about 65–90%), which
is considered to be “clinically useful” (62). The SDI summed
product score, using a cut-off for disturbed sleep of five or more
or six or more had the highest Youden’s Index values. Both cut-
offs yielded a sensitivity of 70%, a specificity of 78%, a positive
predictive value (PPV) of 73% and a negative predictive value
(NPV) of 76% for predicting disturbance defined as <6 h in TST
defined by actigraphy. The SDI summed frequency score had the
highest AUC score, however, obtained a slightly lower maximum
Youden’s index. The maximum Youden’s index on this summary
was also obtained by both a cut-off of five or more and six
or more, yielding a sensitivity of 67%, a specificity of 81%, a
PPV of 75%, and a NPV of 74%. Because it is important to be
as sensitive to disrupted sleep as possible, we believe that the
SDI summary providing the highest sensitivity should be used
(i.e., the SDI summed product score), and also that the lower
cut-off (≥5) should be used. Thus, we suggest a clinical cut-off
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for the presence of disturbed sleep in institutionalized dementia
patients to be a SDI summed product score of five or more. Even
though the SDI was developed for home-dwelling seniors and
their caregivers (30), the present study demonstrates that the SDI
can be clinically useful for the identification of sleep disturbance
when administered by daytime staff in a nursing home context.
The present finding of the clinical utility of a proxy-rated sleep
tool stands in contrast to the findings by Blytt et al. (25), where
the sleep items of the CSDD and the sleep item from the NPI-
NH underreported sleep problems when compared to actigraphy
parameters. Other than using different subjective sleep outcomes,
the discrepancy between the present results and the results from
Blytt et al. (25) may in part be explained by differences in the
choice of actigraphy-based cut-offs for defining disturbed sleep.
In the present study, disturbed sleep was defined as sleeping
<6 h between 22:00 and 06:00, corresponding to a SE of 75%
or less. More conservatively, Blytt et al. (25) defined disturbed
sleep as having <85% SE, in each participants’ individual rest
interval (based on light, activity, and event marker information
in the actogram, indicating bedtime and wake time), which is a
common cut-off for defining disturbed sleep (55, 56), albeit in
normal populations.
In the original paper by Tractenberg et al. (30), they defined
a rest interval from 20:00 to 08:00. To avoid the inclusion of
time spent out of bed, we instead used a rest interval from
22:00 to 06:00, reflecting a more realistic interval in this specific
population. The use of a common night-time interval for all
participants in our sample reflects a period when patients are
expected to be in bed. Using a wider rest interval might have
increased the variability of SDI ratings across wards or nurse
raters, as problematic night-time behavior in one ward could,
for example, be classified as afternoon or evening restlessness in
a ward with later bed time. Conversely, a narrow rest interval
may have excluded time when many patients were in bed and
asleep, as nursing home patients spend substantial time in
bed (25).
In the original study, Tractenberg et al. (30) found a higher
prevalence of symptoms than in the present study. However,
in their study, participants were recruited based on sleep
complaints, while disrupted sleep was only one of several
optional inclusion criteria in the present study. Also, bed-sharing
caregivers [as in (30)] are likely to be more sensitive to nocturnal
behavior than nursing home staff, as staff generally do not
attend to the patients at night unless they get up or call for
assistance. Further, sleep difficulties or nocturnal behavior might
not be reported consistently in the patient records and may not
always be conveyed to the day shift staff. This might explain
the low clinical cut-off suggested in the present study: A sum
frequency of five is low, given that the maximum score is 84.
This suggests that even this slight subjective impression of sleep
disturbance among patients on the nursing home staff, may
reflect a significant disruption of sleep. However, we did observe
that the distributions of SDI summary scores were skewed toward
the low-scoring end of the continuum, and 44% of the sample
would be qualified as “sleep disturbed” using the cut-off of 5, as
compared with 46% characterized as “sleep disturbed” using the
clinical and objective TST cut-off of <6 h.
The present study suggests that the SDI, rated by daytime
staff, may be used to detect sleep problems in institutionalized
dementia patients. The cut-off score identified can be used as
a means of identifying patients for inclusion in clinical trials of
sleep interventions. To treat disturbed sleep, it is necessary to
identify the underlying cause. In line with this, the SDI can serve
as a screening tool to identify patients who struggle with sleep
problems, and form the basis for a more deliberate mapping
of sleep problems. For example, sleep disturbance caused by
nocturia requires a different treatment than sleep disordered
breathing. Hoeckert et al. (27) used the CSINAPS scale, that
specifically asked about snoring, breathing problems and unusual
movements. These items were rarely endorsed despite high
prevalence of sleep disordered breathing and periodic leg
movements in dementia patients (68), reflecting the need tomore
deliberately evaluate these symptoms. Importantly, the use of
objective measurements presents a challenge as many patients
struggle with tolerating the equipment (69). Thus, deliberate and
continuous observation of patients that struggle with sleep, for
example patients identified by the SDI, is probably necessary
in order to identify the specific underlying problems. However,
the routine use of validated sleep scales may encourage the
awareness among staff of how clinically relevant sleep problems
in these patients are, increasing staff sensitivity to the importance
of detecting signs of poor sleep as a significant component in
understanding the patient’s overall behavioral problems.
Strengths and Limitations
The majority of the included participants provided good quality
actigraphy data for a minimum of 5 nights (mean 7.6 nights).
The patients who agreed to wear the actigraph generally wore
it continuously until it was collected by the researchers. Because
the presence of disturbed sleep was not a required criterion for
inclusion, the participants exhibited a wide range in scores on
the sleep parameters. The present study demonstrated the utility
of the SDI in a heterogeneous sample that is representative of
institutionalized patients suffering from dementia.
One important limitation is the choice of an actigraphy-based
outcome as the reference against which the SDI was validated.
Wrist actigraphy has been shown to be a reliable method of
assessing sleep in different clinical populations, compared to
the “gold standard” of polysomnography and observation (70),
including nursing home patients with severe dementia (69).
However, studies have demonstrated that actigraphy has low
specificity (poor wake detection) (71) and that it overestimates
sleep in people with very disturbed sleep (8, 72). Thus,
actigraphy has acknowledged weaknesses in terms of detecting
wakefulness, hence the correlations between SDI summaries
and actigraphic data found in the present investigation might
represent overestimates. Another limitation is the suboptimal
use of the event marker and consequently the use of a fixed
rest interval. Future studies should secure a robust indication of
bedtime and rise time to obtain more accurate reports of each
participants’ sleep.
Further, even though the ROC curve analysis revealed a
clinically useful cut-off for the SDI summaries, the AUC scores
of 0.77 (SDI average total) and 0.78 (SDI summed product,
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SDI summed frequency) still correspond to a relatively low
discriminatory power (62). The confidence intervals for the
AUC scores were quite wide and ranged from about 0.65,
corresponding to no clinical value, to 0.90, corresponding to high
clinical value (62). This indicates somewhat uncertainty about
value of the SDI summaries. We thus suggest that the findings
should be replicated in a larger sample.
The correlation between the SDI summed product score
and actigraphically-measured TST was 0.43, corresponding to
a moderate correlation (73), but also shows that there is
significantly residual variance in TST not captured by the SDI.
In fact, the amount of shared variability was <20% (0.43 ×
0.43 = 0.185) and over 80% of the variability in SDI scores
was not explained by the TST value. As the actigraphy-based
TST was a summary across a minimum of 5 days (mean 7.7),
and the SDI is a summary across 2 weeks, there was not an
exact temporal overlap between the two measures. The SDI
covered the last 14 days and was completed in the same week
that the actigraph was worn by the participants. Hence, the
temporal overlap between the two measures was incomplete, and
thus the SDI includes behavior not captured by the actigraph.
Importantly, there is however a well-documented discrepancy
between subjective and objective measures of sleep (74, 75), and
this discrepancy is probably a strong contributor to the residual
variance in actigraphically measured TST in the present study,
in addition to the lack of temporal correspondence. Further,
there is a lot more complexity to “disrupted sleep” than what
is captured by actigraphically assessed TST alone, which is, at
its core, a reflection of immobility. However, both outcomes
(actigraphy-measured TST and the SDI summary) were used
as approximations of general sleep disturbance, where both can
serve as indicators that a more deliberate evaluation of sleep
is warranted.
The completion of the SDI was part of a larger data
collection project and all questionnaires were completed by
nurses during the day. Few nurses are at work during the night
and our data collection corresponds with clinical assessments
in nursing homes, which are normally performed during the
day in collaboration with the nursing home physician. The
night time staff are obliged to write reports and to note in
the medical record if clinically relevant events have taken place
during night shifts. It is also common that staff share information
orally during handover. Thus, daytime staff should be informed
about any nocturnal events. It would however be preferable
to obtain both night and daytime staff reports on the SDI.
Nevertheless, the fact that we did achieve an AUC score of
0.78 and significant correlations between the SDI and actigraphy
demonstrates that daytime staff have significant information
about patients’ behavior outside their own shift. It also suggests
that the usual procedure of administering tests during the day
is feasible also with the SDI, provided adequate communication
between the night and day shift.
While the SDI summed product score and the SDI summed
frequency score both led to the same cut-off value (≥5) for
identifying disrupted sleep, the sample size of the present study
was relatively small and confirmatory studies in larger samples
are warranted. We did not interrogate the specific diagnoses
or prescriptions of sedatives of the participants included in the
trial, and there may be important differences among those with
AD, dementia with Lewy bodies, and vascular dementia. Future
studies should address these issues.
CONCLUSION
Overall, the results of the present study showed that the scores
on the proxy-rated Sleep Disorder Inventory correspond well
to objectively measured sleep disruption (defined as a TST<6 h,
corresponding to a SE<75%) in institutionalized dementia
patients, using a clinical cut-off of a summed product score
of five or more. The present results should be interpreted
with caution bearing in mind that actigraphy was used as
the reference outcome measure of sleep. Even though the SDI
seems to identify patients with disturbed sleep successfully, some
patients suffering from disturbed sleep may still go undetected.
The recommended cut-off score (≥5) is low, suggesting that
only a slight clinical impression of disrupted sleep may reflect
significant sleep disruption. Nursing home staff should be vigilant
to document any signs of sleep problems among patients at all
times. The SDI appears to be useful as a screening tool to identify
patients with probable sleep problems. However, determining
the cause of the disrupted sleep normally would require a more
deliberate approach, such as continuous observation and/or
polysomnografic/polygraphic recordings.
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